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2. Abstract
Aging is a multidimensional process of physical, psychological, and social changes. 
Understanding how we sleep and how this dynamic process evolves across life span will help to 
identify normal developmental aspects of sleep over time and to create strategies to increase 
awareness of sleep disturbances and their early management. In normal sleepers from HypnoLaus 
cohort, we evaluated the effects of age and gender on both subjective and objective sleep 
measurements. Our results indicate that normal aging is not accompanied by sleep complaints, 
and when they exist suggest the presence of underlying comorbidities. Polysomnographic data 
revealed that slow wave sleep was more affected with age in men, and age affected differently 
NREM and REM spectral power densities.  Both sleep structure and spectral analysis profiles 
may constitute standards to delineate pathological changes in sleep, both for aging women and 
men. 
Another important aspect in the management of sleep and its disorders is a detailed 
characterization of sleep-inducing medications. Gamma-hydroxybutyrate (GHB) is an inhibitory 
neurotransmitter derivative of GABA, but its mode of action and the range of effects are not well 
understood. Several properties, as growth hormone stimulation in humans and the development 
of weight loss in treated patients suggest an unexplored metabolic effect.  In different 
experiments we assessed the effects of acute, short term and chronic GHB administration on 
central (cerebral cortex) and peripheral (liver) biochemical processes involved in the metabolism 
of the drug, as well as the effects of the drug on metabolism in C57BL/6J, GABAB knock-out 
and obese (ob/ob) mice. We showed that GHB treatment affects weight gain in C57BL/6J and 
GABAB knock-out mice. Metabolomic analysis indicated large central and peripheral metabolic 
changes induced by GHB with important relevance to its therapeutic use. 
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3. Résumé 
 
Le vieillissement est un processus multidimensionnel accompagné par de multiples 
changements dans les domaines physique, psychologique et social. Comprendre comment nous 
dormons et comment ce processus dynamique évolue sur la durée de vie nous aidera à identifier 
les aspects normaux du développement du sommeil au fil du temps, et à créer des stratégies pour 
accroître la connaissance et compréhension des troubles du sommeil et leur prise en charge 
précoce. Chez les sujets normaux de la cohorte HypnoLaus nous avons évalué les effets de l'âge 
et du sexe sur les mesures subjectives et objectives du sommeil. Nos résultats indiquent que le 
vieillissement normal ne s'accompagne pas de troubles du sommeil, et quand ils existent ceux-ci 
suggèrent la présence de comorbidités sous-jacentes. Les données polysomnographiques ont 
révélé que le sommeil profond était plus affecté avec l'âge chez les hommes. De plus, nous avons 
montré comment l'âge modifie la composition spectrale du sommeil lent et paradoxal. La 
structure du sommeil et les profils d'analyse spectrale peuvent donc constituer des standards 
permettant de définir les changements pathologiques du sommeil chez les personnes âgées. 
Parmi les aspects importants de la gestion du sommeil et de ses troubles, la caractérisation 
détaillée des médicaments hypnotiques utilisés est essentielle. L’acide gamma-hydroxybutyrique 
(GHB) est un acide gras à courte chaîne dérivé du GABA, principal neurotransmetteur inhibiteur 
du cerveau, mais son mode d'action et tous ses effets sont toujours largement méconnus. 
Plusieurs propriétés, comme la stimulation de la sécrétion de l'hormone de croissance chez 
l'homme et le développement d’une perte de poids chez les patients traités suggèrent un effet 
métabolique inexploré. Dans différentes expériences, nous avons évalué les effets d'une 
exposition aiguë, à court terme et chronique de GHB sur les processus biochimiques centraux 
(cortex cérébral) et périphériques (foie) impliqués dans le métabolisme du médicament. Nous 
6 
avons aussi évalué les effets du médicament sur le métabolisme des souris C57BL/6J, GABAB 
KO et obèses (ob/ob).  que le GHB diminue le gain de poids chez les 
souris C57BL/6J et GABAB KO. L’analyse métabolomique a indiqué des changements 
importants induits par GHB au niveau central et périphérique, et ces effets  sont  importants pour 
son utilisation thérapeutique. 
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4. Résumé pour un large public 
 
Notre sommeil change continuellement, depuis la naissance jusqu’aux âges avancés. Les 
personnes âgées se plaignent souvent de la qualité ou de la quantité de leur sommeil mais les 
causes restent inconnues. Les maladies du sommeil augmentent aussi chez les personnes âgées ; 
cependant nous ne savons pas si ce phénomène est dû à une dégradation normale du sommeil ou 
à d’autres facteurs.  Un autre aspect important est l’utilisation des hypnotiques, très fréquente 
chez les seniors avec des effets secondaires plus ou moins importants. 
Nous avons voulu savoir si le sommeil physiologique change en fonction de l’âge, en 
dehors de toute pathologie connue du sommeil. Nous avons aussi voulu savoir si ces 
changements sont différents en fonction du sexe des individus. Pour ce travail, nous avons 
analysé des questionnaires relatifs au sommeil de 2211 individus et les enregistrements du 
sommeil de 890 d’entre eux. Cette population appelée HynoLaus est représentative de la 
population générale lausannoise. Nous avons aussi étudié les conséquences métaboliques de 
Gamma-hydroxybutyrate (GHB), une substance hypnogène utilisée dans le traitement de 
plusieurs maladies. Cette étude a été menée chez les souris. 
Nos travaux indiquent que la durée du sommeil ne change pas avec l’âge. Contre toute 
attente, nous avons aussi trouvé que les individus les plus âgés se plaignaient moins de la qualité 
de leur sommeil et se sentaient moins somnolents dans la journée. Les enregistrements de 
sommeil indiquent des changements significatifs dans la structure du sommeil avec un effet plus 
marqué chez les hommes. Ces résultats indiquent que les plaintes de sommeil chez les personnes 
âgées ne sont pas dues aux changements physiologiques du sommeil et doivent être investiguées 
systématiquement pour en trouver les causes. 
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Nos études pharmacologiques chez la souris indiquent que le GHB induit des 
changements majeurs dans le métabolisme, aussi bien cérébraux que périphériques. Ces 
changements sont responsables d’une diminution de poids et d’une meilleure répartition des 
sources d’énergie. Nous avons aussi démontré que le GHB avait des effets antioxydants et 
favorisait la disponibilité des acides gras oméga-3. Nos résultats suggèrent que ces effets 
métaboliques ne seraient pas d’origine cérébrale mais périphérique. 
Les résultats obtenus pendant ce travail de doctorat constituent une base normative pour le 
sommeil en fonction de l’âge et du sexe. Nos travaux ont aussi permis de comprendre comment 
un hypnotique peut, en dehors de ses actions centrales, modifier le métabolisme général.  
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5. Introduction
« Chercher n'est pas une chose et trouver une autre, mais le gain de la recherche  c'est la 
recherche même ». 
Saint Grégoire de Nysse 
Complexity of sleep and its interconnection with all other biological functions partly 
explains why, after almost one century of sleep research, basic questions are still unanswered. 
Fascinating and intriguing, this state of apparent unresponsiveness to external stimuli and reduced 
information processing is still waiting for scientist to discover “why” starting from “how”. The 
detailed steps and mechanisms by which different neurotransmitters (acetylcholine, histamine, 
noradrenaline, dopamine, serotonin, orexin, gamma-aminobutyric acid, adenosine, etc) are 
controlling and regulating sleep are yet to be discovered. Nevertheless, it is known that the 
alterations in sleep duration or structure, or the acute or chronic lack of sleep have important 
impacts on most other biological functions in terms of metabolism 1-9, brain energy10-15, 
cardiovascular response16-30, immune function31-47, performance48-59 and many other 
functions17,60-70.  
Like all major governing processes within our body, sleep is evolving with age, affecting 
its three major characteristics: timing, duration and quality71. While normal structure of sleep in 
children and during adulthood is well established and standards are available, normative data for 
normal sleep in aging are missing. Studying sleep in older subjects is challenging because of 
important overlapping of comorbidities, which can impact sleep. Since deviations from normal 
patterns are often subject to interventions, characterization of normal sleep in aging population 
becomes of increasing importance. Moreover, description of modifications in sleep structure in 
different age groups represents the first step in finding the substrates involved. Published studies 
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indicate changes in sleep architecture72-97 such as increase in wake after sleep onset and stage 1 
NREM sleep on the expense of slow wave sleep (SWS, Stage 3) and REM sleep, but these 
changes per se are not always associated with subjective changes in sleep quality98,99 or daytime 
sleepiness measured by Epworth Sleepiness Scale. Attempts made to discover genes related with 
sleep duration71 showed, for example, that an intronic variant in ABCC9 gene explains about 5% 
of sleep duration in unrelated subjects. Twin studies showed significant heritability estimates for 
sleep length, quality and variations in sleep patterns100. Pharmacogenetic studies identified 
genetic variations involved in different responses to wake-promoting medications.101 Inbred mice 
studies showed that genetic contribution is stronger for the EEG spectral composition than for 
sleep duration and structure.100 Given the complexity of sleep and wakefulness, it is likely that 
both intrinsic and extrinsic factors participate in the modulation of sleep architecture with aging.  
Moreover, aging is associated with increase in the prevalence of sleep disorders, 
especially insomnia102, obstructive sleep apnea103 and restless leg syndrome.104 All sleep-related 
disorders alter significantly sleep structure, but their higher prevalence in elderly might suggest 
that age-related changes in sleep structure facilitate the development of these disorders.  
An important factor affecting the modulation of sleep with aging is gender. Previous 
studies reported poorer subjective sleep quality in women105, but polysomnographic data showed 
that they have a better sleep structure81 in terms of SWS amount and wakefulness after sleep 
onset106. It was proposed that different psychosocial factors in men and women may contribute to 
dissimilarities in the perception and evaluation of symptoms106 and this may contribute to the 
differences observed in self-rating sleep quality. Women usually complain about difficulties in 
falling asleep107 and this is consistent with increased prevalence of insomnia with aging in 
women108, while men have more problems in sleep maintenance, lighter sleep and more frequent 
sleep related breathing disorders109. Gender differences in sleep were mostly attributed to 
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hormones, but also social and cultural factors might participate110. Other studies offer 
contradictory gender differences, with men complaining more about their sleep111. Even if there 
is an important amount of published work on the evolution of sleep with age, the large variability 
in methodology, sample size, or design are just a few reasons why for the same hypothesis the 
results are discordant.  
More recent results pointed to gender differences in the sleep EEG. If some studies 
concluded that ageing in men and women are similar112, other showed that disentangling the 
effect of gender on EEG spectral composition might be confounded by methodological issues113. 
It was proposed that men have lower spectral power in delta-theta frequency bands114, but 
different analysis showed the opposite effect of gender especially depending on the environment, 
which may explain the fragility of women’s sleep in disturbed environments115. 
Increase in demand for sleep-inducing medication, especially in older populations, to 
overcome longer sleep latency or altered sleep maintenance raises the need to discover 
pharmacologic tools which can mimic physiological sleep. Different neurotransmitters are 
involved in the induction and generation of sleep. Gamma-hydroxybutyrate, a gamma-
aminobutyric acid agonist, has proven hypnotic properties. Of special interest is to investigate 
central effects of this drug, aiming to identify its mode of action. Additionally, very few data are 
available on its peripheral effects or consequences on metabolism. 
The first aim of my PhD project was to characterize sleep patterns and main EEG 
features, as well as the subjective impact of changes in sleep dynamic on the daytime functioning 
in relationship with age and gender in a cohort of normal sleepers representative of the general 
population of Lausanne. Investigating the main differences in sleep in subjects without sleep 
complaints will contribute to the understanding of the substrates responsible and of their 
functional significance and establish the normative data on sleep in aging populations. 
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The second part of my project was designed to investigate the metabolic effects of sodium 
oxybate (gamma hydroxybutyrate, GHB), a drug used in sleep medicine to treat narcolepsy with 
cataplexy. If the efficacy of this drug in treating narcolepsy patients is established116 117 and the 
impact of the drug on sleep in healthy subjects is described118, the metabolic changes induced in 
narcolepsy patients gained attention only recently119-122. Furthermore, the distribution of 
endogenous GHB is not limited to the nervous system. It is normally present in other tissues such 
as the kidney, heart and skeletal muscle, with markedly greater concentrations than in the brain123 
and might have several actions. The goal of this part was to identify the metabolic pathways 
affected by acute and chronic administrations of the drug in mice. Since narcolepsy patients are 
chronically treated with GHB, we investigated also how long-term administration of the drug 
affects body weight and body composition in different mouse strains.  
Before the detailed presentation of these two projects, the sleep structure, neurobiology 
and regulation, the relationship between sleep and aging, and sleep pharmacology with special 
emphasis on GHB will be summarized. 
 
 
 
 
 
 
 
 
 
 
 
13 
 
5.1 Sleep architecture  
The gold-standard tool for recording and analyzing sleep in humans and other mammals is 
polysomnography (PSG). This method allows collecting physiologic information on cerebral 
cortex activity, muscle tone, eyes movements, respiration, and cardiovascular activity during 
sleep. Based on electroencephalographic signals altogether with eye movement and muscle tone, 
sleep stages are scored according to criteria published almost 50 years ago by Rechtschaffen and 
Kales and revised in 2007 by AASM.124 
Sleep is divided into two major states: non-rapid eye movement (NREM) sleep and rapid 
eye movement (REM) sleep which alternate cyclically.  NREM sleep has three distinct stages: 
stage 1, stage 2 and stage 3, each stage having distinct electroencephalographic (EEG) features. 
Stage 1 NREM sleep has a transitional role, is shallow and occupies about 5% of the total sleep 
amount.  This stage is characterized by low EEG amplitude, and the dominating frequencies are 
theta (4.75-8 Hz) and alpha (8.25-11 Hz); vertex sharp waves and slow eye oscillations may be 
present during this stage. Stage 2 NREM sleep is defined by the presence of special EEG 
features, such as K-complexes and spindles and represent 45-50% of total sleep time. 25% of 
NREM sleep is represented by the deepest stage of NREM sleep, slow wave sleep (SWS, stage 
3). The dominant frequency in SWS is delta (0.75-4.5 Hz), with high amplitude and slow 
frequency waves. REM sleep is defined by wake-like and “activated” (high-frequency, low-
amplitude) EEG125, muscle atonia and rapid eye movements. The main EEG pattern of this sleep 
stage is represented by “saw tooth” waves.  
The evolution of sleep stages across the night is not random. During the night there are 
four to five NREM-REM sleep cycles (80-100 minutes each), with the two states alternating. At 
the beginning of the night, NREM is deeper and longer, while REM sleep is shorter or even 
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absent. As the night progresses, REM sleep duration increases and NREM sleep becomes lighter 
and shorter (Figure 1).  
 
 Figure 1.  Hypnogram (A) and polysomnographic characteristics for each sleep stage (B). NREM sleep is divided in 
three different stages with stage 3 (SWS or N3) being the deepest. EEG and electromyogram (EMG) for each state 
illustrate the main features of each sleep state. Specific EEG patterns for stage 2 (K-complex and spindles) are 
outlined in green (modified from reference 126).  
 
5.2  Neurobiology of sleep and wakefulness and sleep regulation 
The development of the two-process model of sleep regulation127-129 was one of the most 
important advances in understanding the regulation of sleep-wake system. As a result of 
interactions between a circadian (sleep independent, dependent on circadian oscillator) and a 
homeostatic (sleep and waking dependent), two distinct but complementary processes, sleep and 
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wakefulness alternate in a specific manner.  Sleep propensity is assumed to be the result of the 
combined action of these two processes128. 
The timing and the organization of sleep architecture are strongly influenced by the 
circadian system (process C), while sleep need and intensity are homeostatically regulated. The 
circadian and homeostatic processes contribute equally to the sleep consolidation and wake 
performance130. The circadian pacemaker, with intrinsic oscillatory properties, is situated in the 
suprachiasmatic nucleus which, under normal circumstances, is reset on a daily basis by external 
time cues, the most important being light inputs from the retina (melanopsin photosensitive 
ganglion cells, via retinohypothalamic tract) during the day, and by melatonin secretion from the 
pineal gland during the dark period131. The circadian system mediates rhythmic outputs to sleep-
wake activity and to all functions of the body and is connected with neurons involved in the 
maintenance of wakefulness and in the generation of NREM and REM sleep131. Recent animal 
studies showed that the circadian system influences the amount of vigilance states and also the 
intensity of NREM sleep, actively promoting wake or sleep at opposite phases of its cycle132,133. 
The signals sent by the circadian clock to maintain wakefulness attenuate after melatonin 
secretion. During wakefulness, sleep pressure (or sleep need) progressively builds up. Sleep 
homeostasis (process S) regulates the amount and intensity of sleep as a function of prior 
wakefulness. The best EEG indicator of sleep intensity is delta power (0.75-4.50 Hz) while theta-
alpha power (6.25-9.00Hz) increases as waking accumulates and is associated with the 
homeostatic build-up of sleepiness134,135.  
The discovery of main anatomical structures and neurotransmitters involved in sleep or 
wake generation and maintenance dates back to the beginning of the 20th century, when von 
Economo reported a different type of encephalitis associated with very long sleep duration. In 
these patients, von Economo identified lesions at the junction of midbrain and diencephalon. He 
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proposed that these structures are part of an arousal system that keeps the brain awake. Decades 
after, Moruzzi and Magoun136 described the ascending arousal pathway which they named 
ascending reticular activating system (ARAS). ARAS is originating in the brainstem and send 
projections through reticular formation of the midbrain. Further studies identified two arousal 
pathways (a dorsal and a ventral) contributing to the wake-sleep alternation. The ventral arousal 
pathway starts from upper brainstem and includes projections from reticular formation (RF) to 
the basal forebrain (BF), posterior hypothalamus, and cortex. These projections originating from 
the locus coeruleus (LC - noradrenergic), dorsal and median raphe (serotoninergic), brainstem 
cholinergic nuclei, and mesencephalic dopaminergic nuclei, arouse the cortex both directly and 
through the thalamus. The ventral arousal pathway receives inputs from basal forebrain 
cholinergic, tuberomammillary histaminergic, and lateral hypothalamus (melanin concentrating 
hormone neurons and orexin neurons) and project diffusely to the cortex.  
 
Wakefulness – cortical activation 
Cholinergic neurons located in RF, pedunculo-pontine and laterodorsal tegmental nuclei 
project to the BF and thalamus, and those located in the BF project to all cortical areas. 
Noradrenergic neurons located in the LC (the most prominent noradrenergic nucleus) and 
serotonergic raphe neurons send projections to the thalamus and the cortex.  Dopamine 
containing neurons from the ventral tegmental area and substantia nigra project to BF and cortex, 
and histamine producing neurons from tuberomammillary nuclei (located in the posterior 
hypothalamus) project diffusely to the cortex. The excitatory neuropeptides orexin A and B are 
produced by the neurons in the lateral and posterior hypothalamus and are involved in sustaining 
wakefulness. They project to the cortex, BF and brainstem, and their excitatory properties are 
exerted on acetylcholine, histamine containing hypothalamic neurons, noradrenergic, and 
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serotonergic neurons. Glutamate and aspartate, two excitatory aminoacids, are contained in many 
neurons located in subcortical regions and cortical pyramidal cells, which project widely to the 
cortex, forebrain and brainstem. Wakefulness and cortical activation can be maintained by other 
neuromodulatory substances such as: vasoactive intestinal peptide, corticotropin-releasing factor, 
thyreotropin-releasing factor, thyreotropin-stimulating hormone, adrenocorticotropic hormone 
and adrenaline. Arousal systems, apparently redundant, are independently able to promote 
wakefulness, but they interact in order to generate behavioral arousal and all excite thalamic and 
cortical neurons137. The EEG markers of arousal are high theta and gamma oscillations. 
Descending projections of neurons from arousal systems impact the sensorial and motor 
responsiveness, muscle tone and other physiological functions138.  
 
NREM sleep 
von Economo also observed that encephalitis patients with lesions in preoptic area and BF 
presented with insomnia, suggesting these neurons are involved in sleep generation. Two regions 
situated in preoptic area (ventrolateral preoptic or VLPO and median preoptic area or MNPO) 
contain GABA and galanin releasing neurons and start firing during NREM sleep (VLPO) or 
during both NREM and REM sleep (MNPO) and inhibit many arousal nuclei: LDT/PPT, LC, 
DR, TMN, and orexin neurons (Figure 2). MNPO neurons are involved in the initiation of NREM 
sleep, while the main role of VLPO neurons is to maintain NREM sleep. GABA containing 
neurons were identified also in the thalamus, where they inhibit thalamocortical relay neurons. 
Besides GABA, an important role in initiation of NREM sleep is played by adenosine, which 
inhibits wake active neurons from BF through A1 receptors, contributing to the initiation of 
sleep139. Two main EEG features characterize NREM sleep: spindles and delta waves. 
Synchronization of cortical activity is facilitated by projections from thalamus. The feedback 
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loop between two circuits – thalamocortical (excitatory aminoacids) and reticulothalamic 
(GABAergic) – results in spindles production. When thalamocortical neurons reach a certain 
level of inhibition they change to an intrinsic firing mode, leading to the generation of SWS.  
 
REM sleep 
Within a sleep cycle, a NREM sleep episode is followed by a REM sleep episode. This 
complex sleep state is generated in the brainstem, is actively promoted by cholinergic neurons 
and suppressed by serotoninergic or noradrenergic neurons. Besides EEG specific features, rapid 
eye movements and muscle atonia differentiate REM sleep from NREM sleep or wakefulness. 
Two types of neurons were described: REM-on and REM-off neurons, based on their firing 
during this state. An important site for the generation of REM sleep is perilocus coeruleus, with 
GABA and glutamate containing neurons, but recent observations suggest an important role of 
GABA, glutamate, glycine and neurons producing melanin concentrating hormone (MCH) in the 
regulation and maintenance of REM sleep.  
Even if numerous neuronal structures are involved in the precise alternation between 
sleep and wakefulness, none is sufficient or necessary. Pathological alteration, genetic 
manipulations, or pharmacological interventions in each of these pathways affects the initiation, 
duration, and the quality of the vigilance states, with significant impact on the quality of life, but 
none can completely abolish any vigilance state. 137 
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Figure 2. Main pathways involved in arousal (a) and sleep (b).  An important contribution to wakefulness is 
represented by cholinergic inputs from the brainstem projecting to the thalamus which then activates the cortex 
(laterodorsal tegmental [LDT]; pedunculopontine nuclei [PPT]). Moreover, thalamocortical pathways participate to 
wakefulness maintenance through noradrenergic (locus coeruleus [LC]), serotoninergic (dorsal raphe [Raphe]), 
histaminergic (tuberomammilary nucleus [TMN]), dopaminergic (ventral periaqueductal grey matter [VPAG]) and 
orexinergic (from perifornical neurons [PeF]) inputs.NREM is initiated by GABAergic and galanin inhibitory 
signals (from the ventrolateral preoptic nucleus [VLPO) to arousal centers. REM sleep is controlled by cholinergic 
and non-cholinergic projections from the brainstem, and REM sleep atonia is mediated by glutamatergic (from 
sublaterodorsal nucleus [SLD]) and  glycinergic projections to the spinal cord (figure from 140). 
 
5.3 Main EEG sleep characteristics 
 
The analysis of sleep stage duration and distribution is rather limited nowadays, therefore 
transformation of EEG signal by fast Fourier transform is used to assess the contribution of EEG 
frequency composition and density of different frequency bins. Main EEG rhythms used to 
characterize sleep are delta, theta, spindles and beta waves. Delta rhythm or delta power (0.5-
4.5Hz) is used as a marker of sleep need and intensity, since the power in this frequency range 
increases after sleep deprivation and decreases exponentially across the night. Delta waves have 
both cortical and thalamic origins, and the highly synchronized activity is the result of cortico-
cortical and thalamocortical interplay. Also, slow oscillations (<1Hz) have entirely cortical 
origins141. Studies in animal models and in humans showed that slow oscillations have an anterior 
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frontal origin and after sleep deprivation the increase in delta power is larger in this area. These 
oscillations propagate fast to the posterior parts of the brain141. If delta activity is the marker of 
sleep propensity, EEG theta oscillations (4-8Hz) characterize wakefulness quality, being a good 
indicator of sleep pressure during extended wakefulness. Spindles are waxing-and-waning 
oscillations, lasting 0.5–2s, a hallmark of non-NREM sleep142. Based on EEG frequency, region 
and origin, two different types of spindles were described: slow spindles (10-12Hz), mostly 
present in the frontal cortical areas, and fast spindles (12-15Hz), which predominate in the central 
and parietal regions. 143  Alpha activity (8-10Hz) was proposed as a marker of REM sleep 
homeostasis, due to its attenuation in REM sleep after both total or selective REM sleep 
deprivation144. Also, across and within REM sleep episodes, alpha activity decreases. During 
NREM sleep, alpha activity is also decreased145.  It was suggested that fast rhythms (beta and 
gamma) are generated by the cortical neurons projecting to thalamus141. During wakefulness they 
were correlated with cognitive processes while during REM sleep they were associated with 
dreaming, although they are also present in NREM sleep. The main model explaining the 
difficulties in initiating and maintaining sleep is based on the cortical hyperarousal model146, and 
beta frequency activity was found increased during both NREM and REM sleep in insomnia 
patients.147 
 
5.4 Sleep and aging 
 
Age-induced changes in sleep affect its duration, timing, and quality. Aging affects not 
only the duration and the architecture of sleep, but also the EEG features of sleep.148 Important 
gender differences accompany most of these modifications across the life span, but the exact 
relationship with gender is largely unknown112. Not all studies support the decrease in sleep 
duration with aging, but they agree on most architectural changes with proportional increase in 
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lighter stages of sleep, more stage shifts, and less deep sleep149. The decrease in sleep depth, 
intensity, and continuity is also accompanied by a reduced amplitude of circadian rhythm output 
signals150. Reduced sleep efficiency and state instability are thought to be determined by 
increased brain arousal during sleep and decreased ability to maintain NREM sleep151,152. Also, 
during NREM sleep, the arousal threshold is diminished in elderly, especially in women115. This 
decrement in NREM sleep stability might be correlated with decreased spindle acitivity153. Note 
that although older subjects have lower absolute SWS levels, the homeostatic response to 
increasing sleep need is basically operational150. 
Circadian system is also affected in aging with a circadian  phase advance, attenuated 
amplitude of circadian markers such as melatonin, core body temperature154 and cortisol155, all of 
which can be linked to changes in sleep structure. Nevertheless, age-related changes in the 
circadian physiology are substantially different between individuals based on their genetic 
background, as for instance a polymorphism in PER3 gene, is associated with different responses 
to sleep deprivation and performance156.  
Sleep alteration observed in humans could be seen also in old mice and rats. 157,158. 
Deterioration of the orexin system 158,159, ageing-related decline in adenosine A1 signaling 160, 
and cholinergic hypofunction in the basal forebrain161 may play a role in sleep changes associated 
with aging. Nevertheless, age-related alterations might not be the result of loss of critical neurons, 
but to more subtle changes in cell-cell interactions in brain regions involved in sleep-wake 
control162. Moreover, recent mouse studies showed that age-related changes in sleep architecture 
and EEG activity are strongly under a genetic control.163  
The first subjective outcome of inadequate or insufficient sleep is sleepiness, which can 
be measured by using questionnaires, and objectively, by multiple sleep latency test (which 
measures the time needed to fall asleep) or maintenance of wakefulness (which measures the 
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ability to stay awake). Published studies are discordant concerning sleepiness in aging subjects, 
with some reporting increased164 and others reduced daytime sleepiness92. Even if sleep 
disorders, an important cause of sleepiness, may not be part of the normal healthy aging, their 
presence should be identified and managed accordingly.  
 
Subjective evaluation of sleep and sleep disorders 
In clinical practice, sleep-related questionnaires are commonly used to evaluate the effects of 
disturbed nocturnal sleep on daytime activity and quality of life, and to screen for the presence of 
sleep disorders.  The most widely used questionnaire to evaluate the presence of excessive 
daytime sleepiness is Epworth Sleepiness Scale (ESS), which evaluates the chance of falling 
asleep in 8 different situations. A final score higher than 10 is suggestive for pathological 
daytime sleepiness (score range: 0-24)165. Karolinska sleepiness scale (KSS) is a single item scale 
used to measure subjective sleepiness at a specific time point. Possible scores range from 1 to 9.  
Higher scores represent higher subjective sleepiness.  The KSS scores were highly correlated 
with polysomnographic measures of sleepiness166. In the general population, aging was found 
associated with less daytime sleepiness167,168, and it was suggested that subjective sleepiness has 
a significant heritable component.169 Pittsburgh Sleep Quality Index (PSQI) evaluates sleep 
quality on seven domains170: subjective sleep quality, sleep latency, sleep duration, sleep 
efficiency, sleep disturbances, use of sleep medication, and daytime dysfunctioning over the last 
month. For each domain the score ranges between 0 and 3, where 3 is the negative extreme.   A 
total score higher than 5 (out of maximum 21) is associated with poor sleep quality. Longitudinal 
studies using PSQI showed its ability to predict the development of sleep disturbances or sleep 
complaints with aging. 171 
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  One of the first questionnaires used to assess chronotype was Horne and Ostberg 
Morningness-Eveningness questionnaire (MEQ), which asks for time preference for different 
activities, and sleep preferred schedules. Later, Munich Chronotype was developed, which 
differentiate sleep timing during working days and week-ends.172 Age is the major factor 
affecting MEQ scores, with morningness increasing with aging. Also, the association between 
PER3 polymorphism and diurnal preference is strongest in young subjects.173 Restless leg 
syndrome rating scale was elaborated by International RLS Study Group, and in ten questions 
evaluates the severity of the disorder altogether with the impact on subjects daily life and 
mood.174 The final score allows scaling of disease severity from mild to very severe. Berlin 
questionnaire is designed to evaluate the risk of obstructive sleep apnea syndrome, addressing the 
presence and frequency of snoring, witnessed apneas, daytime sleepiness, obesity or 
hypertension.175 Restless leg syndrome and obstructive sleep apnea syndrome have higher 
prevalence with aging, both with important consequences on sleep quality and health outcomes. 
176  The 11 items instrument, Ullanlina narcolepsy scale is used to measure the symptoms of 
narcolepsy.177  With a cut-off of 14, this scale is very well discriminating narcolepsy patients 
from obstructive sleep apnea, multiple sclerosis and epilepsy. Munich Parasomnia Screening is a 
self-rating instrument based on 21 items, which asses the presence at any time during life and the 
frequency of parasomnias in adults.178 It has high specificity and sensitivity for both psychiatric 
patients and healthy participants. Almost all questionnaires described above were completed by 
the HypnoLaus participants, but only outcomes from ESS, MEQ and PSQI will be discussed in 
section 7.  
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5.5  Sleep pharmacology 
“Coming back to where you started is not the same as never leaving.” 
Terry Pratchett 
Up to now, different drug classes, which act on major neurotransmitters involved in sleep, 
are used to treat sleep disorders. Benzodiazepines which act by enhancing the γ-aminobutyric 
acid A (GABAA) receptor function in the central nervous system increase sleep duration and 
decrease stage 1, REM sleep duration, and latency179,180. Z-drugs were shown to have fewer side 
effects than benzodiazepines, decrease sleep onset latency and REM sleep181. Antihistaminics are 
often used as self-administrated sleep promoting medication, but due to their concurrent 
anticholinergic properties, side effects are common182. Another pathway contributing to 
wakefulness, serotonergic pathway, was explored, and it was shown that nonselective serotonin 
5-HT(2A/2C) receptor antagonists, selective 5-HT(2A) receptor antagonist and the 5-HT(2A) 
receptor inverse agonists increase SWS in both normal sleepers and in patients with chronic 
insomnia183. EVT 201, a partial GABAA receptor agonist, was shown to decrease sleep onset 
latency and wake after sleep onset (WASO) in elderly primary insomnia patients184. Pregabalin, 
an antagonist of neuronal calcium ion channels, currently approved for epilepsy, postherpeutic 
neuralgia 185, neuropathic pain186, fibromyalgia187 and generalized anxiety disorders188 was shown 
recently to improve insomnia symptoms in fibromyalgia patients189.  More recently, dual 
hypocretin antagonsits are emerging as new hypnotics 190. 
Symptomatic treatment is applied also in sleep disorders such as idiopathic hypersomnia 
and narcolepsy, characterized by excessive daytime sleepiness and irresistible sleep episodes. To 
promote wakefulness in patients with central hypersomnia, standard recommended treatment is 
Modafinil (or its R-enantiomer with a longer half-life), a non-amphetamine stimulant which binds 
to dopamine and noradrenaline transporter, inhibiting their action and increasing the extracellular 
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level of these catecholamines.191 Amphetamine, methamphetamine, dextroamphetamine, and 
methylphenidate modulate the level of dopamine and, to a lesser extent, of noradrenaline and 
their efficacy in treating daytime sleepiness was proven. Manipulation of other neurotransmitters 
allows re-establishing, on a daily basis, of the balance between sleep and wakefulness. For 
example, 5-HT(2C) receptor antagonist, agomelatine, is expected to increase arousal192.  
 
5.6 Gamma-hydroxybutyrate (GHB) 
GHB is a unique GABAB receptor agonist, with a variety of dose-dependent behavioral 
effects, ranging from euphoria and anxiolysis to deep sleep. The increase in SWS observed after 
GHB administration in animals and humans attracted attention on this specific molecule, because 
the positive modulation of SWS is not observed with other sleep-inducing drugs.  
Sodium oxybate (Xyrem®, sodium salt of gamma-hydroxybutyrate) is, as from 2007, 
standard recommendation for the treatment of cataplexy and excessive daytime sleepiness in 
narcolepsy with cataplexy patients193. The efficacy of GHB on main features of narcolepsy – 
cataplexy and excessive daytime sleepiness – is well established194. The greatest reduction in 
cataplexy frequency was obtained after two weeks of treatment, and was correlated with the dose. 
195. Also, daytime unintended sleep duration decreased, and night sleep architecture was 
significantly improved, with less stage 1 NREM sleep, longer SWS and less fragmentation. 196,197. 
Data on the effects of GHB treatment on hypnagogic hallucinations and sleep paralysis are 
inconsistent195. Nevertheless, GHB treatment has some well-known side-effects: nausea, 
vomiting, dizziness, or transient events as enuresis, and groaning. De novo central apnea198  and 
deterioration of sleep-related breathing disorders in obstructive sleep apnea patients199 were also 
reported.  
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GHB is not only used for the treatment of narcolepsy with cataplexy. Alcohol withdrawal 
syndrome (AWS), mediated by reduced GABAergic activity, may be treated with GHB. The 
mechanism by which GHB reduces AWS symptoms is believed to be the results of indirect activation 
of GABAA receptors by GHB. Recent studies demonstrated that GHB was more effective than 
diazepam in treating AWS200, improved the abstinence rate in reducing craving for alcohol201 and 
maintenance of long term abstinence from alcohol202. 
 In recent years GHB was investigated in placebo-controlled clinical studies for the treatment 
of fibromyalgia. One year of GHB treatment was associated with clinically relevant improvements in 
pain and daytime functioning, which were maintained during 52 weeks of treatment203. GHB 
improved nocturnal sleep and reduced the intensity and frequency of headaches in four patients with 
chronic cluster headache, with long-standing effects, but the mechanism is unknown204. Due to the 
small sample size, double-blind randomized controlled studies are needed for confirming the efficacy 
of GHB in cluster headache treatment. Interestingly, altered human mitochondrial metabolism may 
affect GHB treatment tolerability205.  
History 
GHB was synthetized for the first time by H. Laborit in 1960, who was trying to produce 
a GABA-derivative able to penetrate blood-brain barrier.206 Soon after the development of GHB, 
some of its properties, as sedation and relaxation, were discovered and GHB began to be used as 
an anesthetic. Intravenous (IV) administration of GHB (60-70 mg/kg) in more than 5000 patients 
allowed Laborit to detail benefic effects of this atypical anesthetic, like muscle relaxant, absence 
of respiratory depression, facilitation of induction and maintenance of hypothermia, but also 
decreased serum potassium level, deficient control of pain and difficulties in predicting the 
duration of drug induced state207. 
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In 1964, Laborit showed that GHB was beneficial in obstetrics due to the absence of 
respiratory depression in newborn and to the important dilatation of the cervix206. Its effects on 
normal labor were already noted, but in 1968 Tunstall recommend it also for caesarean section, 
due to the lack of negative effects on the fetus.208 Just before its release in Great Britain, available 
data showed that GHB acts as a basal hypnotic, acting primarily on the cerebral cortex, with a 
peak detected in plasma at 40 min and 140 min in CSF after IV injection of 70 mg/kg207. In spite 
of the lack of analgesic effects, the differences in EEG pattern compared with barbiturates, the 
increase in amplitude and frequency of uterine contractions, altogether with anti-arrhythmic and 
anti-anoxic effects, indicated GHB as safe and less toxic alternative to cocktails used in 
anesthesia, even for children.207 Potential metabolic effects of GHB, as modification of post-
operative catabolism, hypokalemia and hypoglycemia, were also reported.209 Because of weak 
analgesic effects and dose-dependent development of seizures in some cases, the drug was 
precluded from use as an anesthetic agent in most countries. At the beginning of 1980s body-
builders started to self-administrate GHB to increase muscle mass210 and there are also some 
reports of GHB use as weight reducer,211. GHB is used as recreational drug, and at doses of 20-30 
mg/kg induces euphoria and amnesia212. Doses higher than 50-60 mg/kg may result in coma, 
which persists for short time and is followed by uneventful recovery212. Intoxications due to GHB 
overdose (or simultaneous alcohol and GHB) present with aggressive behavior, amnesia, 
vomiting, bradycardia, respiratory depression, coma and even death213.  
Metabolism of GHB 
GHB exists naturally in very small concentration in mammalian brain, derived from 
conversion of GABA, and also in other tissues like heart, kidney and muscle. Metabolism of 
GHB is described in Figure 3. Main pathway of GHB degradation is through GHB 
dehydrogenase, which has as a final breakdown product succinic semialdehyde. Succinic 
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semialdehyde is either converted to succinate, which is further degraded into Krebs cycle, or is 
transformed into GABA, by GABA transaminase, although results regarding increase in GABA 
after GHB administration are contradictory214.  Two other degradation pathways were also 
proposed: beta-oxidation with glycolate as the final breakdown product, and dehydrogenation by 
2-hydroxyglutarate transhydrogenase. The latest enzyme has a poorly understood general 
function but is active in the nervous system and peripheral tissues, and its final product is 2-
hydroxyglutarate.212,215   
 
Figure 3. Proposed metabolism of GHB212. Three possible pathways for GHB degradation and the conversion to 
GABA are illustrated 
 
 
GHB actions 
Previous studies showed that GHB has a sleep-promoting effect, especially by inducing SWS and 
decreasing sleep latency and fragmentation, and these changes are GABAB mediated118,216. Since 
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GHB is a drug of abuse, the evaluation of its impact on dopaminergic system is important. 
Interestingly, it was shown that GHB effects on dopamine release are dose dependent: while at 
low doses GHB disinhibit dopamine neurons, enhancing dopamine release in different brain 
regions, at high doses it has hypodopaminergic effects.217 Despite its increasing medical use, very 
little is known about the effects on arousal mediating nuclei. Recent animal data imply that GHB 
exerts its sleep and motor effects by inhibiting serotonergic neurons from dorsal raphe and 
cholinergic neurons from laterodorsal tegmentum, which might explain the hypotonia and NREM 
and REM sleep-promoting effects218.  
 
Neuroendocrine and protective effects of GHB 
  Early human studies, which preceded GHB use by body-builders, pointed to the 
stimulation of growth hormone and prolactine release219,220,221. Nevertheless, administration of 
GHB in rats and dogs failed to reproduce the effectiveness of GHB as a growth hormone 
secretagogue.222 Interestingly, GHB was shown also to increase cortisol release after acute 
administration both in humans223,224 and animals225,226 but the mechanism is not identified.  
Protective effects of GHB administration were tested on different tissues. For example, 
GHB reduced affected myocardial fibers after brain-induced (ischemia) myocardiac injury227 or 
prevented the myocardial fibers death228, limited histological and functional consequences of 
focal ischemic or excitotoxic insult of the brain229-231, antagonized alloxan’s diabetogenic 
actions232, improved liver function and integrity after hypothermic preservation and increased the 
acceptable storage time of donor liver before transplantation233,234.  
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6. Research outline, personal contribution and main results 
a. Effects of age and gender on sleep and sleep EEG 
Increased life expectancy as a result of reduced mortality, progresses in treating major 
age-related disorders, and increased quality of life, raises the need for healthcare strategies to 
tackle the complex problematic of aging. For this, an integrated approach is needed. Sleep is one 
of the elaborate neurological processes linking health, mood and cognition. The first part of my 
PhD thesis covers a subjective (questionnaires) and objective (polysomnography) approach to 
examine normal sleepers across age and gender. The major aims were to identify how sleep 
perception and sleepiness are affected by aging, to test if sleep architecture and EEG are 
dramatically affected as a result of aging per se, and to evaluate if effects of aging on sleep and 
sleep EEG are modulated by gender.  
We found important interactions between age and gender affecting sleep. Women had 
better preserved sleep architecture and less sleep complaints, while their EEG spectral 
composition was more altered in low frequencies compared with men. Conversely, altered sleep 
structure in men was paralleled by increase in high frequency EEG. These results are of particular 
interest since normative sleep and EEG data for normal aging populations are spars. We 
concluded that sleep complaints in elderly must not be considered as merely a consequence of 
aging but should be investigated for sleep disorders or other underlying conditions. 
 
b. Central and peripheral effects of gamma-hydroxybutyrate 
The second part of my PhD thesis investigates the metabolic effects of gamma-
hydroxybutyrate (GHB) in mice. Currently used to treat narcolepsy with cataplexy, non-hypnotic 
effects of GHB were reported more than 40 years ago, and recently became of interest in 
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narcolepsy patients. Moreover, the mode of action of this drug is still controversial. Previous 
work in our lab assessed receptors involved in hypnotic effects of GHB in mice and evaluated its 
effects on sleep in healthy volunteers. The increase in the growth hormone in humans, which 
might be the reason why GHB is abused by body-builders, the weight loss described as side 
effect in some of treated patients and decreased heat production suggest yet unexplored metabolic 
effects. In different experiment we have evaluated the effects of GHB on metabolism and central 
(cortex) and peripheral (liver) biochemical processes influenced by the drug administration in 
different mouse strains. 
Acute administration of GHB increased corticosterone levels both in wild type and in 
GABAB ko mice, but growth hormone and prolactin were not significantly affected. 
Metabolomic profiling identified oxidation to succinic semialdehyde through hydroxyacid-
oxoacid transhydrogenase as the major pathway activated by the drug.  Interestingly, even at 
doses as high as 300mg/kg, GHB is not converted to GABA. Four days of GHB treatment 
resulted in decreased respiratory ratio independently of food intake, suggesting a shift in energy 
substrate from carbohydrates to lipids. Body composition evaluated by EchoMRI after 4 weeks of 
GHB administration showed a more balanced distribution of fat and lean mass in treated mice. 
Both C57BL/6J and GABAB ko treated mice showed slower weight gain, suggesting that weight 
change is not GABAB mediated. Fatty acids synthesis and omega-3 fatty acids were increased in 
the liver of the mice treated after 4 weeks. In the cortex, oxidized glutathione and s-
adenosylhomocysteine were significantly reduced in treated mice while reduced glutathione was 
increased, suggesting possible anti-oxidant effects of GHB. In conclusion, GHB has important 
complex central and peripheral metabolic effects suggesting anti-oxidant and anti-obesity 
beneficial effects.  
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Personal contribution 
For the human study, I helped preparing participants for polysomnographic recording, 
calculated questionnaires outcome, transformed polysomnographic recordings in EDF format, 
prepared recordings for spectral analysis, performed spectral analysis and analyzed all the data 
with the help of my supervisor Prof. Mehdi Tafti. I wrote the manuscript together with my 
supervisor and with inputs from the co-authors, and I created the figures and the tables. This 
work is ready for submission. 
For the metabolic project, I participated in the design of the experiment with the help of 
my supervisor. I organized the administration of the drug with the help of Yann Emmeneger and 
Angelique Vaucher, performed the calorimetric and body composition experiments (with the help 
of Frederique Preitner), performed EchoMRI measurements,  weighed mice and collected the 
blood, brain and liver (with the help from Yann Emmeneger, Angelique Vaucher and Sonia 
Jimenez), and analyzed all the data. The manuscript was written together with Julie Vienne and 
Mehdi Tafti, and was accepted for publication in the journal SLEEP. 
Additionally, I have participated in several other projects. Amongst these, I collected 
clinical and laboratory findings in 1099 narcolepsy patients recruited by the European Narcolepsy 
Network, analyzed and wrote a paper as the first author (Luca G et al., J Sleep Res. 2013, 22:482-
95; Annex I). This work is considered as a reference (first year citation: 15) in the largest ever 
narcolepsy with cataplexy population. I also participated in a study correlating subjective and 
objective sleep measures (similar to the work presented here) with cardiovascular risk factors and 
metabolic syndrome (Haba-Rubio J et al., Sleep, 2014, in press; Annex II). This important study 
shows for the first time that normal variations in sleep contribute little if any to metabolic 
syndrome and cardiovascular risk. 
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7. Discussions and perspectives 
 
7.1 Normal sleep across age and gender  
 
Even if we still do not know the answer to the apparently simple question “Why do we 
sleep?” there is unquestionable evidence that sleep duration and quality are important 
determinants of health235.  A recent report of Centers for Disease Control and Prevention calls for 
promoting increased awareness of sleep, a behavior as important as dietary habits, smoking 
cessation, and physical activity236. The impact of sleep duration and quality on inflammatory 
processes237, weight control238, diabetes239 240, and cardiovascular disorders 241 has been studied, 
but further longitudinal studies to distinguish between effects of sleep per se and those of sleep 
disorders and other determinants are required. Also, associations between mood disorders and 
sleep have been described242,243 suggesting that many of the conditions with important social and 
economic burden influence sleep or might be triggered by sleep disturbances. Examining sleep 
characteristics across age and gender contributes to a better understanding of sleep functions and 
reveals how even subtle alterations in its structure may impact daily life and health. Also, given 
the association between age and several neurologic conditions (Alzheimer’s disease), it is of 
major interest to track sleep changes, which precede and/or accompany these disorders.  
In this study we explored the effects of age and gender on subjective sleep evaluation, 
sleep structure and sleep EEG in normal sleepers from one of the largest European cohorts, 
HypnoLaus. We have analyzed how 2211 subjects (40-80 years old) without sleep complaints 
evaluate their sleep and time-of-day preference (chronotype). Benefiting from a large age range 
with balanced gender distribution we could confirm and extend previous findings demonstrating 
the morningness preference in aging populations, independent from gender as previousely 
reported 244. Nevertheless, a recent study, where over 14 000 Brazilian volunteers completed the 
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same chronotype questionnaire (MEQ), reported that men became more morning-oriented than 
women245.  Even if in our sample no gender differences were identified with MEQ scores, they 
were present in sleep timing extracted from Pittsburgh Sleep Quality Index (PSQI). Used as an 
estimate of daytime quality and altered sleep, PSQI surprisingly revealed improved sleep quality 
and better functioning during the day with aging in subjects without sleep complaints.  
Excessive daytime sleepiness in older subjects is associated with a number of factors, 
such as the presence of obstructive sleep apnea, pain, respiratory pathology, medication with 
sleepiness as side-effects, increased REM duration, male gender and increased PSQI score,246 
indicating that sleepiness in aging population might not result from age-related changes in normal 
sleep. The dissociation between age per se and sleep complaints was also previously 
suggested247. One of the important predictors of reporting sleep complaints is ethnicity248 
suggesting the need for future research on genetic contributions. For the majority of sleep 
components evaluated by PSQI genetic influences were also identified249. More recently it was 
shown that heritability of PSQI components (except sleep medication) ranged between 0.15 to 
0.31 and contributed to approximately one-third of the variability of global subjective sleep 
quality250. Our PSQI results together with genome-wide SNP markers are currently being 
analyzed by an international consortium. 
We showed that in the absence of sleep disorders, medication or alcohol, sleep 
architecture is not dramatically affected by normal aging. Since the observed changes in sleep 
structure are progressive in both genders, there is probably a gradual adjustment to these changes, 
ultimately leading to even improved self-assessed sleep quality with aging.  
Sleep architecture and sleep EEG were shown to be under genetic control. Twin studies 
showed that temporal sequence of sleep stages across the night is completely concordant in 
monozygotic twins251. Homozygosity for the longer PER3 allele (PER3(5/5)) has a considerable 
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effect on sleep structure, including SWS156. PER3 polymorphism was also associated with higher 
homeostatic sleep pressure252 conferring vulnerability to sleep loss and circadian misalignment253. 
Moreover, repeated polysomnography revealed significant stability in sleep architecture between 
nights, reflecting a trait-like signature254. Different genes, like ADA, BDNF, and COMT were 
associated with EEG sleep characteristics. For example, ADA (adenosine deaminase, which 
catalyzes the irreversible degradation of adenosine to inosine and contributes to the regulation of 
extracellular adenosine levels) polymorphism affects waking quality, the amount of SWS and 
delta power both in NREM and REM sleep255. Val66Met polymorphism of BDNF (brain-derived 
neurotrophic factor) affects theta EEG frequency and also response to citalopram treatment in 
patients with depressive disorders256. Val158Met polymorphism of COMT (catechol-O-
methyltransferase) predicted interindividual differences in brain alpha oscillations in wakefulness 
and 11–13 Hz EEG activity in wakefulness, rapid-eye movement (REM) and non-REM sleep257. 
In addition, it was demonstrated that COMT polymorphism affects the response to chronic sleep 
deprivation258, narcolepsy symptoms and the response to modafinil101. Given these associations, a 
genetic approach in our sample might explain interindividual variability and how these 
polymorphisms impact age effects on sleep.  
Due to the cross-sectional nature of our study, some questions may be addressed: 
- What is the natural course of sleep in our selected normal population with age? Is 
there a role for gender? In order to answer these questions a longitudinal reevaluation of this 
cohort will uncover insights about the evolution of normal sleep architecture and sleep EEG (the 
follow-up study will start soon). 
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- What is the impact of genetic variations on our findings? HypnoLaus cohort 
participants had undergone comprehensive genetic, somatic, and psychiatric investigations, 
which allow beside the characterization of sleep phenotypes and of sleep quality a GWAS 
approach to reveal candidate genes for sleep and sleep EEG parameters (ongoing work).  
 
7.2 Metabolic effects of GHB 
 
GHB is a “neurotransmitter” whose actions remain incompletely understood. If the effects 
of GHB on sleep were studied in narcolepsy patients, healthy volunteers and some 
mammals121,122,216,259, its influence on metabolism started to be explored only recently in 
narcolepsy treated patients, mainly because of weight loss121,122. Potential metabolic effects were 
suggested by early observations, as changes in selected brain metabolites206,226,260 and more 
recently, the stimulation of growth hormone222,223, cortisol261 and prolactin262. Moreover, weight 
loss reported by treated patients263,264 strengthens the presence of important non-sleep related 
effects. One major difficulty in studying the effects of GHB is its variable actions at different 
doses and possible species-specific effects222.  
Our main interest in this project was to evaluate the central versus peripheral metabolic 
changes induced by GHB in different mouse strains (C57BL/6J, leptin deficient ob/ob, GABAB 
ko mice) after acute, short term, and chronic administration. For this aim, blood analysis, 
calorimetric evaluation, echoMRI and metabolomic approaches revealed unexpected significant 
metabolic changes  
Increased in corticosterone after acute GHB administration is consistent between 
published studies223,265, and this effect was considered to be centrally mediated, but GABAB 
independent266.  This important finding needs further investigations due to the major metabolic 
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impact of corticosterone as well as the possible interaction with development of depression in 
some (predisposed) GHB-treated patients. 
GHB effects on growth hormone in humans and mice raised debates about possible 
GABAA or other neurotransmitter receptors’ involvement. For example, GHB promoted growth 
hormone increase in Parkinson patients, while sodium valproate and baclofen (GABAB agonist) 
had no effects.221 The suppression of GHB-induced growth hormone release by pirenzepine, a 
muscarinic receptor antagonist, suggested a possible cholinergic involvement.267 Nevertheless, in 
our experiments, the growth hormone secretagogue effect was not observed 1 hour after 
administration of 300 mg/kg GHB in mice, and similar results were also reported in rats and 
dogs222. Weight loss after GHB administration was reported in narcolepsy patients 268 but the 
mechanisms is not understood. It was proposed that weight loss is a result of improved sleep 
architecture, reduced narcolepsy specific symptoms and increased daytime activity268. However, 
in several cases the weight loss amounts up to 10-20 kg that cannot be explained by an increase 
in daytime activity, which is not actually documented. Also, in our study GABAB ko mice 
insensitive to GHB in terms of changes in sleep or motor activity presented a decrease in weight, 
suggesting that this effect is not centrally mediated, at least through GABAB pathway.  
Acute and chronic administration of GHB resulted in increased succinate, metabolized by 
hydroxyacid-oxoacid transhydrogenase. An oxidation fate of GHB was described also by in vitro 
studies in the rats’ liver269. Identification of the gene encoding for hydroxyacid-oxoacid 
transhydrogenase (ADHFE1) on chromosome 8q 13.1270 opens new perspective in studying GHB 
metabolism. A dysregulation of this gene in ob/ob adipocytes and kidney suggests that the 
putative metabolic pathways wherein Adhfe1 functions are among those that are altered in 
obesity271.  
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Metabolomics profiling after acute administration of GHB confirmed the increase in 
corticosterone level. Simultaneous serum measures are needed to link the systemic increase of 
corticosterone to changes in lipids and biliary acids. Interestingly, chronic administration of GHB 
revealed a few potential beneficial effects of the drug. Reductions found in glutamate levels, s-
adenosylhomocysteine, and of the oxidative stress confirm previously reported GHB protective 
properties in the brain, cardiomyocytes, and pancreas227,228,232,272.  
Our findings raise several questions and new hypotheses, which may be addressed in future 
projects: 
- What are the differences in the pathways affected by GHB administration in 
narcolepsy patients?  The same protocol may be used to assess GHB metabolic effects in mouse 
models of narcolepsy. Also, similarities and differences between these results and the 
metabolomic profiles in GHB-treated narcolepsy patients (ongoing in our lab) might help our 
understanding of the causes of weight loss in these patients and eventually reveal new pathways 
contributing to cataplexy mechanisms.  
- Which are the metabolic effects independent of corticosterone increase? 
Adrenalectomized mouse models can be used to answer this question. 
- Since sleep and locomotion effects of GHB are conditioned by the presence of 
functional GABAB receptors, the metabolic effects of GHB seem independent of central 
GABAergic mechanisms. Whether pharmacologic pre-treatment with 
cholinergic/serotoninergic/dopaminergic inhibitors alter somatotropic response in mice needs 
further work. 
- Adhfe1 gene might play an important role in the metabolism of GHB. Studying 
how GHB alters the expression of Adhfe1 in different tissues and the effects of GHB in mice 
lacking Adhfe1 will allow further understanding of GHB metabolic effects. 
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Abstract 
The effects of age and gender on sleep are increasingly recognized. However, available 
studies either compared young to middle age/old subjects or included populations with mixed 
normal and pathological sleep. Here, we re-evaluated these effects in normal sleepers from a 
large representative sample of the general population: the HypnoLaus cohort. Subjective 
evaluation of sleep was assessed by questionnaires in 5064 subjects, among whom 2211 were 
considered as free of any sleep disorder. Objective evaluation was performed by 
polysomnography in 2160 subjects and 890 were considered normal sleepers. We confirm that 
the old age is strongly associated with morning chronotype. This chronotype is also strongly 
associated with a better daytime functioning independent of age and gender. Surprisingly, aged 
normal sleepers, especially older women, complained less about sleepiness during the day and 
even pathological sleepiness (Epworth Sleepiness Score > 10) was significantly lower than 
younger subjects. Also, self-reported sleep quality and daytime functioning improved with aging. 
Although women slept (objectively) slightly more than men, total sleep time was not affected by 
age. Sleep latency increased with age in women only while sleep efficiency decreased with age in 
both genders, especially in women. Deep slow wave sleep also decreased with age but men were 
more affected. Spectral power densities within slow waves (< 5Hz) and fast spindle (14-14.75Hz) 
frequencies decreased while theta-alpha (5-1Hz) and beta (16.75-25Hz) power densities in non-
rapid eye movement (NREM) sleep increased with aging. In REM sleep, aging was associated 
with a progressive decrease in delta (1.25-4.5Hz) and increase in higher frequencies but beta 
frequencies were not affected in women. Our study constitutes normative data on natural history 
of sleep across age and gender and can be used as standards to evaluate changes induced by 
pathological aging. Our findings indicate that the presence of sleep complaints should not be 
viewed as part of normal aging, but should prompt the identification of underlying comorbidities. 
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Introduction 
As many other biological functions, sleep is altered with aging. The exact contribution of 
aging per se or of the interaction between age and multiple factors (e.g., biological, socio-
economical, psychological) to sleep changes is difficult to disentangle. Sleep structure, duration 
and quality have different dynamics during aging, and common patterns can be identified both in 
healthy aging and in subjects with intrinsic sleep disorders. These include increased sleep onset 
latency and wake after sleep onset, increased non-rapid eye movement (NREM) sleep stage 1 
(shallow sleep) and reduced amount of slow wave sleep (SWS or deep sleep)1-3. Objectively 
measured sleep duration, by polysomnography, was found to be shorter in the elderly in 
comparison to young and middle-aged adults4, but when comparing subjects aged 60 with 
subjects over 70 years this trend was not observed, suggesting that the decline is not linear till old 
age5.  
Beyond sleep architecture, normal aging affects also specific electroencephalographic 
(EEG) features. For example, not only the amount of slow wave sleep was reported to decrease, 
but aging was also associated with diminished power density within the slow frequency range 
(0.5-4.5 Hz) during NREM sleep, the so-called delta power, a highly reliable index of sleep 
intensity6,7. While many studies agree about the reduction in delta power with aging, there are 
also reports indicating a significant interindividual variability in delta power in elderly.8 With 
aging, the beta power density, that measures high frequency EEG activity, was shown to increase, 
along with decreases in sigma, delta and theta band powers in almost all sleep stages.4  
An important factor affecting the modulation of sleep with aging is gender. Previous 
studies reported poorer subjective sleep quality in aging women9, but polysomnographic data 
showed a better sleep structure10 in terms of increased SWS and decreased wakefulness after 
sleep onset11 compared to aging men.  It was proposed that different psychosocial factors in men 
and women may contribute to dissimilarities in the perception and evaluation of symptoms11 
which may contribute to the differences in self-rating sleep quality. Women usually complain 
about difficulties in falling asleep12 and this is consistent with increased prevalence of insomnia 
with aging in women13, while men have more problems in sleep maintenance, lighter sleep and 
more frequent sleep related breathing disorders14. Gender differences in sleep were mostly 
attributed to hormones, but social and cultural factors might also participate15. Other studies offer 
contradictory gender differences, with men complaining more about their sleep16.  
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More recent studies revealed gender differences in the sleep EEG. If some studies 
concluded that aging in men and women are similar4, others showed that disentangling the effect 
of gender on EEG spectral composition might be complicated because of  methodological issues 
related to spectral analysis data processing1. Differences between men and women were 
suggested in terms of brain maturation, perceived sleep, NREM-REM distribution, or EEG 
features17-24. 
A major source of sleep alteration in aging populations is the increasing occurrence of 
sleep disorders. Insomnia is one of the most common sleep disorders with a major impact on 
daytime functioning, alertness, medical status,25 sleepiness and cognitive functions. Its 
prevalence and severity increases with aging, especially in women.26 The prevalence of 
obstructive sleep apnea syndrome varies between 4-7% in men, and between 2-5% in women27. 
Restless legs syndrome (RLS) affects between 4 and 29% of the general population28-30 and is 
associated with depressive symptoms, decreased sleep quality31 and reduced quality of life32.  
Given the high prevalence of sleep disorders in older subjects with their well-documented impact 
on sleep structure, careful exclusion of those subjects is necessary to evaluate the natural history 
of sleep changes across age and the effect of gender. 
Thus, the aim of this study was to perform a detailed characterization of sleep in relation 
with age and gender in one of the largest European sleep cohorts: the HypnoLaus study. 
Moreover, the impact of changes in normal sleep on daytime sleepiness, perceived sleep quality 
and daytime functioning, as well as their interactions were also analyzed. 
 
 
Methods and participants 
1. Participants’ selection 
HypnoLaus Sleep Cohort Study participants were recruited from the original CoLaus 
sample during the first follow-up. The CoLaus study was designed to assess the prevalence of 
cardiovascular and metabolic disorders, their risk factors and to identify their genetic 
determinants33. All subjects (6733 participants, aged 35-75 years), randomly selected between 
2003 and 2006 from the adult general population of Lausanne-Switzerland, underwent a 
comprehensive somatic and genetic investigation. HypnoLaus participants completed a series of 
self-rating sleep pattern and disorder questionnaires. 5064 participants, who accepted to 
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participate in the follow-up, correctly filled in the sleep questionnaires (46.5% women). There 
were no demographic differences between original CoLaus cohort and HypnoLaus sub-
population. Out of these, 3051 consecutive subjects were invited for an ambulatory full-night 
polysomnography, without any prior selection based on the questionnaires. 2168 subjects (71.1% 
of contacted) accepted to participate. Those who declined were 8.2 years older, sleepier, and BMI 
and PSQI scores were slightly higher (+0.4kg/m2 and +0.3 points, respectively).  In 60 recordings 
technical issues were encountered but 54 of these subjects accepted to repeat the study, resulting 
in a final population of 2162 subjects (51.2% women). 
 
2. Sleep questionnaires 
All participants were asked to fill in questionnaires to assess sleep quality, sleepiness, and 
chronotype. Chronotype was assessed by the Horne and Ostberg Morningness-Eveningness 
Questionnaire (MEQ), which is based on 19 questions. The chronotype classification of subjects 
was performed according to Taillard et al.,34. Epworth Sleepiness Scale is widely used to asses 
sleepiness in the general population and in different sleep disorders, and rates the chance of 
falling asleep in eight different situations.35 Scores higher than 10 (range 0-24) are associated 
with excessive daytime sleepiness.  The Pittsburgh Sleep Quality Index (PSQI) is an effective 
instrument for subjective evaluation of sleep quality over seven domains36: subjective sleep 
quality, sleep latency, sleep duration, sleep efficiency, sleep disturbances, use of sleep 
medication, and daytime dysfunctions over the last month. For each domain, the score ranges 
between 0 and 3, where 3 is the negative extreme. A total score higher than 5 (out of 21) is 
associated with poor sleep quality36. There was a 6 to 18 month delay between the questionnaire 
administration and the polysomnographic evaluation. Therefore, in the morning following the 
polysomnographic recording participants completed another questionnaire providing information 
about the quality of their sleep in the previous night, the amount of alcohol consumed 4 hours 
before going to bed, and their current medication.   
 
3. Polysomnography 
Full ambulatory polysomnography was performed using a digital portable sleep/wake 
recording system (EMBLA Titanium®, Embla systems, Inc, Broomfield, CO, USA). Sensors 
were placed by a trained technician at CIRS (Center for Investigation and Research in Sleep, 
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Lausanne University Hospital, Lausanne). The following measurements were performed: 
electroencephalogram (EEG) from frontal, central and occipital areas (F3-M2, F4-M1, C3-M2, 
C4-M1, O1-M2, O2-M1) according to the international 10/20 electrodes configuration system, 
right and left electro-oculogram (EOG), submental electromyogram (EMG), right and left leg 
EMG, thoracic and abdominal breathing movements (inductance plethismography), 
electrocardiography, pulse oxymetry, respiratory airflow via nasal cannula connected to a 
pressure transducer, and body position.  
Sleep stages, leg movements and arousals were scored according to the 2007 AASM 
criteria37. Apneas/hypopneas were scored according to the AASM 2013 rules38. The average 
number of apneas/hypopneas per hour of sleep (apnea-hypopnea index [AHI]) was calculated. 
Analyzed PSG variables were: sleep duration or total sleep time (TST): total minutes of any stage 
of sleep from sleep onset to morning awakening; wake after sleep onset (in minutes); percentage 
of stage 1, stage 2, SWS, and REM sleep: percentage of TST spent in  each sleep stage; sleep 
efficiency: ratio between the total sleep time and time spent in bed; arousal index (AI), periodic 
leg movements index during sleep (PLMSI), 4% oxygen desaturation index (ODI): number of 
events (AI, PLMSI, and ODI, respectively)  divided by hours of TST. 
 
4. Spectral analysis 
Signals were filtered by a high-pass filter (EEG and EOG: −3 dB at 0.5 Hz; EMG: 10 
Hz), a low-pass filter (EEG: −3 dB at 35 Hz, EMG: 70 Hz), and a notch filter at 50 Hz. Data were 
sampled at 256 Hz. C3-M2 EEG derivation was subjected to spectral analysis. Sleep stages and 
the events were visually scored by two registered PSG technologist on a 30-s epoch basis 
(Somnologica® Software, Medcare Embla® Flaga, Reykjavik, Iceland) according to AASM 
criteria37. The EEG power spectra of consecutive 30-s epochs (average of 4-s epoch interval with 
50% overlap, fast Fourier transform routine, Hamming window, frequency resolution 0.25 Hz) 
for NREM sleep (stage S2 and stage S3) and REM sleep were calculated using PRANA® 
software39. Movement, arousals and respiratory events were considered artifacts and removed 
from the analysis. An automatic artifact detection and removal was performed using PRANA® 
software39, but each recording was also visually inspected for the correction of the artifact 
selection and additional artifacts were manually marked. All epochs containing artifact were 
removed from spectral analysis. NREM-REM cycles were defined according to Feinberg and 
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Floyd40. Sleep-onset REM period was defined as at least one epoch of REM sleep occurring 
within the first 15 min of sleep. NREM and REM spectral analysis was separately calculated for 
the first four sleep cycles. Besides EEG spectral composition, delta (0.75-4.5Hz), theta (4.75-8 
Hz), alpha (8.25-11 Hz), slow spindles (11.25-13 Hz), fast spindles (13.25-15 Hz) and beta (15-
25 Hz) bands were calculated. To account for interindividual differences, EEG power spectra 
were normalized by dividing the power in each 0.25 Hz bin by the total power for NREM and 
REM sleep over 0.75-30 Hz frequency range.  
5. Selection of subjects without sleep complaints
To assess the effects of age and gender on subjective measures a “non-complaining” 
population was selected based on information obtained from PSQI. Subjects who declared sleep 
complaints (mainly environmental), shift workers, those taking any sleep medication, 
experiencing pain during night (more than twice per week), sleep related breathing problems, and 
those with estimated sleep efficiency less than 85% and increased sleep latency (>30 minutes) or 
frequent awakenings during the night or early in the morning (more than twice per week) were 
considered “not-normal”.  
For the polysomnographic data the normal population was defined based on the absence 
of medication which interferes with sleep structure and/or duration, less than 2 glasses of wine 
(or equivalent) consumed 4 hours prior to the sleep recording, sleep duration >5 hours, sleep 
efficiency >80%, absence of sleep onset REM periods, 4% oxygen desaturation index and 
periodic leg movement index less than 15/hour. Available criteria indicate >85% sleep efficiency 
as “normal”. Since in older populations this criterion reduces significantly the number of 
included subjects, we compared those with sleep efficiency between 80-85% with the rest of the 
sample, and no significant differences were found in terms of gender, BMI and sleep architecture. 
6. Statistical analysis
Subjective parameters analyzed were: MEQ scores and chronotype, ESS score, PSQI total 
score and, separately, each domain and sleep estimates (bedtime, sleep onset latency, wake up 
time, total sleep duration). Subjective habitual sleep duration was used as continuous variable or 
as categorical (less than 6h, between 6-7.5h and more than 7.5h of sleep). The following 
 
 
60 
 
polysomnographic data were used: total sleep time, sleep onset latency, wake after sleep onset, 
sleep efficiency, arousal index and sleep stages distribution, periodic leg movement and 
respiratory events during sleep scored according to. Another factor analyzed was body mass 
index (BMI) (used in analyses as continuous or categorical variable, with subjects classified as 
“normal” (if BMI<25kg/m2), overweight (25≤BMI<30kg/m2) or obese (BMI ≥30 kg/m2).  
To analyze the effects of age, four 10-year age groups were created (40-49y; 50-59y; 60-
69y; 70-80y) and one-way ANOVA/Kruskal Wallis Test or χ2 were used to test the effect of age 
(as categorical variable). T-tests or Fisher’s exact tests were performed to test the effect of 
gender. To assess the interaction between age and gender for questionnaires, polysomnographic 
and spectral analysis data, two-way ANOVA (followed by post-hoc multiple comparisons tests) 
was performed. To derive the mid-sleep point, bedtime, sleep onset, wake-up time sleep estimates 
from PSQI were used. Multinomial logistic regression was used to evaluate the chronotype in 
relationship with age (unadjusted model) or in relationship with daytime functioning (adjusted for 
age and gender), and the association between BMI and subjective sleep duration (adjusted for age 
and gender). Partial correlation analysis was used for testing the association between 
demographic, subjective, and objective data. 
 
Results 
Subjective sleep evaluation 
After removing subjects with declared disturbed sleep, 2211 participants (51.3% women; 
mean age 56.57±10.25 years) were considered “non-complaining” and included in the analysis. 
Population characteristics and self-rated sleep pattern results are summarized in Table 1.  
 
Chronotype 
Aging was associated with a gradual shift towards morningness. The risk of being 
morning type was 7.62 times higher in older subjects compared with younger ones (Table 2). The 
diurnal preference measured by the MEQ could also be approximated by mid-sleep point, time to 
go to sleep, time to fall asleep and time to wake up from the PSQI (r=-0.537, r=-0.483, r=-0.485 
and r =-0.444, p<0.001 respectively, partial correlation, adjusted for age and gender). Daytime 
functioning was associated with chronotype: morning type subjects had higher chance to report a 
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better daytime functioning compared with evening type subjects, independent of age and gender 
(unadjusted model: odds ratio [OR] 6.63, 95% confidence interval [95%CI] 1.32-33.21, p<0.001; 
adjusted model for age and gender: OR 5.61, 95%CI 1.11-28.48, p<0.001). By aging subjects 
went to bed and fell asleep earlier and their sleep duration was longer. Gender effect was stronger 
for younger subjects, with women going to bed and falling asleep earlier, and sleeping longer. It 
was expected that mid-sleep point advances by age, but due to the increase in sleep duration, the 
mid-sleep point was shifted towards morning (Table 1).  
 
Daytime sleepiness 
The ESS score decreased with aging, and the reduction was larger in women (two-way-
ANOVA for “age”, “gender”, “age x gender”, p<0.001, Holm-Sidak correction for multiple 
testing). Also, the prevalence of pathological sleepiness, evaluated by an ESS higher than 10 
diminished with aging. If in subjects aged between 40-60 years the prevalence was around 12%, 
in the very old ones it decreased to 5.4% in men and 2.8% in women (Table 1). The only self-
assessed sleep variable correlated with increased daytime sleepiness was short sleep durat ion. 
Subjects who slept less than 6h/night had the highest ESS scores, compared with normal/long 
sleepers (two-way ANOVA, p < 0.001 for “age” and “total sleep time category”, p = 0.77 for the 
interaction).  
 
Subjective sleep quality 
Self-reported sleep quality and daytime functioning measured by PSQI improved with 
aging (Table 1). Besides age and gender, subjective sleep duration was correlated with BMI: the 
“best” duration for a normal BMI was between 6 and 7.5h and short sleep duration (less than 6h) 
was associated with increased BMI, compared with long sleep duration (multinomial logistic 
regression, for BMI>30kg/m2 OR: 4.62, 95%CI 2.26 to 9.36, p<0.001, adjusted for age and 
gender).  
 
Polysomnographic data 
890 subjects out of 2160 subjects who underwent polysomnographic recording (PSG) 
were considered normal sleepers. Women slept on average 19 min longer than men, but overall, 
sleep duration was not affected by age. Sleep latency increased with age in women only (two-
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way ANOVA for age p=ns, gender p=0.009 and their interaction p=0.4). Sleep efficiency 
decreased with age especially in women (two-way ANOVA for age p<0.0001, gender p=0.02, 
interaction p=0.11). SWS amount decreased with age independent of age and gender (but men 
were more affected). REM sleep duration was inversely correlated with REM sleep latency (r=-
0.282, p<0.0001), and the same negative correlation was found between SWS latency and SWS 
amount (r=-0.303, p<0.0001). As expected, higher proportion of S1 was associated with 
decreased sleep efficiency (r=-0.258, p<0.0001) and increased sleep fragmentation (r=0.319, 
p<0.0001). Men, who spent more time in S1, independent of age, had less SWS and REM sleep 
(Table 3). 
  
To summarize, sleep onset latency, stage 1 and SWS amounts were gender dependent, 
irrespective of age, sleep duration, and BMI, while sleep efficiency, number of awakenings and 
wake after sleep onset were age dependent, irrespective of gender and BMI (p < 0.003, general 
linear model with factors “age group”, “gender”, “age group x gender”, corrected for sleep 
duration and BMI).  
 
Subjective versus objective sleep evaluation 
The best estimators of sleep duration were subjects older than 70 years, while younger 
ones underestimated their sleep amount (Spearman correlation between declared sleep in PSQI 
and PSG recorded sleep: r=0.13, p=0.012 for the subjects aged 40-49 years and r=0.451, p=0.003 
for those aged 70-80 years). SWS and REM sleep amounts were not associated with any of the 
sleepiness or sleep quality measures.  The relationship described between BMI and declared sleep 
duration was not significant when taking into account the total sleep time recorded during 
polysomnography.  
 
Spectral analysis 
Out of 890 PSG recordings of normal sleepers, 776 recordings were subjected to spectral 
analysis. 114 recordings were not used in the analysis due to: lack of signal on C3-M2 EEG 
channel, mirror of ECG in EEG channels, increased amount of artifacts which increased the 
probability that remaining amount to be non-representative for the whole night EEG. There were 
no age or gender differences between excluded subjects and remaining ones. 
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NREM sleep  
In Fig. 1(left) are represented the average relative NREM EEG spectra for each age 
group. A significant decrease with increasing age was observed in low frequencies (1-3 Hz; 4.25-
5.00 Hz) and spindles (14.00-14.75 Hz) and an increase in theta-alpha (5.00-11.00 Hz), and beta 
frequencies (16.75-25 Hz) (two-way ANOVA, “age group”, “bin” and “age group x bin”, 
p<0.001). When analyzing the association of different sleep stages with spectral results, men and 
women were differently affected. For example, increased amount of stage 1 in older women was 
negatively associated with spindles frequency power (r=-0.393, p=0.02), while in men, no 
association was found. This finding suggests important gender differences in spectral EEG 
composition and its relationship with sleep architecture. We therefore tested first the effect of 
gender overall, and then assessed the effect of age separately for women and men. When 
considering the absolute powers of spectral analysis, women had higher power in a large 
frequency range (0.75-1.25 Hz; 4.75-13 Hz, p<0.001) compared with men, but after normalizing 
for total power, women had lower power for a small frequency range in the delta (2-2.75 Hz) and 
beta band (16.25-25 Hz) and higher power in theta-alpha band (5.75-10.25 Hz) (p<0.001, t-test) 
(Fig 1, right). With aging, women showed an increasing trend in power density in high 
frequencies (Fig. 2, left), except fast spindles. In men (Fig. 2, right) the largest age-related 
increase was found in the beta band.  
 
REM sleep 
Spectral composition of REM sleep was not affected by sleep structure, duration, or 
efficiency. Nevertheless, higher index of spontaneous arousal was associated with higher alpha 
power (r=0.112, p=0.001), and total arousal index was correlated with power in slow spindles 
frequency band (r=0.136, p=0.0003, partial correlation adjusted for age and gender).  
Except very low frequencies (0.75-1.25 Hz), which were not altered, aging was associated 
with a progressive decrease in delta power and an increase in power in high frequencies (Fig. 3, 
left). The interaction between age and gender was also evident in REM sleep. Women had higher 
theta and lower beta frequency powers, while men had higher power in low frequency range (Fig. 
3, right).  To understand how age affects specifically each gender, age groups were compared 
separately in men and women. For women the only decrease was observed in delta frequency 
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range, while alpha and spindles power increased. Importantly, very high frequencies (high beta) 
were unchanged in women with aging. On the contrary, the most important increase in men was 
found in beta frequency range (Fig. 4), followed by increase in spindles band. Delta frequency in 
REM sleep was not affected in men with aging, yet theta power decreased.  
  
Sleep cycles 
To answer the question if the previous described findings are influenced by the time 
course of the night sleep, EEG spectra were compared between each sleep cycle. Different EEG 
frequency bands were analyzed for each sleep cycle. During NREM sleep an important age effect 
was observed in alpha, theta and delta bands in women (Fig. 5). Women aged between 70-80 
years had the largest reduction in delta and the highest increase in alpha and theta power density. 
Age effect in men was observed only for the last sleep cycle within delta and alpha bands (Fig. 
5).  
 
Discussions 
The present work aimed to reassess sleep, with special focus on its natural history across 
age and gender in a large representative sample of normal sleepers from the general population of 
Lausanne. To that end, subjective and objective measurements of sleep and sleep habits were 
analyzed.  
 
Chronotype  
Our results confirm that old age is associated with higher prevalence of morning types, 
when using MEQ.41, 42-45 Both circadian clock and environmental factors regulate the chronotype. 
The difference between morning and evening types in terms of daytime functioning and total 
PSQI score was also described and explained previously by “social jetlag” experienced on a daily 
basis by evening-type subjects.46 Dissipation of gender differences due to aging is also supported 
by previous work45. Shifting to morningness explains the earlier time in bed while later time to 
wake up and longer sleep duration with aging might contradict the circadian phase advance 
hypothesis in older subjects. Recent data suggested that sleep duration seems independent of 
chronotype47-50. One important environmental factor might be the retirement, which would 
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attenuate the difference between work and free days (social jetlag). The exact time of retirement 
was not available in our population. 
Daytime sleepiness 
Surprisingly, by aging people declare themselves less sleepy. Young age was previously 
associated with increased sleepiness51,52 but it was shown that, at very old age, people experience 
again increased sleepiness52, which is not supported by our results. Also, in our study, the lowest 
ESS scores were obtained in subjects over 70 years of age. Taking into account the variability in 
reported prevalence of sleepiness in general population, the one identified in our study is lower 
than previously reported53-56 suggesting that reported sleepiness is not related to normal 
variations in night sleep, but is a consequence of sleep disorders or other age-related 
comorbidities, which impact daytime alertness.  
Subjective sleep quality 
Declared sleep quality improved with age, as well as the daytime functioning. Similar 
results were reported in other cohorts57 58. Increased reports of pain (as a result of accumulation 
of chronic disorders) and the use of sedatives can contribute to subjective sleep alterations59. For 
this reason, we considered only those subjects who were free of medications affecting sleep and 
those who did not complain about pain. One possible explanation for better rating of daytime and 
sleep quality is an adaptation of expectations about sleep in older populations16 or an 
acclimatization to sleep changes over time60. Recent data58 suggest an association between self-
rated sleep quality and duration in aging populations with markers of cellular aging, as telomere 
length, which reinforce the importance of promoting and maintaining healthy sleep in aging.  
Effects of age and gender on sleep structure 
Sleep structure is strongly influenced by age and gender. These findings are supported by 
previous studies, especially the fact that men have more shallow sleep than women2,11,61. 
Alterations in sleep structure with aging, especially the decrease in SWS amount could be 
attributed to hormonal influences, such as a decrease in growth hormone pulse observed both in 
men and women62,63. Sleep architecture is more affected in men. Age-related differences in sleep 
stage amounts are more pronounced after 60 years of age, and this may be one of the reasons why 
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other studies, which analyzed sleep in young and middle age adults64, did not find differences in 
REM sleep amount. The decrease in SWS starts earlier, in the middle age, both in men and 
women and was well-documented previously3,24,65,66. Interestingly, despite the fact that SWS is 
an index of sleep quality and intensity, aged subjects are less sleepy than younger ones even if 
they lose most of their SWS67. Experimental disruption of SWS in elderly resulted in increased 
sleepiness67, but the daytime functioning was not impaired68, suggesting that at this age subjects 
manage better their sleepiness.  A meta-analysis of sleep studies published between 1978 and 
1983 identified gender as one of the most frequent variable affecting sleep structure and sleep 
disturbances, and despite the fact that both genders experience increased sleep alteration with 
age, older women reported the changes more accurately11.  
An interesting factor, possibly affected by sleep duration and sleep disturbances, is 
increased BMI. In terms of subjective data, higher BMI was associated with both long and short 
sleep duration, but the strongest effect was found in very old men with short sleep. The same 
significant association between increased BMI and short sleep duration was reported by several 
other studies69-71 but in most population studies the presence of sleep disorders were not taken 
into account. Nevertheless, a lack of association between sleep duration and BMI in subjects 
without sleep disturbances was also described,72 implying that overweight/obese subjects might 
subjectively underestimate their sleep duration or they present yet undetected sleep disturbances. 
Note that we found no association with objectively measured total sleep time and BMI.  
Effects of age and gender on EEG spectral composition 
Age-related changes in the sleep EEG spectral composition, as the progressive power 
density decrease in low frequencies accompanying the reduction in SWS amount are concordant 
with previous results64,73. Important gender differences prompted us to test the effect of age 
separately in men and women. Another major component of aging, accentuated by gender, was 
the spindles frequency spectrum. Our findings showing an increase in slow spindle frequency and 
attenuation in fast spindle frequency band confirm the hypothesis of two distinct components64, 
differently affected by the aging process. EEG and brain imaging studies demonstrated different 
origins74 and distinct temporal dynamics75 of spindles, which might be differentially affected by 
aging. If delta and spindles activity during NREM sleep were extensively studied because they 
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share a mutual temporal relationship, the same thalamocortical mechanism, and  similar 
homeostatic regulation,76 the role of theta-alpha bands is less examined.  
In spite of a better preservation of sleep architecture with aging in women, they had lower 
delta and beta power and higher alpha and sigma power densities than men. Previous studies 
which used the same principle for normalizing the data77  reported also that, in spite of a higher 
absolute delta power, women had lower delta power contribution to the total power, while beta 
band was attenuated compared with men. The functional significance of these changes are 
unknown but might be of major importance in terms of gender differences in sleep need and 
associated daytime alertness and cognitive processes. 
Fast EEG frequencies (>15 Hz) were previously associated with insomnia,78 a sleep 
disorder with increased prevalence in women with aging, 79 but it was also suggested that in 
middle age subjects it is difficult to distinguish between age-related changes and insomnia80.  In 
our study beta frequency was higher in men than in women, both in NREM and REM sleep. Age-
related elevated EEG beta power found in NREM sleep in men may not be a marker of central 
arousal, since the same pattern was also found in REM sleep. Contrary to previous findings, 
which suggested a better preservation of delta power in NREM sleep in men and in REM in 
women,77 in our sample women had lower relative delta power also in REM sleep, and age effect 
on this frequency band was more pronounced in women compared with men.  Methodological 
issues (e.g. normalization of data, larger sample size) may explain some of the differences 
between previous findings and ours.  
Limitations 
We report in this study how age and gender contribute to the natural changes in sleep 
quality, structure, and EEG spectral composition in one of the largest population-based cohorts. 
The main contribution of age and gender on normal sleep evolution with age was assessed both 
subjectively and objectively, and the presence of sleep pathologies was carefully excluded. In 
spite of these strengths, our study has several limitations.  One of the limitations (as in previous 
studies) is that sleep-related questionnaires were self-administrated. Although errors in filling in 
the answers or misunderstanding of the questions cannot be excluded, the strong correlation 
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found between MEQ and timing described in PSQI as an example, suggests that the rate of error 
was low. Also, there was a time gap between the administration of the questionnaires and 
polysomnography. However, it was shown that PSQI score remains stable over a year81 and sleep 
quality estimated in the morning following the polysomnography in our study was strongly 
correlated with PSQI, with better sleep quality in those with lower PSQI scores. Finally, lack of 
information about napping during the day before polysomnography could impact our findings, 
especially our spectral analysis results. Finally, our study did not include subjects younger than 
40 years (well-studied previously). 
Conclusions 
Age-related changes in sleep do not affect subjective sleepiness or daytime quality. 
Normative data for normal sleep should be adapted for aging populations to reduce 
overmedication in elderly. Presence of sleep complaints should not be viewed as part of normal 
aging, but should prompt the identification of underlying comorbidities. Moreover, aging men 
and women are affected differently by changes in sleep pattern, which start progressively, at 
around 40 years of age. In spite of better sleep structure and less sleep complaints, women’s sleep 
seems to be more affected in terms of spectral profiles with so far unknown consequences. The 
presence of significantly higher beta power in men suggests that they are more vulnerable to 
sleepiness and shallow sleep, and changes in this frequency range might be more important than 
the decrease in delta power. How our findings relate to changes in brain structures generating low 
(delta), spindles, and high frequency (beta) oscillations in NREM and REM sleep or to frequent 
neurologic comorbidities (e.g., Alzheimer’s disease) in aging populations needs a close follow up 
of our cohort (in progress). 
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Table 1. Effects of age and gender on sleep habits. 
40-49.9y.o. 
(N=708) 
50-59.9y.o. 
(N=688) 
60-69.9y.o. 
(N=553) 
70-80y.o. 
(N=262) 
Women 
(N=362) 
Men 
(N=346) 
Women 
(N=348) 
Men 
(N=340) 
Women 
(N=301) 
Men 
(N=252) 
Women 
(N=124) 
Men 
(N=138) 
PSQI_category (% positive) 
(2) 20.6 18.8 18.9 18.1 11.1 11.0 10.4 7.4 
Psqi_total score (2) 4.00 ± 1.9 4.04 ± 1.7 3.88 ± 1.8 3.84 ± 1.7 3.32 ± 0.1 3.44 ± 1.7 3.20 ± 1.5 3.01 ± 1.6 
Component 1-sleep quality (2) 0.81 ± 0.6 0.82 ± 0.6 0.78 ± 0.6 0.77  ± 0.6 0.71 ± 0.5 0.63 ± 0.5 0.64 ± 0.6 0.55 ± 0.5 
Component 2-sleep latency (1) 12.10 ± 8.4 11.70 ± 7.4 12.50 ± 8.2 11.20 ± 7.4 12.8 ± 8.2 12.10 ± 7.9 14.50 ± 8.5 10.9 ± 7.4 
Component 3-sleep duration 
(1,2) 
7.20 ± 0.9 6.67 ± 0.8 7.21 ± 0.8 6.93 ± 0.9 7.58 ± 0.9 7.43 ± 1.1 7.73 ± 0.9 7.67 ± 0.9 
Component 4-sleep efficiency 
(2) 
95.14 ± 5.1 95.11 ± 4.5 94.85 ± 5.3 95.12 ± 5.1 93.70 ± 5.3 94.06 ± 5.4 93.25 ± 5.5 93.19 ± 5.3 
Component 5-sleep 
disturbances (1,2) 
1.01 ± 0.4 0.94 ± 0.4 1.09 ± 0.4 0.93 ± 0.4 1.03 ± 0.4 1.02 ± 0.4 0.99 ± 0.4 1.06 ± 0.4 
Component 6-sleep medication 
Component 7-daytime 
dysfunction (2,3) 
0.67 ± 0.7 0.60 ± 0.6 0.54 ± 0.6 0.57 ± 0.7 0.36 ± 0.6 0.49 ± 0.7 0.46 ± 0.6 0.30 ± 0.5 
Time to go to bed (1,2) 23:00 ± 0.9 23:15 ± 0.9 22:53 ± 0.7 23:05 ± 0.9 22:58 ± 0.9 23:05 ± 0.9 22:57 ± 0.9 23:03 ± 0.9 
Time to fall asleep (1,2) 23:13 ± 0.9 23:28 ± 0.8 23:06 ± 0.8 23:17 ± 0.9 23:11 ± 0.9 23:17 ± 0.9 23:13 ± 0.9 23:14 ± 0.8 
Time to wake-up (1,2) 6:45 ± 1.0 6:40 ± 0.9 6:40 ± 0.9 6:31 ± 1.1 7:15 ± 1.0 7:09 ± 1.1 7.29 ± 0.8 7:27 ± 0.8 
Mid-sleep point (2) 2.59 ± 0.4 3:01 ± 0.4 2:53 ± 0.4 2:53 ± 0.4 3:13 ± 0.3 3:13 ± 0.4 3:21 ± 0.4 3:20 ± 0.4 
Epworth Sleepiness Scale 
(1,2,3) 
6.58 ± 3.7 6.11 ± 3.6 6.06 ± 3.7 6.28 ± 3.8 4.72 ± 3.2 5.46 ± 3.3 4.11 ± 3.1 5.02 ± 3.1 
Epworth Sleepiness Scale 
_category (%positive) (2) 
14.7 10.4 12.8 11.2 5.4 5.8 2.8 5.4 
BMI (1,2) 24.60 ± 4.5 26.01 ± 3.4 24.92 ±4.5. 26.36 ± 4.0 25.98 ± 4.9 27.44 ± 4.4 26.50 ± 4.7 27.40 ± 4.1 
Horne and Ostberg 
questionnaire (2) 
57.20 ± 9.2 57.81 ± 8.1 59.29 ± 8.2 59.47 ± 8.5 60.82 ± 8.9 61.57 ± 8.4 62.08 ± 7.5 63.61 ± 7.1 
Definite morning (%) 8.4 5.9 11.6 9.6 17.2 16.5 16.1 22.0 
Moderate morning (%) 13.4 14.8 16.5 20.7 19.5 24.3 30.1 27.1 
Neither (%) 50.0 53.1 51.4 50.6 45.7 44.3 44.1 44.1 
Moderate evening (%) 14.0 18.2 13.5 11.1 12.4 9.1 6.5 5.9 
Definite evening (%) 14.2 8.0 7.0 8.0 5.2 5.7 3.2 0.8 
BMI: body mass index (kg/m2). Data are presented as mean ± SD, or percentage where specified. All subjects who declared they 
take sleep medication (prescribed or not) were not considered as “not complaining”, so they were not included in the analysis. If 
analysis showed a significant effect, it was specified as: (1) – gender differences; (2) – age differences; (3) – age x gender 
differences, p<0.05. 
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Table 2. Effects of age  on chronotype. 
50-59 y.o. vs 40-49 y.o.  60-69 y.o. vs 40-49 y.o. 70-79 y.o. vs 40-49 y.o. 
95% CI p value 95% CI p value 95% CI p value 
Chronotype 0.002 p<0.0001 p<0.0001 
Morning type 1.89[1.38; 2.59] 3.04[2.16; 4.27] 7.62[4.36; 13.31] 
Neither 1.36[1.04; 1.80] 1.46[1.08; 2.00] 2.89[1.67; 5.00] 
Evening type 1 1 1 
Multinomial logistic regression, unadjusted model; “evening type” was used as reference for chronotype; “definite morning” and 
“moderate morning” were unified in “morning type” category; also, “evening type” resulted from unification of “definite 
evening” and “moderate evening” participants. 
76 
Table 3. Effects of age and gender on variables assessed by polysomnography 
40-49.9y.o. 50-59.9y.o. 60-69.9y.o. 70-80y.o. 
women men women men women men women men 
Total sleep time 
(2) 
434.63 ± 
57.2 
414.5 ± 55.4 
433.18 ± 
51.2 
400.99 ± 
56.3 
430.60 ± 59.8 423.60 ± 59.9 425.60 ± 49.9 410.83 ± 61.6 
Sleep efficiency 
(%) (1,2,3) 
91.50 ± 4.6 91.27 ± 4.2 91.06 ± 4.2 89.63 ± 4.4 88.98 ± 4.5 88.02 ± 4.7 86.28 ± 4.8 87.86 ± 4.2 
Wake after sleep 
onset (1,2,3) 
41.11± 24.3 40.33± 21.7 43.13 ± 22.1 47.23 ± 22.7 54.26 ± 25.4 58.07 ± 25.1 67.9 ± 24.8 56.73 ± 24.3 
Sleep onset 
latency (to any 
stage) (2) 
15.23 ± 19.8 12.90 ± 15.6 15.50 ± 19.1 13.98 ± 14.5 16.5 ± 20.1 12.30 ± 14.1 19.69 ± 16.8 9.01 ± 24.3 
Sleep onset 
latency ( to stage 
2) (2)
18.95 ± 18.7 17.37 ± 16.9 18.71 ± 19.6 17.86 ± 15.2 19.5 ± 21.3 15.40 ± 14.1 22.75 ± 16.8 11.75 ± 10.2 
Latency to SWS 
(1) 
21.59 ± 22.3 21.05 ± 17.2 17.01 ± 12.9 22.22 ± 4.8 26.93 ± 26.4 34.95 ± 60.9 27.64 ± 25.8 28.7 ± 31.6 
Latency to REM 
sleep 
82.21 ± 35.6 80.04 ± 31.5 83.50 ± 40.7 77.92± 30.8 77.06 ± 36.7 76.28 ± 36.6 88.75 ± 53.1 70.73 ± 22.6 
Stage 1 % (1,2) 8.37 ± 3.8 10.30 ± 4.3 8.81 ± 3.9 11.97 ± 4.7 8.98 ± 3.4 11.51 ± 6.0 9.24 ± 4.6 13.11 ± 4.7 
Stage 2 % (1) 43.66 ± 7.4 44.72 ± 7.5 44.09 ± 7.5 44.29 ± 7.3 47.52 ± 8.6 48.76 ± 10.2 48.14 ± 11.7 50.45 ± 12.9 
Slow wave sleep 
% (1,2) 
22.64 ± 7.7 21.92 ± 6.9 23.34 ± 7.7 21.60 ± 7.8 20.41 ± 6.8 17.28 ± 7.8 20.53 ± 6.9 16.93 ± 7.8 
REM sleep (%) 
(1,2) 
25.36 ± 4.5 23.05 ± 4.9 23.73 ± 4.8 22.12 ± 4.8 23.07 ± 5.3 22.43 ± 5.1 22.08 ± 4.5 19.48 ± 5.0 
Oxygen 
desaturation index 
4% (1,2) 
1.62 ± 2.4 4.11 ± 3.7 3.03 ± 3.02 4.97 ± 4.0 4.07 ± 3.6 5.84 ± 4.1 4.34 ± 3.5 6.43 ± 4.1 
Periodic leg 
movements index 
during sleep (1) 
1.76 ± 3.5 2.15 ± 3.8 2.31 ± 3.77 2.33 ± 3.9 3.12 ± 4.6 2.61 ± 3.8 3.01 ±  4.2 5.28 ± 5.5 
Total arousal 
index (1,2) 
14.53 ± 5.7 17.80 ± 7.0 14.81 ± 5.8 18.26 ± 5.7 16.45 ± 5.8 19.47 ± 3.9 17.24  ± 5.6 21.36 ± 4.9 
Spontaneus 
arousals (1) 
10.69 ± 4.2 10.60 ± 4.7 9.80 ± 4.3 9.73 ± 4.3 10.32 ± 4.5 10.38 ± 5.2 10.32 ± 3.9 11.72 ± 4.7 
Respiratory 
arousal index (1,2) 
2.02 ± 2.4 4.88 ± 4.5 3.21 ± 3.3 6.31 ± 4.7 4.05 ± 3.3 7.43 ± 6.7 4.93 ± 3.7 7.74 ± 4.8 
Periodic leg 
movements 
arousals (2) 
0.78 ± 1.8 0.61 ± 1.5 0.71 ± 1.44 0.44 ± 0.9 1.07 ± 1.9 0.62 ± 1.2 1.23 ± 1.8 1.38 ± 1.9 
Two-way ANOVA with factors “age group”, “gender” and interaction (N=860) for the main polysomnographic variables. 
Significant effect was specified as: (1) – gender differences; (2) – age differences; (3) – age x gender differences, p<0.05. 
. 
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Figure 1.  Effect of age on NREM relative EEG spectral power (left). Down oriented triangles connect 
significant frequencies which were decreased with age, while up-oriented triangles connect significant 
frequencies which were increased with age (p<0.05). Effect of gender (right) on NREM relative EEG 
spectral power. 
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Figure 2. Effect of age on NREM EEG frequency bands (relative to the first age group) separately for men 
and women. Stars mark EEG bands significantly affected by age (p<0.05); s. spindles= slow spindles; f. 
spindles= fast spindles. 
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Figure 3. Effect of age (left) and gender (right) on REM sleep spectral composition. Down oriented 
triangles connect significant frequencies which were significantly decreased with age, while up-oriented 
triangles connect significant frequencies which were significantly increased. 
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Figure 4. Effect of age on REM sleep EEG frequency bands (relative to the first age group) separately for 
men and women. Stars mark bands significantly affected by age (p<0.05); s. spindles= slow spindles; f. 
spindles= fast spindles. 
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Figure 5. Effect of age on NREM (left) and REM spectral power densities across sleep cycles. Stars 
connect age groups which differ within the sleep cycles (two-way ANOVA for “cycle”, “age group” and 
interaction, p<0.05).  
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Abstract 
Study Objectives: Gamma-hydroxybutyrate (GHB) was originally introduced as an 
anesthetic but was first abused by bodybuilders and then became a recreational or club drug.1 
Sodium salt of GHB is currently used for the treatment of cataplexy in narcolepsy patients. The 
mode of action and metabolism of GHB is not well understood. GHB stimulates growth hormone 
release in humans and induces weight loss in treated patients, suggesting an unexplored 
metabolic effect. In different experiments the impact of GHB administration on central (cerebral 
cortex) and peripheral (liver) biochemical processes involved in the metabolism of the drug, as 
well as the effects of the drug on metabolism were evaluated in mice. 
Design: C57BL/6J, GABAB knock-out and obese (ob/ob) mice were acutely or 
chronically treated with GHB at 300mg/kg. 
Measurements and Results: Respiratory ratio decreased under GHB treatment, 
independent of food intake, suggesting a shift in energy substrate from carbohydrates to lipids. 
GHB treated C57BL/6J and GABAB null mice but not ob/ob mice gained less weight than 
matched controls. GHB dramatically increased the corticosterone level but did not affect growth 
hormone or prolactin.  Metabolome profiling showed that an acute high dose of GHB did not 
increase the brain GABA level. Both in the brain and the liver, GHB was metabolized into 
succinic semialdehyde by hydroxyacid-oxoacid transhydrogenase. Chronic administration 
decreased glutamate, s-adenosylhomocysteine, oxidized gluthathione, and increased omega-3 
fatty acids. 
Conclusions: Our findings indicate large central and peripheral metabolic changes 
induced by GHB with important relevance to its therapeutic use. 
Keywords: GHB, brain, liver, metabolomics, anti-oxidant 
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Introduction 
Gamma-hydroxybutyrate (GHB), a short fatty acid derivative of GABA, is an inhibitory 
neurotransmitter, naturally present in the mammalian brain2, 3. In sleep medicine, sodium 
oxybate, a sodium salt of GHB, is used for the treatment of narcolepsy with cataplexy 4. GHB is 
an agonist of GABAB receptors but its mode of action and the range of effects are not well 
understood 5. Originally introduced as an anesthetic in early sixties 2, GHB was soon proposed to 
produce a physiological sleep with increased slow wave sleep (SWS) 6. However, studies in 
animals suggested that the GHB-induced changes mimicked the state of absence seizure with 
abnormal electroencephalogram (EEG) 7, 8. More recently, we extensively studied the effects of 
GHB on the EEG and vigilance states in mice and humans 5, 9. GHB dose-dependently increased 
EEG slow waves but at higher doses the EEG and behavior were very similar to classical 
anesthetics 5. We also showed that both in humans and mice, the GHB-induced behavioral 
changes were different from physiological sleep. Finally, we showed that exogenous GHB acts 
solely through GABAB receptors since GHB had no behavioral and/or EEG effects in GABAB 
knock-out (KO) mice 5. 
An increase in growth hormone, simultaneously with the first slow wave sleep episode 
was reported in healthy young volunteers 10 and in narcolepsy patients treated with sodium 
oxybate 11. The increase in growth hormone is believed to be the reason why GHB was 
commonly abused by bodybuilders 12. GHB is also abused as a recreational drug and was 
associated with euphoria, behavioral disinhibition, dizziness, myoclonus, retrograde amnesia 
(date rape drug), nausea and vomiting, confusion, and coma 13. GHB overdose, both in fatal and 
non-fatal cases, presents with respiratory depression, bradycardia, and hypotension. 14 
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Given the major behavioral effects of GHB, mostly central actions of GHB have been 
studied, although GHB is also present at periphery and might have several actions. For instance, 
one of the side effects observed in GHB treated narcolepsy 15, fibromyalgia 16, and binge eating 
disorder 17 patients is weight loss, suggesting metabolic effect that remains ill-defined. Early 
studies on GHB central mode of action pointed to a dose-dependent reduction of cerebral glucose 
utilization in the rat brain 6, 18, 19, which was interpreted as an adaptation to decreased brain 
metabolic needs. GHB was also tested for potential protective properties in animal models of 
stroke and hypoxia 20, 21, head trauma 22, and transient global cerebral ischemia 23. Also, GHB 
administration induced hypothermia in rats by decreasing metabolic heat production. 
Nevertheless, it is not understood how these metabolic effects are produced. It was proposed that 
GHB shifts the intermediary metabolism toward the pentose-phosphate pathway (PPP) by 
activating glucose-6-phosphate dehydrogenase 24. As most other central depressants, GHB does 
not increase glucose supply to the brain but decreases its use by widespread neuronal inhibition 
but whether the same happens at periphery is not known. 
 
Thus, the aim of the present study was to determine which metabolic pathways are 
affected by acute and chronic administration of GHB and how chronic administration of the drug 
impacts body weight as well as brain and body composition in different mouse strains.  
 
Methods 
 
Animals: All experiments were performed according to the protocols approved by the State of 
Vaud Veterinary Office, Switzerland. All mice were male and kept in individual polycarbonate 
cages under 12 h light/dark cycles, at 25°C. GABAB KO mice (lacking either GABAB1 or 
GABAB2 subunit, generated in BALB/c background) were generously provided by Dr. Bernard 
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Bettler (University of Basel, Switzerland) and were generated as previously described 5, 25. Both 
GABAB1 and GABAB2 -/- mice do not have functional GABAB receptors. Ob/ob mice (C57BL/6J 
background, leptin deficient due to a spontaneous obese “Ob” mutation) were purchased from 
Charles River laboratory. 
 
 Experimental design: To evaluate the metabolic effects of GHB, we designed 3 
different experiments to assess, separately, the acute, short term, and chronic metabolic effects of 
the drug (Fig. 1). We chose 3 different genotypes: C57BL/6J mice as wild type (and the strain 
commonly used for metabolic studies), GABAB KO mice due to the fact that previous research 
showed these mice are behaviorally insensitive, in terms of sleep and locomotor activity, to 
GHB5, and ob/ob mice to test if the effects found in the previous two genotypes are leptin-related. 
 Experiment 1: Acute effects of GHB administration 
 To test the acute metabolic changes, blood and tissue metabolites were assessed 1 hour 
after the drug administration. C57BL/6J mice (N=16, age 12 weeks) were split in two groups: 
treatment and placebo. Drug (300 mg/kg of Xyrem®, oral solution, 500mg/ml, UCB Pharma SA, 
Basel, Switzerland, hereinafter “GHB”) or placebo (NaCl 0.9%, B.Braun Medical AG, 
Emmenbrücke, Switzerland) were administrated intraperitoneally (i.p.) with a volume of 5ml/kg 
body weight. The dose and the duration were based on previous experiments performed in our 
lab5, which showed that the maximum effects were obtained at 300 mg/kg and lasted for 
approximately 1 hour. Blood and tissues were collected one hour after GHB/placebo 
administration. Blood cholesterol, triglyceride, glucose, and free fatty acids were measured. The 
brain and liver were removed, stored at -80°C and used for metabolome analysis.  
 
To evaluate the effects of the drug on corticosterone, prolactin, and growth hormone we 
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used the same protocol but in two genotypes: C57BL/6J and GABAB KO mice (lacking either 
GABAB1 or GABAB2), age 12-13 weeks. One hour after i.p. injection of 300mg/kg of GHB, 
animals were rapidly decapitated and trunk blood was collected, centrifuged at 1,000g for 15 min 
at 4°C and the supernatant stored at -80°C. Corticosterone was quantified by an EIA kit (Enzo 
Life Sciences AG, Lausen, Switzerland) according to the manufacturer instructions. Test samples 
(duplicates) were diluted 40 times in the provided buffer, and optical density was measured (λ = 
405 nm). Prolactin and growth hormone were measured by ELISA kits (Mouse prolactin ELISA 
kit, Sigma Aldrich, St. Louis, MO, USA and Rat/Mouse growth hormone ELISA kit, EMD 
Millipore, St. Charles, MO, USA). Test samples (duplicates) were diluted 1:10 in provided buffer 
and absorbance (λ =450 nm for prolactin and the difference between λ =450nm and 590 nm for 
growth hormone) was recorded. 
Experiment 2: Effects of subchronic administration of GHB  
In a second step, mice were studied in the calorimetric chambers for 8 days: 4 baseline 
days and 4 days under drug administration. After one day of habituation, 10 C57BL/6J mice, 12 
weeks old, were recorded for 2 sessions of 96 hours in calorimetric chambers (Oxymax). First 
group of 5 mice received 300 mg GHB/kg/day in drinking water, starting at first evening. The 
second group of 5 mice received the same dose of drug in the same manner, from hour 97 of the 
experiment (balanced design). Placebo (water) was administered on the opposite order. At the 
beginning of the experiment mice were weighed, and measured parameters were adjusted for 
each mouse weight. Energy expenditure (EE) was calculated as: 3.815*VO2 +1.232*VCO2 
26. 
Locomotor activity, oxygen consumption (VO2) and CO2 production (VCO2), respiratory 
exchange ratio (RER), food and water intake and heat production were calculated by Oxymax 
software. 
Experiment 3: Effects of chronic GHB administration 
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For chronic metabolic changes, mice were studied 4 weeks under placebo or 300 mg 
GHB/kg/day. Twenty C57BL/6J mice and 16 ob/ob mice were split into two groups, balanced for 
their age (range: 12 weeks old at the beginning of the experiment) and weight. One week before 
the experiment all mice were habituated to drink water only during light (sleep) period to mimic 
the administration of the drug in humans; water bottles were removed at 9.00 pm and reinstalled 
at 9:00 am; and the daily quantity of water was measured. After 1 week of habituation, mice were 
weighed and split in two groups. Treated group received in the drinking water 300 mg 
GHB/kg/day, diluted in 4 ml of water. All mice consumed this quantity of water. Control mice 
received water only during the light period. Lean mass, fat mass and water content were assessed 
on isoflurane-anesthesized animals using an EchoMRI whole-body composition analyzer. Mice 
were evaluated for body composition at the beginning of the experiment and after 28 days of 
treatment. Weight was monitored weekly using an electronic scale. To avoid the effects of 
isoflurane on metabolites analysis, after the second EchoMRI measurement drug/water 
administration continued for another 24h. At the end of the experiment, mice were sacrificed by 
cervical dislocation. Brain and liver of C57BL/6J mice were rapidly sampled, stored at -80°C and 
used for metabolome analysis. 
 
 300 mg GHB/kg/day, diluted in 4 ml of water was also administrated for 4 weeks, during 
the light period, to 4 GABAB1 and 5 GABAB2 KO mice and placebo to 4 GABAB1 and 3 GABAB2 
KO mice, matched for age (12-13 weeks) and weight at the beginning of the experiment. Before 
starting the experiment mice were habituated for 1 week to have access to water only during the 
light period. Weight was monitored weekly.  
 
For metabolome analysis, the cortex was dissected from the frozen brains. A sample of 
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100-140 mg from frozen liver was also collected. All samples were stored at -80°C till 
processing. Sample preparation and analysis were performed by Metabolon, as previously 
described 27.   
Statistical analyses: To test the effects of the treatment on blood biochemistry, 
calorimetric variables and body mass composition, paired t-test or Wilcoxon signed rank test 
were used, when appropriate. Weekly changes in weight were analyzed by One-way repeated 
measures ANOVA. To identify the impact of light/dark variability, effects of treatment, order or 
their interaction, two-way ANOVA was used. Evaluation of the relationship between body mass 
composition and weight changes was analyzed by Deming regression (errors-in-variable model), 
and then the slopes were compared by t-test. Calorimetric data were normalized to the first 4 
hours of the experiment. Metabolomics data were analyzed by Welch t-test and fold change 
(log2(treated/control)) and significance level (-log10(p value)) were calculated. 
Results 
Experiment 1 
Corticosterone is increased by GHB 
One hour after drug administration, no statistical differences were found in plasma 
concentrations of glucose, cholesterol, triglyceride, and free fatty acids. Corticosterone levels 
were significantly increased in both C57BL/6J and GABAB KO treated mice (almost 4-fold), 
independent of genotype (two-way ANOVA, p<0.001 for factor “treatment”, non-significant for 
genotype and interaction, C57BL/6J=17, GABAB KO=7) (Fig. 2a). Prolactin was not affected by 
GHB administration, in none of the genotypes (C57BL/6J=18, GABAB KO=6). Growth hormone 
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was slightly (though not significantly) decreased by GHB in both genotypes (C57BL/6J=20, 
GABAB KO=7). Nevertheless, GABAB KO mice had significantly higher values compared to 
C57BL/6J, independent of the treatment (Fig. 2b). 
Acute metabolic effects of GHB 
Metabolomics was used to evaluate the impact of GHB administration on central (cortex) 
and peripheral (liver) biochemical processes involved in the metabolism of the drug, as well as 
the effects of the drug on metabolism. Overall, 226 metabolites could be identified in the cortex 
and 314 in the liver. Supplemental Table S1 shows all detected metabolites with those that 
display significant differences between treated and control groups highlighted. 
One hour after administration, GHB was found at over 300-fold higher levels in the brain 
and nearly 200-fold in the liver. The major degradation pathway activated was GHB oxidation to 
succinic semialdehyde catalyzed by hydroxyacid-oxoacid transhydrogenase28. The rate of 
catabolism was higher in the liver than in the brain (2-hydroxyglutarate raised 29-fold in the liver 
but only 3-fold in the brain), but surprisingly glycolates as the final breakdown products were at 
7-fold in the brain and 5-fold in the liver. Interestingly, GABA was not changed despite the large 
increase in GHB, strongly suggesting that GHB is not converted to GABA even at such high 
doses. 
Glucose and many of the glycolysis metabolites glucose-6-phospahate, fructose-6- 
phosphate, fructose 1,6-diphosphate/glucose 1,6-diphosphate, were significantly increased in 
the cortex of GHB-treated mice. In GHB-treated mice there was a significant increase in 
pyruvate and  acetyl-CoA,  but  metabolites  of  the  TCA  cycle,  citrate  and  malate,  were 
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significantly decreased and, although not statistically significant, fumarate levels were also 
reduced. The limiting factor for acetyl-CoA entrance into the TCA cycle is oxaloacetate, 
which was not measured in these samples. 
A surprising finding was a large increase in lysolipids in the cortex of GHB-treated 
mice. Whether this indicates an increased membrane remodeling or an inhibition of lipid 
reacylation is difficult to disentangle. Long-chain acylcarnitines were also significantly 
increased but the ketone body 3-hydroxybutyrate (BHBA) that is made during β-oxidation was 
actually decreased. 
As opposed to the cortex, most detected metabolites in the liver were decreased in 
acutely GHB-treated mice. Amongst few exceptions, corticosterone was found at 4-fold 
higher levels after GHB. A major pathway affected by GHB in the liver was the bile acid 
metabolism, with almost all detected metabolites significantly decreased in GHB-treated 
mice. Although this finding may suggest a reduced lipid processing, no major changes in 
lipids were detected, except for an increase in docosapentaenoate (22:5n6). There was also a 
general decrease in amino acids (except for the BCAAs, as indicated above), peptides, and 
carbohydrates metabolism. 
Experiment 2 
 Respiratory ratio is reduced by GHB 
For the light period during the calorimetry, the group of C57BL/6J mice who received the 
treatment first, did not show any significant differences between the treatment and control 
sessions. For the second group (which received the placebo first and then the drug), a significant 
decrease in heat production (paired t-test, t= -2.51, p=0.01), CO2 elimination (VCO2) (paired t-
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test, t= -2.78, p=0.006), O2 consumption (VO2)  (paired t-test, t= -2.92, p=0.004) and energy 
expenditure (EE) (paired t-test, t= -2.91, p=0.003) was observed. Due to proportional decrease in 
CO2 and O2, respiratory exchange ratio (RER) was not significantly different. 
 
During the dark period, a significant decrease for Z axis activity (exploratory and possibly 
drinking – paired t-test, t= -2.75, p=0.007) and RER was observed for the first group, while in the 
second group, there was a significant decrease in feeding (Wilcoxon signed rank, W=2153, 
p<0.001) and RER (paired t-test, t= -2.63, p=0.009). There was no significant reduction in 
locomotor activity between the two conditions. In spite of between group differences for 
locomotor activity on Z axis, RER and feeding, analysis of the effect of order, treatment and their 
interaction for the dark period, indicated that the only variable which changed was RER (two-
way repeated measures ANOVA with factors “treatment” p<0.001, “order”, p=0.36, and 
“treatment × order”, p=0.793). 
 
Calculated over 24h, paired t-test (Wilcoxon signed rank) for the first group showed no 
differences between treatment and control conditions for activity, feeding, heat production, VO2 
or VCO2. The only parameter, which decreased significantly was again RER (Wilcoxon signed 
rank test, W=4833, p=0.003), and this decrease was independent of food intake. For the second 
group, feeding, VO2 (paired t-test, t=-2.569, p=0.01), VCO2 (t=-3.594, p<0.001) and RER (paired 
t-test, t=-1.997, p=0.04) were decreased. Again, when taking into account both, “treatment” and 
“order” effects, the decrease in RER was influenced by the treatment only (two-way repeated 
measures ANOVA with factors “treatment” p=0.04, “order” p=0.4 and “order by treatment” 
p=0.79). The RER changes over 96h of the experiment are reported in Figure 3. No changes in 
weight were observed. All calorimetric results are shown in Supplemental Table S2. 
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Experiment 3 
Body composition is changed by GHB 
There were no significant differences between treated and control groups for fat mass, 
lean mass, or water content evaluated by EchoMRI after 4 weeks of treatment. Statistical tests 
were performed on both absolute and relative values (calculated as percentages as compared to 
baseline). Nevertheless, the regression analysis followed by t-test showed a more balanced 
distribution of fat mass and lean mass in treated compared to control mice (t= 9.30, p<0.001). 
The higher the lean mass increase, the lower was the fat content. This suggests that in treated 
group weight loss is determined by initial fat content; body fat content is a determinant of the 
relative proportion of lean tissue loss, but the weight change is inversely correlated with relative 
increase in lean mass (tests for slopes equal 0 and 1, respectively, p<0.005 in treated mice and 
non-significant in control mice). Similar experiment performed in obese (ob/ob) mice showed a 
comparable trend, although not significant (due to a smaller change relative to their weight). 
 
Slower weight gain with GHB 
During chronic (4 weeks) administration of GHB, C57BL/6J treated mice gained less 
weight than matched controls (Figure 4). Note that at this age, weight curve is still increasing in 
both groups (two-way repeated measures ANOVA with factors “treatment” p=0.001, “week”, 
p=0.002, and “treatment × week”, p=0.27) (Fig. 4a). The same treatment in ob/ob mice showed a 
similar trend but non-significant (t-test, P=0.27, Fig. 4b). To test if the decrease in weight 
observed in treated C57BL/6J mice was related to a reduction in activity level or food intake, we 
administrated the drug in GABAB KO mice, who are behaviorally insensitive to GHB in terms of 
behavior and sleep-wake parameters5. The analysis was performed after 3 weeks of treatment in 
11 mice (6 treated and 5 controls, only 3 weeks are considered since 5 mice died during the 
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fourth week due to seizures). A significant decrease in weight was observed in treated mice (two-
way repeated measures ANOVA with factors “treatment” p=0.002, “week”, p=0.20, and 
“treatment × week”, p<0.001) (Fig. 4c). The weight loss observed in GABAB KO mice suggests 
that the effect is not centrally mediated through GABAB receptors. 
Chronic metabolic effects of GHB 
Overall, chronic GHB administration showed a different metabolic effect. As opposed to 
the acute administration, GHB levels were only marginally increased (Supplemental Table S3) 
both in the cortex and the liver while 2-hydroxyglutarate (intermediate metabolite) was still 
increased by 6-fold in the liver. Also, no changes were observed either in the glucose or the 
BCAA metabolism or their metabolites. This finding was anticipated because of the very short 
half-life of GHB (10-20min) and the fact that in the acute situation animals were injected with a 
bolus of 300mg/kg, while they consumed the same dose in their drinking water over the 12h light 
period during the 4 weeks of experiment. Although most lysolipids were unaffected by the 
chronic GHB, 1- and 2-linoleoglycerophosphocholines were still significantly increased in the 
cortex (as in the acute experiment) while significantly decreased in the liver. As in the acute 
experiment, long-chain acylcarnitines tended to be increased in the cortex, while the ketone body 
3-hydroxybutyrate was decreased both in the cortex and the liver (Fig. 5). 
S-adenosylhomocysteine was significantly decreased in the cortex (fold change=0.87, 
p<0.006) and tended to be also decreased in the liver (fold change=0.91, p<0.11). This might 
have important consequences in terms of methionine and cysteine availability. Interestingly, 
oxidized glutathione was significantly reduced together with riboflavin, while reduced 
glutathione tended to increase in the cortex of GHB-treated mice. This finding indicates that 
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GHB might have some anti-oxidant effects, as already suggested. 
GHB treatment increased the nucleotides turnover in the cortex with a significant increase 
in purinic/pyrimidinic nucleotides formation (inosine 5'-monophosphate, guanosine 5'- 
monophosphate and cytidine 5'-monophosphate) together with an increase in N-acetylmethionine. 
Low levels of allantoin, xanthine and xanthosine are in favor of the hypothesis that the increase in 
nucleotides is not resulting from intense catabolism, but rather from increased turnover. 
As opposed to the acute condition, the primary bile acids, conjugated or not, were 
unchanged in the liver after 4 weeks of GHB treatment. However, the levels of conjugated 
secondary bile acids (taurodeoxycholate and 6-β-OH-lithocholate) tended to increase (fold 
changes from 1.22 to 1.50, p values from 0.2 to 0.08), suggesting a role of transformation of 
biliary acids in the intestines and their reuptake for transport to the bile. Chronic GHB treatment 
led to the elongation of fatty acids in the liver (higher stearidonate, important for polyunsaturated 
fatty acids formation, as well as docosadienoate, and 12,13-hydroxyoctadec-9(Z)-enoate), and 
lower phosphopantetheine, suggestive of an increased fatty acids synthesis. Interestingly, treated 
mice had an increased level of omega-3 fatty acids, with known beneficial effects. An increase in 
oligosaccharides metabolism (high maltotriose), especially galactose, and a decrease in fructose 
were also observed. Tagatose, involved in the regulation of glycemic status and contributing to 
weight loss, had also higher levels in treated mice. An alternative energy pathway might be 
activated, with the use of glycerate. 
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Discussion 
Evaluation of multiple variables by indirect calorimetric measurements indicated a 
significant decrease in RER, a good marker for substrate utilization for energy production. RER 
is calculated as the ratio between VCO2 and VO2, and is used to estimate the relative proportion 
of different substrates used to produce energy. Expected values of this parameter range between 
0.7 and 1, with 1 representing pure carbohydrate use and 0.7 pure lipids use. RER values higher 
than 1 are associated with lipid synthesis and values lower than 0.7 are indicative of 
carbohydrates synthesis or ketone body metabolism29. Small changes in RER cover significant 
changes in substrate used: at 0.95, there are 82.9% carbohydrates and 17.1% fat use, while at 
0.90, carbohydrates represent 65.9% and fat 34.1%.30 
The decrease in RER was most significant during the dark period when the mice are 
active. The differences between the treatment and placebo were bigger in the second group 
(placebo given before GHB). The RER decreased progressively over the 4 days of drug 
administration and recovered also progressively during the 4 days of placebo administration, 
leading to a more pronounced effect when the drug was administered after the placebo. The 
presence of a metabolic effect after drug administration seems to be independent of locomotor 
activity and feeding. Decreased heat production observed in the second group may also be a 
consequence of increase in sleep time. Overall, these results suggest that fatty acids are preferred 
to glucose as energy substrate under GHB. An increase in lipolysis and a reduction in 
endogenous glucose production were also described in GHB treated narcolepsy patients after 3 
months.31  
As expected for the age range of the mice, both GHB treated and control animals 
followed a normal ascending growth curve, but treated animals gained significantly less weight. 
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Body composition evaluation was a continuation of the calorimetric experiment, since differences 
in energy expenditure can be explained by difference in lean mass 32. Treated mice showed a 
more balanced distribution of body composition, and the differences in weight gain were not due 
to reduced fat mass, but to increased lean mass. The relationship between lean mass and weight 
change may point to the involvement of growth hormone in the changes in body composition. 
GHB in normal subjects and patients with Parkinson disease increased growth hormone 10, 33, 34, 
and this effect was mediated by cholinergic mechanisms 34. However, growth hormone was not 
modified in our experiments as also not reported by others in rats and dogs 35. This discrepancy 
might be due to the dose (ranging from 10mg to over 1g), to the timing of the measure after drug 
administration (30min or 1h), to the technique (radioimmunoassay or ELISA), or to unknown 
between species difference. Interestingly, GABAB KO mice had constitutively higher growth 
hormone levels, suggesting that these receptors might somehow control the growth hormone 
production and/or release. Flumazenil (GABAA/benzodiazepine antagonist) and metergoline 
(serotonin receptor antagonist) were also shown to reduce or block growth hormone stimulation 
by GHB in humans and suggested a GABAergic-serotonergic mechanism36, 37. The differences in 
weight progression between treated and control mice showed a similar trend in ob/ob mice, while 
a significant difference in weight was observed in GABAB KO mice, strongly suggesting that 
weight changes induced by GHB might not be centrally mediated through either growth 
hormone, leptin, or GABAB receptors. Also, we showed here that even high doses of GHB do not 
increase GABA that could act through GABAA receptors. The lack of significant changes in 
leptin deficient mice may be due to a ceiling effect (given the morbid obesity in these mice, the 
GHB doses used here might have reached the maximum effect) or to the fact that these mice 
might need longer GHB administration to show significant changes. Recent human studies also 
suggest that metabolic effects of GHB are not leptin or ghrelin mediated38 and that GHB 
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treatment does not alter the levels of these two hormones either in narcolepsy patients or in 
healthy controls. 
The large increase in lysolipids and acylcarnitines may suggest membrane remodeling and 
increased -oxidation. Nevertheless, unlike in most tissues where acylcarnitines function in -
oxidation, in the brain they are believed to act as a sink for reacylation of phospholipids and 
triglycerides. The increase in acylcarnitines could be a result of released fatty acids from the 
phospholipids, and explain why there was no increase in overall fatty acids in the brains of GHB-
treated mice. They also may suggest that the proper balance between acyl-CoA, acyl-CoA 
synthetase, and reacylating enzymes are somehow altered in GHB-treated mice. Further 
supporting an inhibition of reacylation was the significant increase in mono- and 
diacylglycerides. 
Metabolomics analysis also revealed interesting pathways both in GHB catabolism and 
affected acutely or chronically by GHB administration. The catabolism of GHB is not well 
understood. GHB can be metabolized through -oxidation or converted to succinic semialdehyde 
either by GHB dehydrogenase or by the more recently identified hydroxyacid-oxoacid 
transhydrogenase (HOT) 28. HOT transformation of GHB into succinic semiahdehyde is coupled 
to the conversion of -ketoglutarate to 2-hydroxyglutarate and final conversion of succinic 
semiahdehyde to 4,5-dihydroxyhexanoate, while succinic semialdehyde produced by GHB 
dehydrogenase is transformed into succinate that enters the TCA cycle. Note that both pathways 
are connected to the TCA cycle through -ketoglutarate and succinate. Although we found 
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changes in all three pathways, the most consistent one was the large increase in 2-
hydroxyglutarate, strongly suggesting that the major catabolic pathway is mediated by HOT. 
 
The most impressive change after a single dose of GHB was a dramatic increase in 
peripheral corticosterone. Most metabolic changes found after acute administration of GHB may 
be mediated by the elevated corticosterone level. Although we did not measure the activity of the 
hypothalamic-pituitary-adrenal axis (especially the adrenocorticotropic hormone levels), several 
results suggest that the effect might not be centrally mediated. Corticosterone levels were 
increased both in C57BL/6J and GABAB KO mice after acute i.p. GHB administration. Also, 
other pituitary hormones, growth hormone and prolactin, were not affected by GHB. As opposed 
to growth hormone and prolactin that are stimulated in humans but not in other species, cortisol 
and corticosterone are reliably stimulated by GHB in all species39, 40. Whether changes in cortisol 
induced by GHB may also contribute to the occurrence of depression in susceptible subjects 41 
deserves further investigations. 
 
Overall, GHB induced different metabolic changes after acute and chronic administration. 
Nevertheless, as originally proposed (Laborit, 1964; Wolfson et al., 1977) glucose utilization did 
not seem to be favored either after acute or chronic GHB administration. The hypothesis that 
GHB is shifting the energy metabolism to pentose phosphate pathway 24 is only partially 
supported by our findings. The glucose availability was confirmed by the presence of very low 
levels of 1,5-anhydroglucitol, a good indicator of glucose levels, which was proposed as a marker 
for glycemic control in diabetic patients 42. GHB by inducing a global central inhibition reduces 
glucose utilization (but not availability), similar to other anesthetics. Normal or increased lactate 
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levels and decreased ketone bodies in both acute and chronic experiments suggest that the cortex 
has no deficit in ATP. 
 
The acute changes in BCAA and lysolipids are difficult to explain, although these 
changes may reflect BCAA utilization as energy substrate and transient activation of 
phospholipase A2 or inhibition of lipid reacylation. One interesting finding was a general 
decrease in bile acid metabolism after acute GHB administration. This might suggest a transient 
reduction in lipid processing resulting in lipid waste. Detailed metabolomics analysis of the 
serum might be necessary to verify if lipid reabsorption and processing is acutely altered by 
GHB. One possibility is that acute administration of high dose (with possible anesthetic-like 
effects on biliary duct and on the receptors from the intestine) blocks the feedback of biliary acids 
for short term. 
 
Given the short life of GHB, chronic administration resulted in a few different metabolic 
changes as compared to the acute situation. Decreased glutamate, s-adenosylhomocysteine, 
oxidized gluthathione, and increased omega-3 fatty acids suggest reduced oxidative stress and 
improved fatty acid metabolism. GHB was originally developed as an antioxidant agent and early 
works suggested that GHB protects against severe hypoxia, radiation, and experimental 
diabetes43-45. Although these observations could be replicated, not only for the brain protection 
but also for peripheral tissues (see review in 46), contradictory results were also reported, the 
major source being the large range of GHB doses used in various studies. Generally, when GHB 
was used at or below 300mg/kg, protective effects were observed while higher doses (500mg/kg 
or higher) suggested oxidative stress47. Nevertheless, a recent study where a single high dose 
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(1g/kg) of GHB was administered to rats, reported increased expression of genes with 
neuroplasticity and metabolic effects similar to our findings 48. 
  
In conclusion, GHB has a large and complex metabolic effect with different central versus 
periphery and acute versus chronic profiles. Overall, changes reported here not only exclude any 
major toxic effect but instead suggest that GHB might have anti-oxidant, anti-aging, and 
potentially anti-obesity properties. 
 
 
Acknowledgments 
We would like to thank Mr Yann Emmenegger for technical assistance.  
 
  
References 
1. Romanelli F, Smith KM. X, Liquid E, and Special K-The Abuse of Drugs at Clubs and Raves. 
American Journal of Pharmaceutical Education 2002;66:197-200. 
2. Laborit H, Jouany JM, Gerard J, Fabiani F. [Generalities concerning the experimental study and 
clinical use of gamma hydroxybutyrate of Na]. Agressologie 1960;1:397-406. 
3. Bessman SP, Fishbein WN. Gamma-Hydroxybutyrate, a Normal Brain Metabolite. Nature 
1963;200:1207-8. 
4. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three 
doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 
2002;25:42-9. 
5. Vienne J, Bettler B, Franken P, Tafti M. Differential effects of GABAB receptor subtypes, 
{gamma}-hydroxybutyric Acid, and Baclofen on EEG activity and sleep regulation. The Journal of 
neuroscience : the official journal of the Society for Neuroscience 2010;30:14194-204. 
6. Laborit H. Sodium 4-Hydroxybutyrate. Int J Neuropharmacol 1964;3:433-51. 
7. Snead OC, 3rd, Yu RK, Huttenlocher PR. Gamma hydroxybutyrate. Correlation of serum and 
cerebrospinal fluid levels with electroencephalographic and behavioral effects. Neurology 1976;26:51-6. 
8. Snead OC, 3rd. Pharmacological models of generalized absence seizures in rodents. J Neural 
Transm Suppl 1992;35:7-19. 
9. Vienne J, Lecciso G, Constantinescu I, et al. Differential effects of sodium oxybate and baclofen 
on EEG, sleep, neurobehavioral performance, and memory. Sleep 2012;35:1071-83. 
 
 
102 
 
10. Van Cauter E, Plat L, Scharf MB, et al. Simultaneous stimulation of slow-wave sleep and growth 
hormone secretion by gamma-hydroxybutyrate in normal young Men. The Journal of Clinical 
Investigation 1997;100:745-53. 
11. Donjacour CEHM, Aziz NA, Roelfsema F, et al. Effect of sodium oxybate on growth hormone 
secretion in narcolepsy patients and healthy controls. American Journal of Physiology - Endocrinology 
And Metabolism 2011;300:E1069-E75. 
12. Snead OC, 3rd. Gamma hydroxybutyrate. Life sciences 1977;20:1935-43. 
13. Wong CG, Gibson KM, Snead OC, 3rd. From the street to the brain: neurobiology of the 
recreational drug gamma-hydroxybutyric acid. Trends Pharmacol Sci 2004;25:29-34. 
14. Morse BL, Vijay N, Morris ME. γ-Hydroxybutyrate (GHB)-Induced Respiratory Depression: 
Combined Receptor-Transporter Inhibition Therapy for Treatment in GHB Overdose. Molecular 
Pharmacology 2012;82:226-35. 
15. Husain AM, Ristanovic RK, Bogan RK. Weight loss in narcolepsy patients treated with sodium 
oxybate. Sleep Medicine 2009;10:661-3. 
16. Spaeth M, Bennett RM, Benson BA, Wang YG, Lai C, Choy EH. Sodium oxybate therapy provides 
multidimensional improvement in fibromyalgia: results of an international phase 3 trial. Annals of the 
Rheumatic Diseases 2012;71:935-42. 
17. McElroy SL, Guerdjikova AI, Winstanley EL, et al. Sodium oxybate in the treatment of binge 
eating disorder: An open-label, prospective study. International Journal of Eating Disorders 2011;44:262-
8. 
18. Wolfson LI, Sakurada O, Sokoloff L. EFFECTS OF γ-BUTYROLACTONE ON LOCAL CEREBRAL 
GLUCOSE UTILIZATION IN THE RAT. Journal of Neurochemistry 1977;29:777-83. 
19. Artru AA, Steen PA, Michenfelder JD. gamma-Hydroxybutyrate: cerebral metabolic, vascular, and 
protective effects. J Neurochem 1980;35:1114-9. 
20. MacMillan V. Effects of gamma-hydroxybutrate and gamma-butyrolactone on cerebral energy 
metabolism during exposure and recovery from hypoxemia-oligemia. Stroke; a journal of cerebral 
circulation 1980;11:271-7. 
21. Sadasivan S, Maher TJ, Quang LS. Gamma-Hydroxybutyrate (GHB), gamma-butyrolactone (GBL), 
and 1,4-butanediol (1,4-BD) reduce the volume of cerebral infarction in rodent transient middle cerebral 
artery occlusion. Annals of the New York Academy of Sciences 2006;1074:537-44. 
22. Yosunkaya A, Ak A, Bariskaner H, Üstün ME, Tuncer S, Gürbilek M. Effect of Gamma-
Hydroxybutyric Acid on Lipid Peroxidation and Tissue Lactate Level in Experimental Head Trauma. The 
Journal of Trauma and Acute Care Surgery 2004;56:585-90. 
23. Vergoni AV, Ottani A, Botticelli AR, et al. Neuroprotective effect of gamma-hydroxybutyrate in 
transient global cerebral ischemia in the rat. European journal of pharmacology 2000;397:75-84. 
24. Taberner PV, Rick JT, Kerkut GA. THE ACTION OF GAMMA-HYDROXYBUTYRIC ACID ON CEREBRAL 
GLUCOSE METABOLISM. Journal of Neurochemistry 1972;19:245-54. 
25. Schuler V, Luscher C, Blanchet C, et al. Epilepsy, hyperalgesia, impaired memory, and loss of pre- 
and postsynaptic GABA(B) responses in mice lacking GABA(B(1)). Neuron 2001;31:47-58. 
26. Zhang S, Zeitzer JM, Sakurai T, Nishino S, Mignot E. Sleep/wake fragmentation disrupts 
metabolism in a mouse model of narcolepsy. The Journal of Physiology 2007;581:649-63. 
27. Hinard V, Mikhail C, Pradervand S, et al. Key Electrophysiological, Molecular, and Metabolic 
Signatures of Sleep and Wakefulness Revealed in Primary Cortical Cultures. Journal of Neuroscience 
2012;32:12506-17. 
28. Struys EA, Verhoeven NM, Ten Brink HJ, Wickenhagen WV, Gibson KM, Jakobs C. Kinetic 
characterization of human hydroxyacid-oxoacid transhydrogenase: relevance to D-2-hydroxyglutaric and 
gamma-hydroxybutyric acidurias. J Inherit Metab Dis 2005;28:921-30. 
 
 
103 
 
29. Riachi M, Himms-Hagen J, Harper ME. Percent relative cumulative frequency analysis in indirect 
calorimetry: application to studies of transgenic mice. Canadian journal of physiology and pharmacology 
2004;82:1075-83. 
30. McLean J.A. TG. Animal and Human Calorimetry: Cambridge Univ. Press, 1987. 
31. Donjacour CE, Aziz NA, Overeem S, Kalsbeek A, Pijl H, Lammers GJ. Glucose and fat metabolism 
in narcolepsy and the effect of sodium oxybate: a hyperinsulinemic-euglycemic clamp study. Sleep 
2014;37:795-801. 
32. Blundell JE, Caudwell P, Gibbons C, et al. Role of resting metabolic rate and energy expenditure 
in hunger and appetite control: a new formulation. Disease models & mechanisms 2012;5:608-13. 
33. Takahara J, Yunoki S, Yakushiji W, Yamauchi J, Yamane Y. Stimulatory effects of gamma-
hydroxybutyric acid on growth hormone and prolactin release in humans. J Clin Endocrinol Metab 
1977;44:1014-7. 
34. Volpi R, Chiodera P, Caffarra P, et al. Muscarinic cholinergic mediation of the GH response to 
gamma-hydroxybutyric acid: neuroendocrine evidence in normal and parkinsonian subjects. 
Psychoneuroendocrinology 2000;25:179-85. 
35. Rigamonti AE, Muller EE. Gamma-hydroxybutyric acid and growth hormone secretion studies in 
rats and dogs. Alcohol 2000;20:293-304. 
36. Gerra G, Caccavari R, Fontanesi B, et al. Naloxone and metergoline effects on growth hormone 
response to gamma-hydroxybutyric acid. Int Clin Psychopharmacol 1995;10:245-50. 
37. Gerra G, Caccavari R, Fontanesi B, et al. Flumazenil effects on growth hormone response to 
gamma-hydroxybutyric acid. Int Clin Psychopharmacol 1994;9:211-5. 
38. Donjacour CE, Pardi D, Aziz NA, et al. Plasma total ghrelin and leptin levels in human narcolepsy 
and matched healthy controls: basal concentrations and response to sodium oxybate. Journal of clinical 
sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2013;9:797-803. 
39. Van Cauter E, Plat L, Scharf MB, et al. Simultaneous stimulation of slow-wave sleep and growth 
hormone secretion by gamma-hydroxybutyrate in normal young Men. J Clin Invest 1997;100:745-53. 
40. Meerlo P, Westerveld P, Turek FW, Koehl M. Effects of gamma-hydroxybutyrate (GHB) on 
vigilance states and EEG in mice. Sleep 2004;27:899-904. 
41. Rossetti AO, Heinzer RC, Tafti M, Buclin T. Rapid occurrence of depression following addition of 
sodium oxybate to modafinil. Sleep Med 2010;11:500-1. 
42. Suhre K, Meisinger C, Döring A, et al. Metabolic Footprint of Diabetes: A Multiplatform 
Metabolomics Study in an Epidemiological Setting. PLoS ONE 2010;5:e13953. 
43. Pierrefiche G, Topall G, Henriet I, Laborit H. Protective effects of gamma-hydroxybutyrate on 
alloxan induced diabetes in mice. Res Commun Chem Pathol Pharmacol 1991;71:309-19. 
44. Laborit G, Baron C, Topal G, Henriet I. [Value of sodium gamma hydroxybutyrate in cerebral 
protection during severe hypoxia in the rat]. Agressologie 1980;21:189-97. 
45. Dana M, Baron C, Laborit H. [Radioprotective action of sodium gamma-hydroxybutyrate 
(preliminary notes)]. Agressologie 1962;3:497-506. 
46. Mamelak M. Alzheimer' s disease, oxidative stress and gammahydroxybutyrate. Neurobiology of 
aging 2007;28:1340-60. 
47. van Nieuwenhuijzen PS, Kashem MA, Matsumoto I, Hunt GE, McGregor IS. A long hangover from 
party drugs: residual proteomic changes in the hippocampus of rats 8 weeks after gamma-
hydroxybutyrate (GHB), 3,4-methylenedioxymethamphetamine (MDMA) or their combination. 
Neurochem Int 2010;56:871-7. 
48. Kemmel V, Klein C, Dembele D, et al. A single acute pharmacological dose of gamma-
hydroxybutyrate modifies multiple gene expression patterns in rat hippocampus and frontal cortex. 
Physiological genomics 2010;41:146-60. 
 
 
 
104 
 
Figure Legends 
 Figure 1. Study design presenting experiments to determine acute, short-term, and 
chronic metabolic effects of GHB. *-start of the experiment; ‡ - end of the experiment; 1- GHB 
was administrated in the drinking water. 
Figure 2. Effects of acute intraperitoneal administration of 300 mg GHB/kg on 
corticosterone (a) and growth hormone (b) in C57BL/6J and GABAB KO mice. Corticosterone 
was significantly elevated in treated C57BL/6J and GABAB KO mice (two-way ANOVA 
followed by Holm-Sidak post hoc test for “treatment”, p<0.001; “genotype”, p>0.05; and their 
interaction, p>0.05, N=20 for C57BL/6J and N=7 for GABAB KO mice). Growth hormone was 
not affected by treatment (p=0.36), but GABAB KO mice had significantly higher levels 
compared with C57BL/6J mice (p<0.001 for “genotype”, p>0.05 for “treatment” and their 
interaction; N=17 for C57BL/6J and N=7 for GABAB KO mice). *p<0.05 between the treated 
and the control group; #p<0.05 between genotypes.  
 
. Figure 3. Effects of GHB administration on RER. Data are presented as percentage of the 
mean of the first 4h of the baseline. Two-way repeated measures ANOVA for factors 
“treatment”, “time-point”, and their interaction, followed by Holm-Sidak post hoc test, p<0.001 
for “treatment” and “time-point”; black lines connect significant different time-points between 
treated and control mice, p<0.05. 
 
Figure 4. Relative weight change calculated as a percentage of the initial weight, in 
GHB-treated and control groups (black and grey bars, respectively).  (a) Two-way repeated 
measures ANOVA for factors “treatment”, “week” and their interaction, followed by Holm-Sidak 
post hoc test showed that the weight gain by C57BL/6J mice in the treated group was 
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significantly less compared to the control group; *p<0.05, N=20. Lines connect weeks for which 
significant differences were found. (b) The weight gain in ob/ob treated group was lower 
compared to the control group, but not significantly different between the treated and the control 
group (N=16). (c) GABAB KO treated mice lost weight compared with the control mice; 
*p<0.05, N=11. 
 
Figure 5. Main metabolic changes after chronic administration of GHB. On the left side 
liver metabolic changes are presented, and brain metabolic changes are represented on the right 
side of the figure. Box plots (p<0.05) for some of significant changes are presented in red for 
liver and blue for the brain. HOT: hydroxyacid-oxoacid transhydrogenase; FA: fatty acids; TCA: 
tricarboxylic acid; beta-Ox: beta-oxidation; GSSG: glutathione oxidized; GSH: glutathione, 
reduced; 5’-AMP: adenosine 5'-monophosphate; 5’-CMP: cytidine 5'-monophosphate; 5'-GMP: 
guanosine 5'- monophosphate; BHBA: 3-hydroxybutyrate. 
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Supplemental Table S1 
Increased p<0.05 Decreased p<0.05 
Suggestive Change 
p<0.1 Suggestive Change p<0.1 
ACUTE 
BRAIN LIVER 
BIOCHEMICAL NAME fold change p value BIOCHEMICAL NAME fold change p value 
4-hydroxybutyrate (GHB) 323.20 < 0.001 4-hydroxybutyrate (GHB) 191.67 < 0.001 
glycolate 
(hydroxyacetate) 7.24 < 0.001 2-hydroxyglutarate 28.75 < 0.001 
1-
docosahexaenoylglycerop
hosphocholine* 
4.15 0.0013 glycolate (hydroxyacetate) 4.96 0.0227 
Isobar: fructose 1,6-
diphosphate, glucose 1,6-
diphosphate 
3.54 0.0376 corticosterone 3.85 < 0.001 
sphingosine 3.32 0.0028 hexadecanedioate 2.11 0.0107 
2-
palmitoleoylglycerophosp
hoethanolamine* 
3.22 0.0019 1-methylimidazoleacetate 2.03 < 0.001 
1-
stearoylglycerophosphoc
holine 
3.22 0.0049 3-(4-hydroxyphenyl)lactate 1.96 < 0.001 
stearoylcarnitine 3.21 0.0112 creatinine 1.92 0.0078 
1-
oleoylglycerophosphochol
ine 
3.09 0.0034 succinyl CoA 1.89 0.0024 
1-
stearoylglycerophosphoet
hanolamine 
3.06 0.0044 isovalerylglycine 1.74 0.0073 
palmitoylcarnitine 3.02 0.0092 glycylproline 1.56 0.0186 
2-
docosahexaenoylglycerop
hosphocholine* 
2.96 0.0014 choline phosphate 1.40 0.0063 
2-
myristoylglycerophosphoc
holine* 
2.90 0.0045 
adenosine 3'-
monophosphate (3'-
AMP) 
1.34 0.0230 
2-
palmitoleoylglycerophosp
hocholine* 
2.86 0.0017 dimethylglycine 1.30 0.0281 
2-
linoleoylglycerophosphoc
holine* 
2.86 0.0022 docosapentaenoate (n6 DPA; 22:5n6) 1.27 0.0433 
2-
arachidonoylglycerophos
phocholine* 
2.86 0.0054 hypoxanthine 1.26 0.0455 
2-
docosapentaenoylglycero
phosphoethanolamine* 
2.84 0.0096 isoleucine 1.23 0.0213 
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oleoylcarnitine 2.81 0.0145 valine 1.22 0.0313 
2-hydroxyglutarate 2.77 < 0.001 flavin mononucleotide (FMN) 1.15 0.0365 
fructose 2.77 0.0011 sucrose 0.20 0.0098 
1-
linoleoylglycerophosphoc
holine 
2.65 0.0302 tauroursodeoxycholate 0.21 0.0034 
2-
linoleoylglycerophosphoet
hanolamine* 
2.57 < 0.001 gamma-glutamylthreonine* 0.25 < 0.001 
2-
palmitoylglycerophosphoc
holine* 
2.53 0.0072 tauro-beta-muricholate 0.40 0.0061 
1-
palmitoleoylglycerophosp
hocholine* 
2.50 0.0035 taurodeoxycholate 0.41 0.0012 
1-
myristoylglycerophosphoc
holine 
2.49 < 0.001 taurochenodeoxycholate 0.43 < 0.001 
2-
oleoylglycerophosphochol
ine* 
2.44 0.0070 cinnamoylglycine 0.44 0.0018 
1-
palmitoylglycerophosphoc
holine 
2.32 0.0062 taurocholate 0.47 0.0011 
2-
palmitoylglycerophosphoe
thanolamine* 
2.32 0.0065 6-beta-hydroxylithocholate 0.47 0.0019 
2-
docosahexaenoylglycerop
hosphoethanolamine* 
2.12 0.0036 alpha-muricholate 0.48 < 0.001 
2-
arachidonoylglycerophos
phoethanolamine* 
1.99 0.0096 valerylglycine 0.53 < 0.001 
2-
oleoylglycerophosphoeth
anolamine* 
1.92 0.0097 beta-muricholate 0.53 0.0057 
S-lactoylglutathione 1.83 0.0335 cholate 0.53 0.0356 
1-oleoylglycerol (1-
monoolein) 1.72 0.0166 ophthalmate 0.54 0.0050 
acetyl CoA 1.65 0.0167 sarcosine (N-Methylglycine) 0.57 0.0012 
2-palmitoylglycerol (2-
monopalmitin) 1.61 0.0074 sorbitol 0.57 0.0013 
1-palmitoylglycerol (1-
monopalmitin) 1.59 0.0118 
2-
methylbutyroylcarnitine 0.57 0.0099 
1-stearoylglycerol (1-
monostearin) 1.48 0.0288 alanylleucine 0.58 0.0095 
2-stearoylglycerol (2-
monostearin) 1.44 0.0099 gulono-1,4-lactone 0.60 0.0013 
beta-alanine 1.42 0.0275 glutamate 0.61 0.0019 
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pyruvate 1.27 0.0497 xanthosine 0.62 0.0019 
valine 1.26 0.0029 N-acetylglutamine 0.65 0.0015 
glycerol 2-phosphate 1.21 0.0484 alanine 0.66 < 0.001 
N-acetylmethionine 1.18 0.0331 glutamine 0.66 < 0.001 
oleate (18:1n9) 1.17 0.0313 1,3-dihydroxyacetone 0.67 0.0016 
lactate 1.15 0.0029 5-aminovalerate 0.69 0.0051 
cis-vaccenate (18:1n7) 1.15 0.0418 3-phosphoglycerate 0.71 0.0282 
aspartate 1.10 0.0473 glycerophosphorylcholine (GPC) 0.72 0.0450 
N-acetylaspartate (NAA) 1.05 0.0082 gamma-glutamylvaline 0.73 0.0132 
2-aminoadipate 0.59 0.0016 alanylvaline 0.74 0.0312 
2-methylbutyroylcarnitine 0.66 0.0046 creatine 0.75 0.0399 
alpha-hydroxyisovalerate 0.67 < 0.001 ribitol 0.75 0.0463 
isobutyrylcarnitine 0.70 0.0071 glycylleucine 0.78 0.0292 
spermidine 0.70 0.0344 ribose 0.78 0.0350 
caproate (6:0) 0.72 0.0029 xylitol 0.79 0.0121 
propionylcarnitine 0.73 0.0124 lactate 0.81 0.0169 
isovalerylcarnitine 0.75 0.0406 beta-hydroxypyruvate 0.81 0.0273 
3-hydroxybutyrate 
(BHBA) 0.77 0.0116 myo-inositol 0.83 0.0451 
butyrylcarnitine 0.78 0.0351 gamma-glutamylleucine 0.84 0.0085 
malate 0.80 0.0027 glycerol 0.89 0.0413 
gamma-
glutamylglutamate 0.81 < 0.001 glucose 0.90 0.0070 
5-methylthioadenosine 
(MTA) 0.82 0.0026 cytidine 1.63 0.0534 
citrate 0.84 0.0453 betaine aldehyde 1.49 0.0928 
glutamate 0.85 0.0028 homoserine 1.37 0.0584 
nicotinamide 0.85 0.0128 
adenosine 2'-
monophosphate (2'-
AMP) 
1.33 0.0781 
carnitine 0.87 0.0213 imidazole lactate 1.27 0.0548 
choline phosphate 0.89 0.0099 lysine 1.23 0.0586 
2-
stearoylglycerophosphoc
holine* 
2.65 0.0569 riboflavin (Vitamin B2) 1.23 0.0903 
alpha-tocopherol 1.50 0.0543 citrulline 1.21 0.0938 
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docosapentaenoate (n6 
DPA; 22:5n6) 1.33 0.0741 tryptophan 1.19 0.0659 
Isobar: ribulose 5-
phosphate, xylulose 5-
phosphate 
1.25 0.0558 inosine 5'-monophosphate (IMP) 0.24 0.0945 
1,3-dipalmitoylglycerol 1.25 0.0861 2-aminoadipate 0.64 0.0535 
prostaglandin E2 1.24 0.0928 acetylcarnitine 0.64 0.0756 
1,2-dipalmitoylglycerol 1.23 0.0979 1-linoleoylglycerol (1-monolinolein) 0.64 0.0821 
tryptophan 1.22 0.0910 phosphoenolpyruvate (PEP) 0.71 0.0858 
docosahexaenoate (DHA; 
22:6n3) 1.15 0.0838 glycerate 0.75 0.0575 
leucine 1.13 0.0889 glycerol 2-phosphate 0.75 0.0938 
cholesterol 1.12 0.0513 3-aminoisobutyrate 0.81 0.0620 
caprylate (8:0) 0.85 0.0797 2-aminobutyrate 0.83 0.0822 
10-heptadecenoate 
(17:1n7) 0.86 0.0775 trans-4-hydroxyproline 0.84 0.0873 
taurine 0.87 0.0513 5-oxoproline 0.87 0.0992 
N-acetylglutamate 0.92 0.0528 methylglutaroylcarnitine 1.24 0.1005 
S-adenosylhomocysteine 
(SAH) 0.90 0.1102 
cysteine-glutathione 
disulfide 1.33 0.1009 
phosphoethanolamine 0.95 0.1123 xanthine 1.15 0.1021 
glucose 1.71 0.1134 glutarate (pentanedioate) 1.30 0.1028 
pipecolate 0.87 0.1146 ribulose 0.84 0.1057 
sorbitol 1.38 0.1164 3-hydroxybutyrate (BHBA) 0.77 0.1090 
uridine 1.11 0.1175 12,13-hydroxyoctadec-9(Z)-enoate 0.75 0.1095 
4-guanidinobutanoate 0.91 0.1228 pyridoxal 1.36 0.1208 
C-glycosyltryptophan* 0.92 0.1248 leucine 1.11 0.1223 
adenosine 2'-
monophosphate (2'-AMP) 1.18 0.1269 
flavin adenine 
dinucleotide (FAD) 1.10 0.1268 
2-phosphoglycerate 1.93 0.1274 thiamin (Vitamin B1) 0.90 0.1348 
1-
palmitoylglycerophosphoe
thanolamine 
1.20 0.1313 threonate 0.72 0.1349 
prostaglandin D2 1.29 0.1389 pyridoxate 1.33 0.1353 
glycerol 3-phosphate 
(G3P) 1.19 0.1407 guanosine 1.34 0.1386 
3-phosphoglycerate 1.58 0.1417 gluconate 0.87 0.1390 
sarcosine (N-
Methylglycine) 1.13 0.1506 cysteinylglycine 0.74 0.1395 
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isoleucine 1.09 0.1533 adrenate (22:4n6) 1.18 0.1422 
glycylleucine 0.72 0.1577 
1-
pentadecanoylglyceroph
osphocholine* 
1.17 0.1466 
palmitoleate (16:1n7) 0.90 0.1686 phenylalanine 1.13 0.1467 
5-aminovalerate 0.79 0.1690 coenzyme A 0.76 0.1469 
pseudouridine 0.93 0.1732 luteolin-7-O-glucoside 0.82 0.1517 
glutathione, oxidized 
(GSSG) 0.90 0.1927 
1,5-anhydroglucitol (1,5-
AG) 0.81 0.1631 
creatinine 0.93 0.1940 beta-alanine 0.74 0.1684 
coenzyme A 1.41 0.1961 hexanoylglycine 0.83 0.1696 
glycine 1.08 0.1999 hydroxyisovaleroyl carnitine 1.16 0.1731 
1-
arachidonoylglycerophos
phoinositol* 
1.19 0.2076 kynurenine 1.23 0.1828 
N-acetylneuraminate 1.09 0.2097 alpha-tocopherol 1.22 0.1853 
acetylphosphate 0.87 0.2139 glycylvaline 1.11 0.1918 
creatine 0.95 0.2165 
cytidine 5'-
monophosphate (5'-
CMP) 
1.15 0.1964 
arginine 0.94 0.2213 
Isobar: fructose 1,6-
diphosphate, glucose 
1,6-diphosphate 
0.47 0.1966 
gamma-aminobutyrate 
(GABA) 0.93 0.2234 
5-methylthioadenosine 
(MTA) 0.79 0.2064 
sedoheptulose-7-
phosphate 1.35 0.2372 malate 0.91 0.2092 
3'-dephosphocoenzyme A 1.52 0.2407 nonadecanoate (19:0) 1.15 0.2123 
N-acetylalanine 0.88 0.2446 ethyl glucuronide 0.47 0.2143 
serine 0.95 0.2475 docosahexaenoate (DHA; 22:6n3) 1.14 0.2162 
ribose 5-phosphate 1.18 0.2483 12-dehydrocholate 0.67 0.2175 
glutamine 1.15 0.2704 glucuronate 1.07 0.2242 
1-
oleoylglycerophosphoeth
anolamine 
1.16 0.2802 
1-
arachidonoylglycerophos
phoinositol* 
1.20 0.2281 
homocarnosine 0.92 0.2888 dimethylarginine (SDMA + ADMA) 1.21 0.2300 
acetylcarnitine 0.86 0.3050 malonylcarnitine 0.87 0.2365 
palmitoyl sphingomyelin 1.08 0.3125 glycine 1.08 0.2367 
7-alpha-
hydroxycholesterol 1.14 0.3221 N-acetylasparagine 0.87 0.2372 
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arabitol 1.14 0.3276 myristoleate (14:1n5) 1.08 0.2372 
 proline 1.07 0.3361 arachidonate (20:4n6) 1.13 0.2381 
 cytidine 5'-
monophosphate (5'-CMP) 0.89 0.3454 
3'-dephosphocoenzyme 
A 0.90 0.2382 
 glycerol 0.97 0.3548 sphingosine 1.11 0.2395 
 
pyrophosphate (PPi) 0.85 0.4002 5-methyltetrahydrofolate (5MeTHF) 1.36 0.2502 
 glutaroyl carnitine 0.92 0.4018 fructose 0.91 0.2514 
 
mannose-6-phosphate 1.33 0.4063 
1-
heptadecanoylglyceroph
osphocholine 
1.20 0.2593 
 adenine 0.94 0.4231 biopterin 1.17 0.2606 
 arabinose 1.11 0.4236 pyroglutamine* 1.15 0.2607 
 
urea 0.96 0.4267 
1-
palmitoleoylglycerophos
phocholine* 
0.89 0.2645 
 1-methylimidazoleacetate 0.91 0.4407 methionine 1.12 0.2682 
 
adenosine 0.86 0.4448 adenosine 5'diphosphoribose 0.37 0.2693 
 pantothenate 0.96 0.4466 threonine 1.08 0.2706 
 
dihomo-linoleate (20:2n6) 1.12 0.4481 glutathione, reduced (GSH) 0.89 0.2717 
 guanosine 0.90 0.4503 6-phosphogluconate 1.14 0.2815 
 N-acetyl-aspartyl-
glutamate (NAAG) 1.06 0.4507 N-acetylglutamate 1.07 0.2921 
 linoleate (18:2n6) 1.11 0.4510 acetylphosphate 0.86 0.2969 
 stearoyl sphingomyelin 1.07 0.4556 spermidine 0.92 0.2996 
 1-
oleoylglycerophosphoseri
ne 
1.11 0.4644 allantoin 0.78 0.2998 
 argininosuccinate 0.96 0.4645 uridine 1.09 0.3015 
 
erythronate* 1.04 0.4737 
1-
stearoylglycerophosphoc
holine 
0.86 0.3059 
 
ribose 1.11 0.4809 
2-
arachidonoylglycerophos
phocholine* 
0.93 0.3181 
 5-HETE 0.95 0.4823 uracil 1.15 0.3331 
 
myo-inositol 0.95 0.4846 
1-
docosahexaenoylglycero
phosphocholine* 
1.18 0.3349 
 
scyllo-inositol 0.92 0.4921 
1-
oleoylglycerophosphoino
sitol* 
1.17 0.3406 
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glycerate 1.07 0.4939 glycylglycine 1.13 0.3411 
 1-
stearoylglycerophosphoin
ositol 
1.07 0.4944 caprylate (8:0) 0.88 0.3546 
 
mead acid (20:3n9) 1.09 0.4989 
2-
arachidonoylglycerophos
phoinositol* 
1.14 0.3587 
 
inositol 2-phosphate (I2P) 1.08 0.5102 dihomo-linolenate (20:3n3 or n6) 1.09 0.3595 
 lysine 0.95 0.5126 myristate (14:0) 1.04 0.3627 
 1-
palmitoylglycerophosphoi
nositol* 
1.07 0.5134 adenine 1.23 0.3667 
 carnosine 1.04 0.5164 taurine 1.09 0.3697 
 
flavin adenine 
dinucleotide (FAD) 1.01 0.5255 
2-
palmitoleoylglycerophos
phocholine* 
0.85 0.3707 
 
ascorbate (Vitamin C) 0.92 0.5287 2-oleoylglycerol (2-monoolein) 0.81 0.3711 
 
phenylalanine 1.06 0.5449 
2-
docosahexaenoylglycero
phosphocholine* 
0.94 0.3747 
 
methionine 0.97 0.5455 glutathione, oxidized (GSSG) 1.08 0.3831 
 fumarate 0.82 0.5462 serine 1.07 0.3856 
 2-pyrrolidinone 1.16 0.5595 maltohexaose 1.17 0.3938 
 1-
oleoylglycerophosphoinos
itol* 
1.05 0.5673 
Isobar: ribulose 5-
phosphate, xylulose 5-
phosphate 
0.83 0.3938 
 inosine 1.03 0.5736 laurate (12:0) 1.05 0.4017 
 deoxycarnitine 0.94 0.5772 N-glycolylneuraminate 0.91 0.4041 
 myristate (14:0) 0.99 0.5989 butyrylglycine 0.89 0.4049 
 13-HODE + 9-HODE 0.92 0.5991 maltopentaose 1.12 0.4104 
 gamma-glutamylleucine 1.06 0.6105 palmitoyl ethanolamide 0.73 0.4199 
 N-acetylglutamine 1.00 0.6159 glycylphenylalanine 0.87 0.4210 
 
adrenate (22:4n6) 1.13 0.6234 glycerol 3-phosphate (G3P) 0.90 0.4229 
 
ophthalmate 0.96 0.6276 methyl palmitate (15 or 2) 1.05 0.4259 
 3-phosphoserine 1.92 0.6330 propionylcarnitine 1.35 0.4312 
 1-
palmitoylplasmenylethano
lamine* 
1.05 0.6338 erythronate* 0.92 0.4347 
 
threonine 1.04 0.6373 2-linoleoylglycerophospho 0.96 0.4399 
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choline* 
stearate (18:0) 0.98 0.6382 
1-
eicosatrienoylglyceropho
sphocholine* 
0.91 0.4400 
 anserine 1.05 0.6408 carnitine 0.95 0.4496 
 3-(4-
hydroxyphenyl)lactate 1.00 0.6480 phenylacetylglycine 0.82 0.4516 
 ergothioneine 0.95 0.6550 urate 1.34 0.4522 
 phosphate 1.01 0.6607 n-Butyl Oleate 0.91 0.4538 
 myristoleate (14:1n5) 0.96 0.6645 tagatose 1.33 0.4544 
 gamma-
glutamylglutamine 1.04 0.6777 
adenosine 5'-
monophosphate (AMP) 0.75 0.4553 
 
tyrosine 1.09 0.6850 10-nonadecenoate (19:1n9) 1.09 0.4566 
 pyroglutamine* 1.08 0.6854 3-indoxyl sulfate 0.91 0.4591 
 1-
arachidonoylglycerophos
phoethanolamine* 
0.94 0.6908 nicotinamide 0.95 0.4597 
 
xanthine 1.04 0.7007 
1-
stearoylglycerophosphoi
nositol 
1.17 0.4630 
 cysteine 1.09 0.7102 phosphoethanolamine 0.91 0.4651 
 hypoxanthine 1.03 0.7121 4-guanidinobutanoate 1.16 0.4657 
 
margarate (17:0) 1.07 0.7165 
1-
arachidonoylglycerophos
phoethanolamine* 
1.28 0.4708 
 arachidonate (20:4n6) 1.04 0.7327 proline 1.06 0.4800 
 palmitate (16:0) 1.03 0.7448 1,3-dipalmitoylglycerol 1.07 0.4800 
 glucose-6-phosphate 
(G6P) 1.26 0.7513 palmitate (16:0) 1.06 0.4872 
 urate 1.12 0.7555 choline 1.07 0.4885 
 pelargonate (9:0) 0.99 0.7567 pro-hydroxy-pro 0.89 0.4906 
 laurate (12:0) 1.01 0.7752 succinylcarnitine 0.87 0.4926 
 methylphosphate 1.04 0.7753 thymidine 1.18 0.4947 
 
3-dehydrocarnitine* 0.97 0.7826 
1-
palmitoylglycerophospho
inositol* 
1.16 0.4997 
 trans-4-hydroxyproline 1.08 0.7830 mannose-6-phosphate 1.17 0.5008 
 
2-hydroxybutyrate (AHB) 0.97 0.7849 
1-
arachidoylglycerophosph
ocholine 
0.81 0.5052 
 adenosine 5'-
monophosphate (AMP) 0.84 0.7866 
cytidine 5'-
diphosphocholine 0.84 0.5155 
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chiro-inositol 1.00 0.8113 dihomo-linoleate (20:2n6) 1.07 0.5206 
 allo-threonine 1.01 0.8188 homostachydrine* 0.89 0.5217 
 homoserine 1.02 0.8260 methylphosphate 0.80 0.5287 
 
caprate (10:0) 0.99 0.8337 nicotinamide adenine dinucleotide (NAD+) 1.05 0.5323 
 glutamate, gamma-methyl 
ester 1.00 0.8415 maltotriose 0.94 0.5340 
 dehydroascorbate 1.05 0.8586 urea 0.96 0.5380 
 docosapentaenoate (n3 
DPA; 22:5n3) 1.08 0.8589 2-hydroxybutyrate (AHB) 1.13 0.5385 
 nicotinamide adenine 
dinucleotide (NAD+) 1.02 0.8607 glutaroyl carnitine 1.20 0.5387 
 hydroxyisovaleroyl 
carnitine 0.99 0.8633 7,8-dihydrofolate 1.08 0.5389 
 allantoin 0.94 0.8674 isobutyrylcarnitine 0.84 0.5409 
 
mannitol 1.02 0.8703 glutamate, gamma-methyl ester 0.75 0.5477 
 dihomo-linolenate (20:3n3 
or n6) 0.99 0.8809 pipecolate 1.06 0.5497 
 7-beta-hydroxycholesterol 1.01 0.8817 C-glycosyltryptophan* 1.05 0.5511 
 cytidine 1.01 0.9030 stearoyl sphingomyelin 0.95 0.5602 
 
fructose-6-phosphate 1.14 0.9091 
2-
docosahexaenoylglycero
phosphoethanolamine* 
1.05 0.5606 
 
linolenate [alpha or 
gamma; (18:3n3 or 6)] 0.99 0.9165 
nicotinamide adenine 
dinucleotide reduced 
(NADH) 
1.09 0.5631 
 10-nonadecenoate 
(19:1n9) 1.01 0.9208 aspartate 0.97 0.5644 
 
inositol 1-phosphate (I1P) 0.99 0.9306 docosatrienoate (22:3n3) 1.11 0.5649 
 
24(S)-hydroxycholesterol 0.98 0.9314 
1-
eicosadienoylglyceropho
sphocholine* 
1.12 0.5750 
 1,5-anhydroglucitol (1,5-
AG) 1.02 0.9358 S-methylglutathione 1.11 0.5823 
 eicosenoate (20:1n9 or 
11) 1.02 0.9370 2-phosphoglycerate 0.88 0.5844 
 alanine 1.00 0.9403 tetradecanedioate 1.16 0.5873 
 
uracil 1.01 0.9495 
1-
linoleoylglycerophospho
choline 
0.94 0.5897 
 
5-oxoproline 1.02 0.9615 
1-
linoleoylglycerophospho
ethanolamine* 
1.09 0.5912 
 ethanolamine 1.02 0.9687 asparagine 0.91 0.5918 
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glycerophosphorylcholine 
(GPC) 1.05 0.9739 hypotaurine 1.09 0.5961 
 N-formylmethionine 1.01 0.9746 phosphate 1.02 0.5988 
 cysteine-glutathione 
disulfide 1.02 0.9774 
dihydroxyacetone 
phosphate (DHAP) 0.80 0.6021 
 glutathione, reduced 
(GSH) 1.09 0.9989 heme* 1.07 0.6076 
 
   
azelate (nonanedioate) 0.92 0.6079 
 
   
gamma-
glutamylglutamate 0.97 0.6122 
 
   
2-
linoleoylglycerophospho
ethanolamine* 
1.04 0.6130 
 
   
docosadienoate (22:2n6) 1.07 0.6202 
 
   
eicosapentaenoate 
(EPA; 20:5n3) 0.96 0.6257 
 
   
stearate (18:0) 1.06 0.6265 
 
   
3-dehydrocarnitine* 1.12 0.6276 
 
   
5-methylcytidine 0.82 0.6342 
 
   
2-
arachidonoylglycerophos
phoethanolamine* 
1.03 0.6436 
 
   
1-palmitoylglycerol (1-
monopalmitin) 1.18 0.6462 
 
   
guanosine 5'- 
monophosphate (5'-
GMP) 
0.73 0.6480 
 
   
margarate (17:0) 1.03 0.6529 
 
   
S-
adenosylhomocysteine 
(SAH) 
1.06 0.6610 
 
   
uridine monophosphate 
(5' or 3') 0.75 0.6728 
 
   
ribose 5-phosphate 0.94 0.6732 
 
   
xylonate 0.97 0.6790 
 
   
ethanolamine 1.05 0.6790 
 
   
N-acetylmethionine 0.96 0.6803 
 
   
cholesterol 1.03 0.6830 
 
   
1-
oleoylglycerophosphoch
oline 
0.97 0.6836 
 
   
13-HODE + 9-HODE 0.97 0.6890 
 
   
1-
palmitoylglycerophospho 0.99 0.6905 
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choline 
   
N-acetylneuraminate 0.96 0.6979 
 
   
Isobar: 2-
propylpentanoic acid, 2-
ethylhexanoic acid 
1.02 0.7054 
 
   
2-
oleoylglycerophosphoch
oline* 
0.97 0.7064 
 
   
10-heptadecenoate 
(17:1n7) 1.02 0.7146 
 
   
cysteine 0.97 0.7161 
 
   
7-alpha-
hydroxycholesterol 1.05 0.7292 
 
   
glycyltyrosine 0.96 0.7300 
 
   
7-beta-
hydroxycholesterol 1.00 0.7336 
 
   
2-
oleoylglycerophosphoeth
anolamine* 
1.03 0.7348 
 
   
pantothenate 0.97 0.7353 
 
   
1-
myristoylglycerophospho
choline 
0.97 0.7367 
 
   
methionine sulfoxide 0.99 0.7382 
 
   
N-acetylleucine 0.96 0.7497 
 
   
16-hydroxypalmitate 1.02 0.7659 
 
   
adenosine 0.96 0.7664 
 
   
N-acetylalanine 1.05 0.7680 
 
   
eicosenoate (20:1n9 or 
11) 0.94 0.7695 
 
   
glucose-6-phosphate 
(G6P) 0.92 0.7778 
 
   
fumarate 0.98 0.7847 
 
   
ergothioneine 1.05 0.7853 
 
   
mannose 1.01 0.7934 
 
   
N-acetylornithine 1.00 0.7934 
 
   
fructose-6-phosphate 0.97 0.8017 
 
   
caproate (6:0) 1.01 0.8063 
 
   
2-
stearoylglycerophosphoc
holine* 
0.87 0.8100 
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phosphopantetheine 1.03 0.8165 
 
   
linoleate (18:2n6) 1.03 0.8201 
 
   
maltose 0.95 0.8221 
 
   
palmitoleate (16:1n7) 0.97 0.8340 
 
   
stachydrine 1.01 0.8371 
 
   
1-
stearoylglycerophospho
ethanolamine 
1.07 0.8375 
 
   
tyrosine 0.99 0.8384 
 
   
1-stearoylglycerol (1-
monostearin) 1.11 0.8394 
 
   
inositol 1-phosphate 
(I1P) 1.03 0.8404 
 
   
docosapentaenoate (n3 
DPA; 22:5n3) 0.99 0.8498 
 
   
17-methylstearate 0.95 0.8541 
 
   
2-
palmitoylglycerophospho
choline* 
0.98 0.8633 
 
   
S-lactoylglutathione 1.12 0.8696 
 
   
inosine 0.99 0.8713 
 
   
dihydrobiopterin 0.97 0.8761 
 
   
pyruvate 0.88 0.8825 
 
   
caprate (10:0) 0.99 0.8829 
 
   
palmitoyl sphingomyelin 1.00 0.8847 
 
   
oleate (18:1n9) 1.02 0.8850 
 
   
2-
palmitoylglycerophospho
ethanolamine* 
1.01 0.8891 
 
   
1-
arachidonoylglycerophos
phocholine* 
1.00 0.8912 
 
   
2-
docosapentaenoylglycer
ophosphoethanolamine* 
1.03 0.8921 
 
   
1-
oleoylglycerophosphoeth
anolamine 
1.03 0.9029 
 
   
15-HETE 1.09 0.9046 
 
   
1-
palmitoylglycerophospho
ethanolamine 
1.01 0.9061 
 
 
 
123 
 
   
betaine 1.12 0.9198 
 
   
ornithine 0.99 0.9202 
 
   
ascorbate (Vitamin C) 0.99 0.9209 
 
   
deoxycarnitine 1.07 0.9330 
 
   
glycylisoleucine 1.01 0.9349 
 
   
campesterol 0.99 0.9360 
 
   
stearidonate (18:4n3) 1.04 0.9493 
 
   
UDP-galactose 0.91 0.9502 
 
   
histidine 1.01 0.9536 
 
   
maltotetraose 1.00 0.9596 
 
   
linolenate [alpha or 
gamma; (18:3n3 or 6)] 1.01 0.9626 
 
   
citrate 1.01 0.9666 
 
   
1,2-dipalmitoylglycerol 0.87 0.9856 
 
   
pyrophosphate (PPi) 0.91 0.9881 
 
   
adenosine 3',5'-
diphosphate 0.95 0.9885 
 
   
3-ureidopropionate 1.00 1.00 
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Supplemental Table S2 
Genotype/Week 
Treated 
(Mean ± SD) 
Control 
(Mean ± SD) 
"treatment" "week" 
"treatment x 
week" 
C57BL/6J (N=20)        
Initial weight 25.54 ± 1.31 25.62 ± 1.18       
Week 1 24.52 ± 1.46  25.04 ± 1.04       
Week 2 25.86 ± 1.25 26.77 ± 1.67       
Week 3 25.86 ± 0.92 27.02 ± 1.40       
Week 4 26.53 ± 0.90 27.40 ± 1.36 0.001 0.002 0.271 
Ob/Ob (N=16)          
Initial  weight 46.03 ± 3.74  46.50 ± 1.65       
 Week 1 44.55 ± 6.13 46.11 ± 1.44       
Week 2 46.72 ± 7.58 48.12 ± 1.69       
Week 3 51.73 ± 8.00 52.85 ± 2.38       
Week 4 51.44 ± 7.73 53.16 ± 1.68 0.596 <0.001 0.783 
GABA-B kO (N=11)          
Initial weight 27.00 ± 0.95 27.12 ± 1.03       
Week 1 28.30 ± 1.68 28.00 ± 1.59       
Week 2 28.00 ± 1.74 28.70 ± 1.41        
Week 3 27.40 ± 1.34 29.50 ± 2.13 0.002 0.196 <0.001 
 
Weight changes in GHB treated and control C57BL/6J, Ob/Ob and GABA-B kO mice. 
Effects of treatment, week and their interaction are represented by p values of two-way RM 
ANOVA. 
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Supplementary Table 3 
CHRONIC 
BRAIN LIVER 
BIOCHEMICAL NAME 
fold 
change p value BIOCHEMICAL NAME 
fold 
change p value 
inosine 5'-monophosphate 
(IMP) 2.83 
0.044
0 
cytidine-3'-
monophosphate (3'-CMP) 21.85 0.0005 
guanosine 5'- 
monophosphate (5'-GMP) 1.77 
0.042
9 2-hydroxyglutarate 5.83 0.0050 
2-
linoleoylglycerophosphocholin
e* 1.45 
0.013
4 6-beta-hydroxylithocholate 1.47 0.0278 
1-
linoleoylglycerophosphocholin
e 1.34 
0.017
6 leucylalanine 1.35 0.0471 
Isobar: UDP-
acetylglucosamine, UDP-
acetylgalactosamine 1.23 
0.018
6 maltotriose 1.31 0.0140 
cytidine 5'-monophosphate 
(5'-CMP) 1.14 
0.023
4 tetradecanedioate 1.29 0.0497 
citrate 1.12 
0.015
1 kynurenine 1.27 0.0252 
nicotinate 1.10 
0.030
3 glycerate 1.25 0.0340 
allantoin 0.53 
0.001
2 N-acetylalanine 1.21 0.0451 
2-hydroxypalmitate 0.71 
0.014
7 
docosahexaenoate (DHA; 
22:6n3) 1.19 0.0231 
3-hydroxybutyrate (BHBA) 0.72 
0.009
9 palmitoyl sphingomyelin 1.16 0.0152 
urea 0.78 
0.000
8 gamma-glutamylglutamate 1.07 0.0251 
xanthosine 0.78 
0.013
3 
1-
heptadecanoylglycerophos
phocholine 0.42 0.0265 
1-methylimidazoleacetate 0.80 
0.009
2 
1-
stearoylglycerophosphoch
oline 0.47 0.0434 
1-
stearoylglycerophosphoinosit
ol 0.80 
0.028
8 
2-
oleoylglycerophosphocholi
ne* 0.55 0.0062 
1-
arachidonoylglycerophosphoi
nositol* 0.82 
0.037
0 
1-
eicosatrienoylglycerophos
phocholine* 0.59 0.0027 
adenine 0.85 
0.031
1 fructose 0.60 0.0148 
S-adenosylhomocysteine 
(SAH) 0.87 
0.004
9 
1-
arachidonoylglycerophosp
hocholine* 0.63 0.0109 
glutathione, oxidized (GSSG) 0.92 
0.009
8 
2-
eicosatrienoylglycerophos
phocholine* 0.63 0.0073 
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myo-inositol 0.93 
0.040
8 sphingosine 0.63 0.0334 
4-hydroxy-2-nonenal 1.29 
0.082
7 
2-
palmitoylglycerophosphoc
holine* 0.63 0.0251 
2-
palmitoylglycerophosphocholi
ne* 1.22 
0.089
3 
2-
docosahexaenoylglycerop
hosphocholine* 0.64 0.0017 
15-HETE 1.14 
0.086
1 
1-
linoleoylglycerophosphoch
oline 0.64 0.0194 
2-palmitoylglycerol (2-
monopalmitin) 1.13 
0.058
2 
2-
linoleoylglycerophosphoch
oline* 0.65 0.0003 
N-acetylmethionine 1.10 
0.084
3 mannose 0.66 0.0178 
2-hydroxystearate 0.70 
0.078
2 
1-
eicosadienoylglycerophos
phocholine* 0.66 0.0051 
2-pyrrolidinone 0.70 
0.069
8 
1-
oleoylglycerophosphocholi
ne 0.68 0.0276 
arabitol 0.77 
0.070
9 4-guanidinobutanoate 0.68 0.0008 
nicotinamide adenine 
dinucleotide (NAD+) 0.81 
0.053
6 
1-
palmitoylglycerophosphoc
holine 0.69 0.0045 
6-keto prostaglandin F1alpha 0.81 
0.088
2 gamma-glutamylthreonine* 0.70 0.0448 
2-
stearoylglycerophosphoinosit
ol* 0.83 
0.066
1 methylphosphate 0.71 0.0112 
1,5-anhydroglucitol (1,5-AG) 0.83 
0.063
8 
2-
arachidonoylglycerophosp
hocholine* 0.71 0.0084 
riboflavin (Vitamin B2) 0.84 
0.075
8 
2-
docosapentaenoylglycerop
hosphocholine* 0.73 0.0266 
N1-methyladenosine 0.85 
0.059
2 trans-4-hydroxyproline 0.73 0.0428 
glucose-6-phosphate (G6P) 0.85 
0.086
5 
2-
arachidonoylglycerophosp
hoethanolamine* 0.74 0.0016 
erythritol 0.86 
0.079
8 
2-
docosahexaenoylglycerop
hosphoethanolamine* 0.74 0.0078 
xanthine 0.88 
0.073
4 phosphopantetheine 0.75 0.0050 
propionylcarnitine 0.91 
0.072
7 
2-
palmitoleoylglycerophosph
ocholine* 0.75 0.0147 
threonine 0.92 
0.061
3 isovalerylglycine 0.77 0.0136 
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serine 0.93 
0.058
7 
sedoheptulose-7-
phosphate 0.77 0.0319 
nicotinamide 0.93 
0.067
8 urea 0.81 0.0155 
1-
palmitoylglycerophosphoinosit
ol* 0.87 
0.100
7 
trigonelline (N'-
methylnicotinate) 0.82 0.0182 
mannose-6-phosphate 0.74 
0.101
3 4-hydroxybutyrate (GHB) 1.63 0.0521 
creatine 1.04 
0.107
8 alpha-muricholate 1.54 0.0747 
spermine 0.62 
0.109
1 docosadienoate (22:2n6) 1.53 0.0776 
oleate (18:1n9) 0.93 
0.110
9 tagatose 1.50 0.0754 
adenosine 2'-monophosphate 
(2'-AMP) 1.19 
0.112
3 
1-palmitoylglycerol (1-
monopalmitin) 1.44 0.0877 
1-
arachidonoylglycerophosphoe
thanolamine* 0.79 
0.117
2 taurodeoxycholate 1.42 0.0769 
prostaglandin E2 1.10 
0.120
3 stearidonate (18:4n3) 1.37 0.0919 
adenylosuccinate 1.49 
0.121
3 
12,13-hydroxyoctadec-
9(Z)-enoate 1.35 0.0762 
catechol sulfate 0.77 
0.126
2 leucylthreonine 1.34 0.0866 
1-
palmitoylglycerophosphocholi
ne 1.16 
0.127
7 
docosapentaenoate (n3 
DPA; 22:5n3) 1.32 0.0503 
sorbitol 0.85 
0.130
9 alpha-hydroxyisovalerate 1.29 0.0650 
2-methylbutyrylcarnitine (C5) 0.82 
0.134
3 serylleucine 1.26 0.0641 
cytidine-5'-
diphosphoethanolamine 1.04 
0.134
3 
eicosapentaenoate (EPA; 
20:5n3) 1.25 0.0596 
acetylcarnitine 0.95 
0.139
9 homostachydrine* 1.24 0.0575 
guanosine 5'-diphospho-
fucose 0.93 
0.141
5 isoleucylalanine 1.20 0.0557 
palmitoylcarnitine 1.23 
0.142
0 uracil 1.17 0.0843 
2-
docosahexaenoylglycerophos
phocholine* 1.22 
0.142
2 inositol 1-phosphate (I1P) 1.16 0.0553 
adenosine 5'-monophosphate 
(AMP) 1.38 
0.147
1 lysine 1.08 0.0506 
oleoylcarnitine 1.26 
0.147
4 
1-
arachidoylglycerophospho
choline 0.42 0.0629 
stearate (18:0) 0.95 
0.150
2 gamma-glutamylglycine 0.66 0.0722 
butyrylcarnitine 0.86 
0.153
0 sphinganine 0.69 0.0860 
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1-
stearoylglycerophosphoethan
olamine 0.77 
0.155
7 ribitol 0.77 0.0511 
carnitine 0.92 
0.164
1 N-acetylleucine 0.78 0.0793 
pyroglutamine* 1.07 
0.164
7 
2-
linoleoylglycerophosphoet
hanolamine* 0.79 0.0858 
homocarnosine 1.13 
0.168
8 hydroxybutyrylcarnitine* 0.79 0.0649 
1-
docosahexaenoylglycerophos
phocholine* 1.21 
0.175
8 N-acetylglutamate 0.82 0.0913 
3-dehydrocarnitine* 0.94 
0.180
0 N-acetylmethionine 0.85 0.0513 
choline phosphate 0.95 
0.180
7 uridine 0.86 0.0577 
deoxycarnitine 1.08 
0.189
8 
1-
palmitoleoylglycerophosph
ocholine* 0.82 0.1030 
cholesterol 0.92 
0.193
4 glycylisoleucine 1.29 0.1039 
gamma-aminobutyrate 
(GABA) 0.93 
0.194
1 tauroursodeoxycholate 1.50 0.1041 
pyrophosphate (PPi) 0.89 
0.194
9 taurine 1.36 0.1047 
N-acetyl-aspartyl-glutamate 
(NAAG) 0.89 
0.198
2 erythritol 1.29 0.1059 
1,2-dipalmitoylglycerol 0.82 
0.210
1 
S-adenosylhomocysteine 
(SAH) 0.91 0.1084 
stearoylcarnitine 1.16 
0.220
4 
tauro(alpha + 
beta)muricholate 1.46 0.1117 
5-HETE 1.10 
0.222
3 adenine 1.21 0.1119 
glycine 0.95 
0.229
5 adrenate (22:4n6) 1.29 0.1131 
glycolate (hydroxyacetate) 0.89 
0.234
7 dihomo-linoleate (20:2n6) 1.35 0.1152 
thymidine 0.92 
0.247
5 cis-vaccenate (18:1n7) 1.62 0.1154 
uridine 1.03 
0.252
6 
10-heptadecenoate 
(17:1n7) 1.26 0.1166 
10-heptadecenoate (17:1n7) 1.08 
0.254
0 
1-
linoleoylglycerophosphoet
hanolamine* 0.84 0.1172 
guanosine 1.07 
0.254
7 
1-
docosapentaenoylglycerop
hosphocholine* 0.83 0.1173 
adenosine 5'diphosphoribose 0.44 
0.256
2 cysteine 1.58 0.1211 
2-
arachidonoylglycerophosphoc
holine* 1.17 
0.259
3 xylitol 0.76 0.1252 
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7-alpha-hydroxycholesterol 1.15 
0.259
8 
1-
docosahexaenoylglycerop
hosphocholine* 0.81 0.1262 
24(S)-hydroxycholesterol 0.92 
0.260
2 gamma-glutamylleucine 0.89 0.1276 
proline 0.96 
0.260
7 glycylvaline 1.22 0.1290 
4-guanidinobutanoate 1.10 
0.275
5 
dihomo-linolenate (20:3n3 
or n6) 1.14 0.1312 
choline 0.94 
0.290
0 oleate (18:1n9) 1.62 0.1313 
lactate 1.03 
0.290
3 choline phosphate 0.79 0.1371 
valine 0.96 
0.292
2 thymidine 0.84 0.1372 
glutathione, reduced (GSH) 1.18 
0.292
4 eicosenoate (20:1n9 or 11) 1.45 0.1385 
2-
docosahexaenoylglycerophos
phoethanolamine* 1.09 
0.297
9 maltose 2.26 0.1390 
ergothioneine 1.07 
0.297
9 dimethylglycine 0.86 0.1394 
pseudouridine 0.95 
0.305
8 
linolenate [alpha or 
gamma; (18:3n3 or 6)] 1.22 0.1395 
scyllo-inositol 0.93 
0.314
4 choline 0.93 0.1458 
glutarylcarnitine (C5) 0.94 
0.331
1 acetyl CoA 0.87 0.1461 
1-
oleoylglycerophosphoethanol
amine 0.78 
0.335
1 glycerol 1.40 0.1471 
glycerol 3-phosphate (G3P) 0.94 
0.335
6 leucine 1.08 0.1471 
2-
arachidonoylglycerophosphoi
nositol* 0.92 
0.336
7 
cytidine 5'-
diphosphocholine 0.84 0.1473 
alpha-tocopherol 0.80 
0.343
0 3-hydroxybutyrate (BHBA) 0.83 0.1479 
alanine 0.97 
0.349
1 
docosapentaenoate (n6 
DPA; 22:5n6) 1.40 0.1480 
2-
palmitoylglycerophosphoetha
nolamine* 1.13 
0.353
5 inosine 0.94 0.1498 
docosapentaenoate (n3 DPA; 
22:5n3) 1.08 
0.357
4 
adenosine 3'-
monophosphate (3'-AMP) 1.97 0.1536 
homoserine 0.91 
0.357
4 
1,5-anhydroglucitol (1,5-
AG) 0.79 0.1540 
methylphosphate 0.93 
0.358
1 
2-palmitoylglycerol (2-
monopalmitin) 1.63 0.1552 
3'-dephosphocoenzyme A 1.20 
0.358
2 hexadecanedioate 2.57 0.1572 
1-stearoylglycerol (1-
monostearin) 0.91 
0.361
3 gamma-glutamylglutamine 3.30 0.1589 
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cysteine-glutathione disulfide 0.92 
0.363
6 catechol sulfate 0.80 0.1598 
N-acetylneuraminate 0.95 
0.380
1 adenosine 0.91 0.1601 
inositol 1-phosphate (I1P) 1.07 
0.384
9 
10-nonadecenoate 
(19:1n9) 1.45 0.1606 
phenylalanine 0.96 
0.385
1 cholate 1.61 0.1636 
1-
oleoylglycerophosphocholine 1.13 
0.387
4 
sarcosine (N-
Methylglycine) 0.84 0.1637 
N-formylmethionine 1.05 
0.389
7 nonadecanoate (19:0) 1.26 0.1643 
glycerol 0.97 
0.394
4 histidine 0.86 0.1680 
tyrosine 0.96 
0.403
3 valerylglycine 0.86 0.1684 
homostachydrine* 1.02 
0.404
2 xanthosine 1.12 0.1701 
caproate (6:0) 0.93 
0.405
7 16-hydroxypalmitate 2.46 0.1709 
Isobar: ribulose 5-phosphate, 
xylulose 5-phosphate 1.08 
0.409
3 
1-linoleoylglycerol (1-
monolinolein) 1.20 0.1721 
prostaglandin D2 1.07 
0.414
9 N-acetylglutamine 0.91 0.1750 
3-(4-hydroxyphenyl)lactate 0.95 
0.427
4 docosatrienoate (22:3n3) 1.70 0.1757 
2-
oleoylglycerophosphoethanol
amine* 0.86 
0.441
4 succinate 1.24 0.1794 
docosahexaenoate (DHA; 
22:6n3) 1.03 
0.450
7 taurocholate 1.38 0.1799 
N-acetylaspartate (NAA) 1.02 
0.458
4 
5-methyltetrahydrofolate 
(5MeTHF) 0.77 0.1817 
hypotaurine 1.07 
0.462
6 2-aminobutyrate 0.82 0.1828 
uracil 0.95 
0.464
8 margarate (17:0) 1.21 0.1845 
glucose 1.26 
0.465
5 ophthalmate 0.79 0.1941 
2-
arachidonoylglycerophosphoe
thanolamine* 0.91 
0.467
2 xanthine 0.90 0.1949 
cytidine 0.95 
0.468
6 
1-
myristoylglycerophosphoc
holine 0.81 0.1953 
citrulline 0.97 
0.475
1 citrate 1.20 0.1960 
1-
palmitoylplasmenylethanolami
ne* 0.80 
0.477
7 linoleate (18:2n6) 1.14 0.1981 
methionine 0.97 
0.490
2 taurochenodeoxycholate 1.28 0.2024 
acetyl CoA 1.12 
0.503
9 proline 0.94 0.2051 
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1-
palmitoylglycerophosphoetha
nolamine 0.83 
0.511
9 palmitoleate (16:1n7) 1.24 0.2096 
palmitate (16:0) 0.97 
0.520
4 cinnamoylglycine 0.85 0.2103 
dihomo-linoleate (20:2n6) 1.05 
0.523
8 17-methylstearate 1.21 0.2138 
1-oleoylglycerophosphoserine 1.09 
0.532
0 12-HETE 0.85 0.2164 
coenzyme A 0.97 
0.534
8 taurolithocholate 1.22 0.2181 
glutamate 1.02 
0.550
1 gulono-1,4-lactone 0.86 0.2190 
trans-urocanate 0.91 
0.551
4 glycylphenylalanine 1.10 0.2224 
malate 0.98 
0.581
0 arachidonate (20:4n6) 1.10 0.2240 
margarate (17:0) 1.03 
0.587
8 
flavin mononucleotide 
(FMN) 0.93 0.2288 
2'-deoxycytidine 1.05 
0.589
1 myo-inositol 0.93 0.2297 
isoleucine 0.97 
0.597
5 ribulose 0.83 0.2302 
fumarate 0.97 
0.611
4 
15-methylpalmitate (isobar 
with 2-methylpalmitate) 1.13 0.2341 
1,3-dipalmitoylglycerol 0.92 
0.614
6 citrulline 0.91 0.2341 
glycerol 2-phosphate 1.05 
0.614
7 
1-
linoleoylglycerophosphoin
ositol* 0.88 0.2360 
cis-vaccenate (18:1n7) 1.03 
0.617
0 
1-
stearoylglycerophosphoino
sitol 0.85 0.2362 
ophthalmate 0.95 
0.619
9 
2-
stearoylglycerophosphoino
sitol* 0.77 0.2379 
C-glycosyltryptophan* 0.98 
0.629
5 phenylalanylaspartate 1.20 0.2430 
palmitoyl sphingomyelin 0.97 
0.632
2 phenylalanylglycine 1.17 0.2453 
4-hydroxybutyrate (GHB) 1.21 
0.634
2 
flavin adenine dinucleotide 
(FAD) 0.94 0.2460 
dihomo-linolenate (20:3n3 or 
n6) 1.02 
0.637
4 guanosine 1.15 0.2508 
gamma-glutamylglutamine 1.02 
0.644
4 
glucose-6-phosphate 
(G6P) 0.75 0.2558 
tryptophan 0.98 
0.651
7 
1-
palmitoylglycerophosphoet
hanolamine 0.88 0.2640 
anserine 0.97 
0.655
1 arachidate (20:0) 1.35 0.2810 
spermidine 0.92 
0.656
0 palmitate (16:0) 1.12 0.2851 
 
 
132 
 
cysteine 0.96 
0.665
8 myristoleate (14:1n5) 1.28 0.2854 
5-hydroxyindoleacetate 1.04 
0.667
7 glucuronate 0.86 0.2868 
lysine 1.02 
0.668
9 campesterol 0.87 0.2890 
adenosine 0.96 
0.669
2 coenzyme A 0.90 0.2938 
stearoyl sphingomyelin 0.97 
0.675
8 phenol sulfate 0.76 0.2962 
1-
stearoylglycerophosphocholin
e 0.78 
0.679
3 3-indoxyl sulfate 0.85 0.2980 
hydroxybutyrylcarnitine* 0.96 
0.691
9 enterolactone 0.81 0.2987 
isovalerylcarnitine 0.95 
0.699
7 glycine 0.95 0.2994 
aspartate 0.98 
0.706
7 hypoxanthine 0.93 0.3012 
cytidine 5'-diphosphocholine 0.99 
0.708
2 tryptophan 0.95 0.3094 
ascorbate (Vitamin C) 1.03 
0.710
7 propionylcarnitine 1.11 0.3100 
succinylcarnitine 1.05 
0.719
0 hippurate 0.84 0.3172 
carnosine 1.04 
0.719
1 2-phosphoglycerate 0.85 0.3173 
arachidonate (20:4n6) 1.01 
0.722
6 beta-alanine 1.14 0.3176 
ribose 0.96 
0.729
3 pantothenate 0.91 0.3179 
sarcosine (N-Methylglycine) 1.03 
0.740
9 pipecolate 0.89 0.3193 
docosapentaenoate (n6 DPA; 
22:5n6) 0.98 
0.747
8 glucose 0.95 0.3196 
5-methylthioadenosine (MTA) 1.01 
0.748
3 
N-acetylglucosamine 6-
phosphate 0.92 0.3209 
1-palmitoylglycerol (1-
monopalmitin) 0.98 
0.751
0 glycylleucine 1.12 0.3211 
Isobar: fructose 1,6-
diphosphate, glucose 1,6-
diphosphate 1.04 
0.759
2 1,3-dihydroxyacetone 0.90 0.3218 
sphingosine 0.96 
0.763
2 
adenosine 2'-
monophosphate (2'-AMP) 1.07 0.3246 
3-indoxyl sulfate 0.95 
0.775
7 myristate (14:0) 1.18 0.3282 
mead acid (20:3n9) 1.02 
0.776
1 
1-
palmitoylglycerophosphoin
ositol* 0.89 0.3285 
pantothenate 0.99 
0.781
3 ribose 0.91 0.3346 
allo-threonine 1.05 
0.788
5 
1-
stearoylglycerophosphoeth
anolamine 0.90 0.3403 
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mannitol 1.04 
0.793
8 beta-muricholate 1.19 0.3446 
ethanolamine 0.96 
0.801
8 
cysteine-glutathione 
disulfide 1.24 0.3471 
linolenate [alpha or gamma; 
(18:3n3 or 6)] 1.03 
0.803
6 cysteinylglycine 0.91 0.3482 
7-beta-hydroxycholesterol 0.97 
0.809
0 mead acid (20:3n9) 1.19 0.3512 
histidine 0.99 
0.813
7 spermidine 1.06 0.3514 
3-phosphoserine 0.97 
0.823
9 pseudouridine 0.92 0.3522 
hypoxanthine 0.99 
0.829
8 
glutathione, reduced 
(GSH) 0.94 0.3532 
N-acetylglutamate 0.99 
0.836
9 
gamma-
glutamylphenylalanine 1.11 0.3553 
glycerophosphorylcholine 
(GPC) 1.02 
0.843
6 creatine 0.83 0.3573 
adrenate (22:4n6) 0.96 
0.845
1 2-hydroxystearate 0.86 0.3578 
leucine 0.99 
0.851
3 
glycerol 3-phosphate 
(G3P) 1.13 0.3595 
erythronate* 1.02 
0.857
2 isoleucylglycine 1.07 0.3632 
linoleate (18:2n6) 0.98 
0.858
7 
1-
pentadecanoylglycerophos
phocholine* 0.87 0.3651 
glutamine 1.01 
0.859
1 
1-
oleoylglycerophosphoetha
nolamine 0.92 0.3716 
inosine 1.01 
0.865
3 2-hydroxybutyrate (AHB) 0.89 0.3817 
arginine 0.99 
0.873
0 
2-
palmitoylglycerophosphoet
hanolamine* 0.87 0.3821 
N-acetylglutamine 0.99 
0.877
0 equol sulfate 0.90 0.3854 
eicosenoate (20:1n9 or 11) 1.02 
0.877
1 pentadecanoate (15:0) 0.88 0.3929 
laurate (12:0) 0.99 
0.878
2 
2-
oleoylglycerophosphoetha
nolamine* 0.87 0.4008 
phosphopantetheine 0.98 
0.882
2 allantoin 1.08 0.4014 
palmitoleate (16:1n7) 1.01 
0.890
4 
inosine 5'-monophosphate 
(IMP) 0.69 0.4110 
gamma-glutamylglutamate 0.99 
0.891
8 S-methylglutathione 1.07 0.4117 
1-
oleoylglycerophosphoinositol* 0.99 
0.900
6 threonate 1.19 0.4123 
2-
oleoylglycerophosphoserine* 1.01 
0.907
7 valylglycine 1.18 0.4172 
phosphoethanolamine 1.00 
0.922
3 
adenosine 3',5'-
diphosphate 0.91 0.4211 
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2-hydroxyglutarate 1.00 
0.932
9 
Isobar: betaine aldehyde, 
N-methyldiethanolamine 0.89 0.4224 
hydroxyisovaleroyl carnitine 1.00 
0.944
0 
dihydroxyacetone 
phosphate (DHAP) 0.90 0.4284 
alpha-hydroxyisovalerate 0.99 
0.949
5 ergothioneine 1.04 0.4332 
10-nonadecenoate (19:1n9) 0.99 
0.950
8 
nicotinamide adenine 
dinucleotide (NAD+) 0.95 0.4364 
5-oxoproline 1.00 
0.951
7 glutarylcarnitine (C5) 1.06 0.4386 
2-aminoadipate 1.01 
0.954
9 genistein 0.81 0.4485 
phosphate 1.00 
0.955
0 
1-
oleoylglycerophosphoinosi
tol* 1.07 0.4538 
dehydroascorbate 1.01 
0.958
8 malate 1.07 0.4557 
beta-alanine 1.00 
0.962
8 5-oxoproline 1.05 0.4609 
arabinose 1.00 
0.969
3 3-(4-hydroxyphenyl)lactate 0.91 0.4610 
isobutyrylcarnitine 1.00 
0.986
1 13-HODE + 9-HODE 1.11 0.4616 
flavin adenine dinucleotide 
(FAD) 1.00 
0.987
7 
adenosine 5'-
monophosphate (AMP) 1.13 0.4622 
taurine 1.00 
0.988
9 pyridoxate 0.94 0.4642 
1-docosahexaenoylglycerol 
(1-monodocosahexaenoin) 1.00 
0.991
5 gamma-glutamyltyrosine 0.90 0.4654 
12-HETE 1.00 
0.991
7 aspartylleucine 1.24 0.4663 
1-oleoylglycerol (1-
monoolein) 1.00 
0.995
5 glycylproline 1.05 0.4721 
5-aminovalerate 1.00 
0.996
1 stearate (18:0) 1.06 0.4740 
   
2-arachidonoyl glycerol 0.92 0.4797 
   
succinylcarnitine 1.10 0.5009 
   
gamma-aminobutyrate 
(GABA) 0.89 0.5060 
   
1-
docosahexaenoylglycerol 
(1-monodocosahexaenoin) 1.07 0.5062 
   
gamma-glutamylvaline 0.92 0.5087 
   
S-lactoylglutathione 0.91 0.5139 
   
ribose 5-phosphate 1.07 0.5209 
   
caproate (6:0) 0.92 0.5251 
   
phenylalanylserine 1.06 0.5319 
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arginine 1.16 0.5344 
   
phenylpropionylglycine 1.11 0.5345 
   
cytidine 5'-monophosphate 
(5'-CMP) 0.96 0.5444 
   
N-acetylglucosamine 1.09 0.5490 
   
valine 1.03 0.5553 
   
carnitine 1.02 0.5562 
   
2'-deoxyinosine 1.07 0.5567 
   
thiamin (Vitamin B1) 1.04 0.5603 
   
kynurenate 0.93 0.5738 
   
glutarate (pentanedioate) 0.88 0.5755 
   
phenylacetylglycine 0.89 0.5843 
   
caprylate (8:0) 1.06 0.5995 
   
maltohexaose 1.04 0.6081 
   
alanylvaline 1.04 0.6104 
   
alanylleucine 1.05 0.6122 
   
beta-hydroxypyruvate 1.05 0.6174 
   
3-phosphoglycerate 1.05 0.6210 
   
glutamate 1.05 0.6230 
   
butyrylglycine 0.92 0.6315 
   
C-glycosyltryptophan* 0.97 0.6319 
   
methionine 0.97 0.6332 
   
maltotetraose 1.04 0.6349 
   
ethanolamine 0.93 0.6368 
   
Isobar: fructose 1,6-
diphosphate, glucose 1,6-
diphosphate 0.94 0.6413 
   
4-methyl-2-oxopentanoate 0.95 0.6614 
   
biopterin 1.04 0.6622 
   
1-
arachidonoylglycerophosp
hoethanolamine* 0.96 0.6648 
   
1-arachidonylglycerol 1.04 0.6663 
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dihydrocholesterol 0.94 0.6705 
   
1-
stearoylglycerophosphogly
cerol 1.09 0.6715 
   
7,8-dihydrofolate 0.98 0.6752 
   
1-stearoylglycerol (1-
monostearin) 1.06 0.6860 
   
adenylosuccinate 1.11 0.6867 
   
glutamine 1.03 0.6941 
   
S-adenosylmethionine 
(SAM) 1.04 0.6951 
   
isoleucine 0.98 0.6960 
   
1-
palmitoleoylglycerophosph
oethanolamine* 0.94 0.6974 
   
alanylphenylalanine 1.04 0.6984 
   
hydroxyisovaleroyl 
carnitine 0.97 0.6993 
   
adenosine 
5'diphosphoribose 1.06 0.7178 
   
nicotinamide 1.02 0.7213 
   
hypotaurine 0.93 0.7227 
   
phosphate 1.01 0.7240 
   
leucylglycine 1.04 0.7302 
   
uridine monophosphate (5' 
or 3') 1.05 0.7374 
   
aspartate 1.02 0.7383 
   
tyrosine 1.02 0.7442 
   
2-
arachidonoylglycerophosp
hoinositol* 0.96 0.7507 
   
threonine 1.02 0.7551 
   
stachydrine 1.04 0.7551 
   
glycerophosphorylcholine 
(GPC) 0.97 0.7645 
   
imidazole propionate 1.07 0.7719 
   
guanosine 5'- 
monophosphate (5'-GMP) 1.04 0.7741 
   
sorbitol 1.04 0.7790 
   
glycerol 2-phosphate 1.03 0.7979 
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betaine 0.98 0.8013 
serine 0.99 0.8102 
2-methylbutyrylcarnitine 
(C5) 0.97 0.8150 
cytidine 1.02 0.8206 
alpha-tocopherol 1.04 0.8215 
3-methylglutarylcarnitine 
(C6) 0.96 0.8250 
1-methylimidazoleacetate 0.96 0.8325 
cholesterol 1.01 0.8336 
dihydrobiopterin 1.01 0.8381 
3-dehydrocarnitine* 0.99 0.8486 
phenylalanine 1.00 0.8775 
riboflavin (Vitamin B2) 0.99 0.8876 
alanine 0.99 0.8942 
glutathione, oxidized 
(GSSG) 0.99 0.8955 
ascorbate (Vitamin C) 1.02 0.8971 
1-
arachidonoylglycerophosp
hoinositol* 0.99 0.9000 
N-glycolylneuraminate 1.02 0.9037 
maltopentaose 1.00 0.9058 
phosphoethanolamine 0.99 0.9061 
heme 1.05 0.9090 
glycocholate 0.97 0.9105 
nicotinate 0.99 0.9141 
5-methylthioadenosine 
(MTA) 1.01 0.9163 
xylonate 0.98 0.9185 
tigloylglycine 0.98 0.9222 
isobutyrylcarnitine 0.98 0.9282 
lactate 1.00 0.9435 
3-hydroxydecanoate 1.01 0.9445 
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hexanoylglycine 1.01 0.9474 
dimethylarginine (SDMA + 
ADMA) 1.00 0.9479 
UDP-galactose 1.01 0.9536 
acetylcarnitine 0.99 0.9583 
fumarate 1.00 0.9651 
2-aminoadipate 0.99 0.9690 
gluconate 1.01 0.9695 
isoleucylglutamine 1.01 0.9703 
ornithine 1.00 0.9717 
Isobar: ribulose 5-
phosphate, xylulose 5-
phosphate 1.00 0.9747 
3'-dephosphocoenzyme A 1.00 0.9804 
glycyltyrosine 1.00 0.9882 
2-linoleoylglycerol (2-
monolinolein) 1.00 0.9885 
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Summary 
The aim of this study was to describe the clinical and PSG characteristics of narcolepsy with 
cataplexy and their genetic predisposition by using the retrospective patient database of the 
European Narcolepsy Network (EU-NN). We have analysed retrospective data of 1099 
patients with narcolepsy diagnosed according to International Classification of Sleep 
Disorders-2. Demographic and clinical characteristics, polysomnography and multiple sleep 
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latency test data, hypocretin-1 levels, and genome-wide genotypes were available. We found a 
significantly lower age at sleepiness onset (men versus women: 23.74 ± 12.43 versus 
21.49 ± 11.83, P = 0.003) and longer diagnostic delay in women (men versus women: 
13.82 ± 13.79 versus 15.62 ± 14.94, P = 0.044). The mean diagnostic delay was 
14.63 ± 14.31 years, and longer delay was associated with higher body mass index. The best 
predictors of short diagnostic delay were young age at diagnosis, cataplexy as the first 
symptom and higher frequency of cataplexy attacks. The mean multiple sleep latency 
negatively correlated with Epworth Sleepiness Scale (ESS) and with the number of sleep-
onset rapid eye movement periods (SOREMPs), but none of the polysomnographic variables 
was associated with subjective or objective measures of sleepiness. Variant rs2859998 in 
UBXN2B gene showed a strong association (P = 1.28E-07) with the age at onset of excessive 
daytime sleepiness, and rs12425451 near the transcription factor TEAD4 (P = 1.97E-07) with 
the age at onset of cataplexy. Altogether, our results indicate that the diagnostic delay remains 
extremely long, age and gender substantially affect symptoms, and that a genetic 
predisposition affects the age at onset of symptoms. 
Keywords: age at onset; diagnostic delay; gender; genome-wide association 
Introduction 
Narcolepsy with cataplexy (NC) affects ~20 per 100 000 individuals, with an incidence of 
~0.3–0.6 per 100 000 person-years (Longstreth et al., 2007; Partinen and Hublin, 2011; Poli 
et al., 2013). Evidence indicates that NC is caused by the loss of ~70 000 hypocretin cells in 
the hypothalamus, and the best biological marker for human narcolepsy is the reduction (or 
complete deficiency) of hypocretin-1 in the cerebrospinal fluid (CSF; Nishino et al., 2000). 
141 
NC displays a strong genetic predisposition: more than 92% of Caucasian patients (Mignot 
et al., 2001) carry the human leukocytes antigen (HLA)–DQB1*06:02, while HLA–
DQB1*06:03 allele confers a strong protection (Hor et al., 2010). The tight association with 
specific HLA alleles, the recent discovery of circulating anti-TRIBBLES-2 antibodies 
(Cvetkovic-Lopes et al., 2010), the potentially elevated antistreptolysin O titers close to 
disease onset (Aran et al., 2009), the association with a polymorphism of T-cell receptor alpha 
gene and a polymorphism of the purinergic receptor P2RY11 gene (Kornum et al., 2011) are 
strong indications of an autoimmune origin. However, the exact mechanism of such an 
autoimmune process remains unknown. 
Despite major advances in understanding the pathophysiology of the disease and despite the 
fact that narcolepsy is a serious chronic sleep disorder with a major impact on performance, 
social relations, quality of life and socio-economic burden (Jennum et al., 2012), many cases 
remain undiagnosed (Dodel et al., 2007; Ozaki et al., 2008; Vignatelli et al., 2004). Variation 
in severity of the condition with incomplete or atypical forms and variable symptoms might 
contribute to under-diagnosis. Also, narcolepsy may be misdiagnosed as another sleep 
disorder, psychiatric disorder, epilepsy or side-effect of medication, or by lack of knowledge 
of the clinical characteristics (Morrish et al., 2004). In addition, the exact nosology of 
narcolepsy is still controversial for different reasons. 
1. Narcolepsy with cataplexy can be diagnosed by history alone (American Academy of
Sleep Medicine, 2005) but this approach may not be accurate (Morrison et al., 2011), 
as excessive daytime sleepiness (EDS) is a common feature of many sleep disorders, 
and cataplexy has common characteristics with experiences reported by healthy 
subjects (Anic-Labat et al., 1999; Overeem et al., 2011). Even if EDS in narcolepsy is 
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different from that in other sleep disorders, a precise description is missing in the 
international criteria for NC. Nevertheless, significant differences exist between the 
cataplexy-like episodes and clear-cut cataplexy, such as the triggers and the muscles 
involved (Anic-Labat et al., 1999; Sturzenegger and Bassetti, 2004). Additional 
symptoms, such as hypnagogic or hypnopompic hallucinations (HH) and sleep 
paralysis (SP) are frequent in the general population (Ohayon et al., 1996, 1999; 
Sharpless and Barber, 2011). 
2. Patients with NC may test negative in the proposed multiple sleep latency test (MSLT)
requirements. On the other hand, patients with sleep apnea (Chervin and Aldrich, 
2000) and even normal subjects (Mignot et al., 2006) may show short MSLT latencies 
and sleep-onset rapid eye movement periods (SOREMPs). Even if the prevalence of 
SOREMPs during MSLT in the general population has not been exhaustively studied, 
some evidence (Singh et al., 2006) suggests that 3.9% of the general population can be 
positive for multiple SOREMPs. Aldrich underlined that 30% of patients in an average 
sleep laboratory fulfilling both criteria, a mean sleep latency <5 min and two or more 
SOREMPs, do not have narcolepsy (Aldrich et al., 1997). With the more recent limit 
of <8 min this percentage will even be greater. 
3. From a clinical point of view, the spectrum of NC is still far from being clearly
delineated. The nosological limits between narcolepsy without cataplexy (presenting 
with all narcolepsy symptoms but cataplexy), with similar polysomnographic (PSG) 
and MSLT abnormalities (Dauvilliers et al., 2003; Mignot et al., 2002), idiopathic 
hypersomnia without long sleep time, and non-organic hypersomnia (Kaplan and 
Harvey, 2009) are in some cases imprecise. There are many common clinical aspects 
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between narcolepsy without cataplexy and idiopathic hypersomnia without long sleep 
time (note also that the delay between EDS and cataplexy onset may be highly 
variable), which may point to the need of confirming proposed diagnostic criteria 
(Bassetti and Aldrich, 1997; Bassetti et al., 2003; Billiard, 2007). 
4. Although NC is tightly associated with HLA, genotype can only support diagnosis, as
the main susceptibility allele (DQB1*06:02) is also found in about 25% of healthy 
controls (Mignot et al., 2001). 
5. Although NC is associated with low or undetectable levels of hypocretin-1 in the CSF
(normal hypocretin levels in NC are exceptional; Knudsen et al., 2010), this measure 
is not routinely used in clinical practice. In addition, low CSF hypocretin-1 levels were 
described in other neurological or sleep disorders, such as in certain cases of Guillain–
Barré syndrome, anti-Ma encephalitis, late stage of Parkinson's disease, head trauma 
and in Prader–Willi syndrome (Baumann et al., 2008; Fronczek et al., 2009; Mignot 
et al., 2002; Overeem et al., 2004; Ripley et al., 2001b). 
6. Many studies emphasize the increased body mass index (BMI) in patients with
narcolepsy, as compared with either idiopathic hypersomnia or the general population 
(Kok et al., 2003; Poli et al., 2009), but the relationship between the metabolic 
alterations and the duration of untreated disease was not explored. 
Given the preceding limitations, the aim of the present study was to provide a reference 
detailed clinical and PSG description of a large sample of patients with NC and their eventual 
genetic predisposition. A major aim was to establish the relationship between symptoms and 
the diagnostic delay. To the best of our knowledge, our sample is the largest population of 
well-defined NC ever reported. 
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Patients and Methods 
Patients were diagnosed in affiliated sleep centers of the European Narcolepsy Network (EU-
NN): France (n = 339); the Netherlands (n = 219); Germany (n = 185); Spain (n = 157); Italy 
(n = 68); Switzerland (n = 52); Denmark (n = 41); Poland (n = 30); and Slovakia (n = 8), with 
a final sample of 1099 patients. The data were gathered as a retrospective EU-NN database 
during a European genome-wide association study (GWAS; Hor et al., 2010) comparing 
sporadic cases of narcolepsy with HLA-matched controls. Patients were examined by 
physicians experienced with narcolepsy, and the diagnosis was based on diagnostic criteria of 
the ICSD-2 (American Academy of Sleep Medicine, 2005; Billiard, 2007). All patients had 
narcolepsy with unambiguous clear-cut cataplexy, defined as sudden episodes of muscle 
weakness triggered by emotions. Given the differences between sporadic and familial cases 
(e.g. the frequency of HLA–DQB1*06:02 negative and CSF hypocretin-1 normal cases; 
Mignot, 1998; Mignot et al., 2002), suggesting a potential different pathogenesis (as 
demonstrated in the canine model of narcolepsy; Ripley et al., 2001a), only sporadic cases 
were included. All patients were from European origin and were HLA–DQB1*06:02 positive. 
The data were derived from a number of research projects, some published (e.g. Dauvilliers 
et al., 2001; Hor et al., 2010). Local ethics committees approved the recruitment of patients 
for research protocols, and all patients gave their consent to participate. 
Patients were investigated in terms of the following. 
1. Demographic characteristics: date of birth, gender, height, weight, BMI at diagnosis.
Circumstances at onset (triggering factors) were not available in most patients. 
2. Age at EDS onset and age at cataplexy onset. We defined the age at onset of NC as the
age at occurrence of EDS and/or cataplexy, determined during the clinical interview. 
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3. Frequency of cataplexy attacks at diagnosis. The frequency of cataplexy was assessed
by a scale from 1 to 5, reporting rare to very frequent cataplexy attacks (Dauvilliers 
et al., 2001): 1 = one or less cataplexy attacks per year; 2 = more than one cataplexy 
attack per year but less than one per month; 3 = more than one attack per month but 
less than one per week; 4 = more than one per week but less than one per day; 5 = at 
least one cataplexy attack per day. 
4. Epworth Sleepiness Scale (ESS) score at diagnosis.
5. Polysomnographic variables [including apnea–hypopnea index (AHI) and periodic leg
movements during sleep index (PLMSI) when available] and MSLT results (mean 
sleep latency, number of SOREMPs) at diagnosis. Even if the recording procedures 
were different amongst centers, most of the patients underwent nocturnal in-lab PSG 
followed by an MSLT as part of the diagnostic evaluation. For PSG and MSLT, sleep 
latency was defined as the time from lights off to the first epoch scored as sleep. A 
SOREMP was defined as the occurrence of an epoch of REM sleep within 15 min 
after the first epoch scored as sleep. Although MSLT was performed according to 
standard methods (Carskadon et al., 1986), the number of scheduled naps could be 
variable. To standardize the results, we calculated the percentage of SOREMPs of the 
total number of naps: percentage of naps with SOREMPs =  [(number of 
SOREMPs/number of MSLT sessions) × 100]. 
6. Cerebrospinal fluid hypocretin-1 (measured by Phoenix RIA kit) level when available.
7. Human leukocytes antigen–DQB1 genotyping was available from affiliated HLA or
blood centers (at least 4 digits typing by standard techniques). 
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8. Associated features, with particular attention to symptoms frequently reported with
narcolepsy: SP; HH; and poor nocturnal sleep. 
9. Co-morbidities (sleep-related, somatic or psychiatric) and treatment when available.
10. Genome-wide association study: to test genetic associations with clinical traits; age
and gender were used as covariates whenever they showed nominally significant 
association with the tested trait (P < 0.05). Continuous clinical phenotypes were 
inverse normal quantile transformed before applying linear regression [including 
relevant covariates and single nucleotide polymorphism (SNP) imputed allele dosage]. 
For dichotomous clinical traits logistic regression was used. 
Statistical analysis 
Descriptive analyses were performed for: gender; age at diagnosis; age of symptom onset; 
symptoms at diagnosis; BMI, ESS, PSG and MSLT results; hypocretin-1 level; frequency 
of co-morbidities and symptomatic treatments. The interval between symptoms' onset and 
diagnosis was calculated. The gender effect on demographic (age at symptoms' onset, age 
at diagnosis, diagnostic delay, BMI) and clinical variables (PSG, MSLT, sleepiness, 
frequency of cataplexy and hypocretin level) was analysed using t-test/Kruskal–Wallis/χ2 
test. Additional statistical analyses were carried out using, when appropriate, t-
test/anova/Kruskal–Wallis to test the effect of origin, BMI, sleepiness and frequency of 
cataplexy. A possible interaction between BMI and gender was evaluated by two-way 
anova. Because not all variables were available in all patients, the number of patients in 
each test was different. To verify that the outcome of our statistical tests was not affected 
by sub-sampling for each variable, the effects of age and gender on BMI, diagnostic delay 
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and sleep characteristics were analysed by multivariate regression analysis in a reduced 
sample with complete information for variables of interest (n = 611). This analysis did not 
reveal any major difference as compared with analyses including the maximum number of 
patients for each variable. Correlation coefficient (Pearson or Spearman) was used to 
assess the relationship between demographic and clinical variables. Statistical significance 
for all tests was assumed when P < 0.05. For the entire sample and separately, for each 
gender, we have performed principal component analysis taking into account 
demographic, clinical, PSG, MSLT and laboratory data. All statistical tests were 
computed using PASW 18.0 Statistics (IBM SPSS Statistics, Armonk, NY, USA). 
Results 
Demographic data 
Data from 1099 patients were analysed. Table 1 shows demographic characteristics of our 
sample. The changes in sample size occurred because of missing data. Discrepancies or 
absence of information in the charts were labeled as data missing. For some data, manifestly 
outlier values were removed [e.g. total sleep time (TST) <2 h, MSLT latency >20 min, etc.]. 
In our sample, 54.8% of the patients were men and 45.2% women. The birth distribution 
ranged from 1905 to 2004. No predominance of any month or season was observed for birth. 
The mean age at diagnosis was 36.9 ± 17.1 years (range: 4–87 years). The age of diagnosis 
varied depending on the country of origin, with a mean age at diagnosis ranging from 
33.1 ± 16.8 years in France to 43.9 ± 17.6 years in Spain (one-way anova for factor ‘origin’, 
F = 9.234, P < 0.001), but it was similar in women (36.9 ± 16.9 years) and men 
(36.8 ± 17.4 years). Age at diagnosis and diagnostic delay were strongly correlated (r = 0.799, 
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P < 0.001). The strength of this correlation was maintained even after excluding patients 
younger than 20 years old from the analysis (r = 0.714, P < 0.001). 
In most of the patients both EDS and cataplexy appeared at the same time (48.8%), EDS 
preceded the onset of cataplexy in 43.8% and cataplexy was the first reported symptom in 
7.4% of patients only. There were no significant differences between countries or by gender. 
Based on clinical interview, the age at EDS onset could be established in 990 patients. The 
mean age at EDS onset was 22.7 ± 11.9 years (range: 3–80 years; median: 20 years), with a 
significant gender difference (t-test; Mann–Whitney U = 107 302, P = 0.003; 
23.7 ± 12.4 years in men versus 21.5 ± 11.8 years in women) but no difference between 
countries. The mean age at cataplexy onset (n = 685) was 25.8 ± 12.8 years (range: 5–
80 years; median: 24 years), with a normal distribution in both genders. The age of cataplexy 
onset was significantly different between countries (F = 3.088, P = 0.009; minimum in Italy, 
23.0 ± 12.1 years; maximum in Germany, 32.9 ± 11.3 years). In seven patients, age at 
symptoms' onset was older than 60 years (EDS was the first symptom or appeared at the same 
time as cataplexy). The mean delay between EDS onset and cataplexy onset (n = 678) was 
2.8 ± 8.0 years. The maximum delay observed between EDS and cataplexy onset was 
48 years, and the maximum delay between cataplexy onset and EDS was 40 years. 
Available data from 738 patients revealed that the mean delay between the onset of the first 
clinical symptom (EDS or cataplexy) and diagnosis was 14.6 ± 14.3 years (median 10.5 years; 
range from <1 to 67 years). The delay between disease onset and diagnosis was larger for 
patients with later age at onset, and for those with EDS as first symptom (r = 0.169, 
P < 0.001). An important variability between countries was observed for diagnostic delay 
(F = 8.042, P < 0.001), with the lowest delay in France (11.9 ±13.7 years) and the highest one 
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in Spain (21.1 ± 14.7 years). Nevertheless, diagnostic delay was influenced by the time of 
diagnosis (for the analysis of the time of diagnosis, groups were created by 10-year intervals). 
For all countries, cases diagnosed before 1991 have a significantly decreased delay (mean 
diagnostic delay before 1991 was 8.0 ± 4.7 years, compared with the ones diagnosed after). 
One explanation could be the accumulation in time of undiagnosed cases. The higher number 
of cases diagnosed before 1991 was in France, while in Spain the increase in number of cases 
was observed starting with 1991. For the entire sample, the best predictors of diagnostic delay 
(forward stepwise regression) were age at diagnosis, first symptom and the frequency of 
cataplexy (Table 2). 
Clinical and laboratory data 
BMI 
The mean BMI at diagnosis (n = 903) was 27.3 ±5.6 kg m−2. About two-thirds of the patients 
were overweight or obese (36.5% had a BMI between 25 and 29.9 kg m−2, and 27.2% a 
BMI > 30 kg m−2). In patients with a normal weight range (BMI < 25 kg m−2) there was a 
predominance of women (men versus women: 41.8% versus 58.2%, χ2 = 40.867, P < 0.001), 
for overweight patients a predominance of men was observed (BMI between 25 and 
29.9 kg m−2, men versus women: 66.7% versus 33.3%; BMI > 30 kg m−2, men versus women: 
54.5% versus 45.5%; χ2 = 21.023, P < 0.001). Patients with a normal BMI had a lower age at 
diagnosis, age of first symptom onset and diagnostic delay. To control for gender by BMI 
interaction, the age at diagnosis, age at symptom onset and diagnostic delay were also 
analysed by two-way anova. Results indicated that gender and BMI affected all three 
variables, but none was affected by gender by BMI interaction (P > 0.3 for all comparisons). 
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We also observed significant differences in PSG data [TST, sleep efficiency (SE), slow-wave 
sleep (SWS) and REM sleep duration are reduced, and S1 duration is increased in overweight 
and obese patients most probably due to an increase in sleep apnea severity; Table 3]. 
Nevertheless, none of the variables that assess the severity of sleepiness (the mean sleep 
latency during MSLT, number of SOREMPs, ESS), or frequency of cataplexy and hypocretin-
1 levels, was different between patients with normal BMI versus overweight/obese. 
Subjective sleepiness 
Subjective sleepiness was assessed using the ESS in 803 patients at the time of diagnosis. The 
mean ESS was 17.4 ± 3.9 with a median score at 18. Only 38 patients (4.7%) had an ESS in 
the ‘normal ranges’ (<11). None of the ‘non-sleepy’ patients was under stimulant medication 
at diagnosis. The mean age at diagnosis in this group was not different from that of the group 
with ESS score > 10 (31.6 ± 14.9 years versus 37.3 ± 17.4 years), but the diagnostic delay was 
shorter (7.8 ± 7.0 years versus 14.7 ± 14.6 years, P = 0.011; Table 4). The first symptom in 
‘non-sleepy’ patients was cataplexy in 12%, higher than in those who declared themselves 
sleepy (7.2%), but the difference was not statistically significant. The variables correlated 
with sleepiness were different between these two groups of patients, but the severity of 
narcolepsy symptoms was similar. The number of SOREMPs was significantly higher in 
patients with high ESS scores (67.94% in high ESS versus 17.32% in normal ESS, t = 15.33, 
P < 0.0001). 
Cataplexy 
The frequency of cataplexy was assessed on a scale from 1 to 5, from rare to very frequent 
cataplexy attacks. In our case series (n = 829), almost two-thirds of the patients had frequent 
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or very frequent cataplexy attacks (scores 4 + 5: 62.6%; score 5: 41.9%), and 48 patients 
(5.8%) had very rare cataplexy attacks. The mean frequency of cataplexy score was 3.7 ± 1.3, 
which corresponds to more than one attack per month. Patients with severe cataplexy (score 
5) had a reduced diagnostic delay (11.9 ± 12.8 years versus 18.3 ± 15.8 years, P < 0.001), and
the percentage of those who experienced sleepiness, HH and SP was higher in patients with 
severe cataplexy (Table 5). 
Associated features 
Hypnagogic or hypnopompic hallucinations were experienced by 63.1% of patients (370 
patients), and 52.6% (257 patients) experienced SP; both symptoms were present in 43.6% 
(175 patients). Only 28.2% (303 patients) of the entire patient population reported either SP or 
HHs alone (Table 6). 
PSG features 
Table 7 shows PSG and MSLT characteristics of patients with NC. The mean TST was 
411.7 ± 80.4 min, with a mean SE of 83.8 ± 11.5%; 42.8% had abnormal SE < 85%. The age 
at diagnosis was negatively correlated with TST (r = −0.389, P < 0.001), SE (r = −0.335, 
P < 0.001), SWS duration (r = −0.293, P < 0.001) and REM sleep duration (r = −0.209, 
P < 0.001), and positively with S1 duration (r = 0.315, P < 0.001). The mean number of stage 
shifts was 108.3 ± 64.6, and the mean wake after sleep onset was 59.5 ± 43 min. The mean 
sleep-onset latency (SOL) was 10.3 ± 23.8 min, with a mean REM sleep latency (REM SL) of 
54.6 ± 65.30 min. Thirty-five percent of patients had a SOREMP during the night PSG (REM 
SL < 15 min), and only 14.2% had a REM SL between 90 and 150 min, with some patients 
showing prolonged REM latency (REM SL > 150 min; 9.1%). The distribution of REM SL 
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was bimodal, with a first peak between 0 and 10 min after sleep onset, and a second less 
marked peak at 50–70 min. Women had a better SE, longer S2 and SWS duration, and shorter 
S1. 
To evaluate whether the ESS and/or MSLT results are influenced by night sleep, a multiple 
regression analysis was performed, controlling for age at diagnosis and gender. None of the 
variables was retained in the analysis, suggesting that changes in sleep structure or duration 
are due to age and gender, but not to the condition. 
The mean sleep latency during MSLT in 927 patients (without treatment) was 3.9 ± 3.0 min, 
with a median at 3 min, indicating severe sleepiness; 92% of the patients had a sleep 
latency < 8 min (Table 7). Although small, the mean sleep latency at MSLT was significantly 
shorter in women (3.68 ± 2.7 min versus 4.10 ± 3.24 min in men). The mean percentage of 
SOREMPs during the MSLT was 65.9 ± 27.2%, which corresponds roughly to 3 SOREMPs 
during a 5-naps MSLT. However, 3.9% of the sample had no SOREMPs during the MSLT, 
and an additional 5.7% had 20% SOREMPs, which corresponds to 1 SOREMP during a 5-
naps MSLT. Laboratory criteria currently used to diagnose narcolepsy (sleep latency shorter 
than 8 min and at least 2 SOREMPs) were present in 90.3% of patients. We found a negative 
correlation between the mean sleep latency at the MSLT and the number of SOREMPs 
(r = −0.326, P < 0.001). Reduced MSLT mean sleep latency predicted SOREMPs 
(r = −0.326, P < 0.001). The MSLT latency was negatively correlated with the ESS 
(r = −0.306, P < 0.001). 
CSF hypocretin-1 
Cerebrospinal fluid hypocretin-1 measurements were available in 294 patients (Table 7). In 
96.3% of the patients hypocretin-1 levels were undetectable (<40 pg mL−1, n = 252) or 
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<110 pg mL−1 (n = 31). In the remaining 11 patients, intermediate (four cases) to normal 
levels (seven cases) were obtained (from 118 to 400 pg mL−1). There were no significant 
correlations between hypocretin-1 levels (analysed as bivariate parameter: <40 pg/ml and 
more than 40 pg/ml) and variables of interest; there were no differences in clinical features 
between patients with undetectable and those with hypocretin-1 levels between 40 and 
110 pg mL−1. Regarding the 11 patients with intermediate to normal values of hypocretin-1, 
the only significant difference was observed in the frequency of cataplexy, which was lower 
(frequency code 1–2: 42.9% versus 11% in patients with low/undetectable levels of 
hypocretin-1, P = 0.004). 
Effect of age and gender on NC features and diagnostic delay 
Diagnosis is more delayed in women of all age groups (two-way anova for ‘age group’ and 
‘gender’, P < 0.001; no interaction; men versus women: 13.8 ± 13.8 years versus 
15.6 ± 14.9 years), independently from the origin or the time at diagnosis. Stage 1 was 
increased in men in all age groups (men versus women 16.5 ± 10.9% versus 13.0 ± 9.2%; 
Mann–Whitney U: 55949, P < 0.001). Younger men were sleepier than younger women (ESS 
in men 20–30 years old versus women 17.4 ± 3.8 versus 16.8 ± 3.9, P = 0.04), but with aging 
women declared themselves sleepier (ESS in men >60 years old versus women 17.6 ± 3.8 
versus 18.8 ± 3.8, P = 0.034). The same pattern was observed in parameters correlated with 
sleepiness: mean SOL during MSLT (young men versus young women 3.7 ± 2.7 min versus 
4.04 ± 2.6 min, P = 0.04; men > 60 years old versus women 4.1 ± 3.6 versus 3.9 ± 2.8, 
P = 0.53) and SOREMPs (young men versus young women 67.3 ± 28.1 versus 63 ± 29; 
men > 60 years old versus women 59.0 ± 26.2 versus 70.8 ± 25.0, P = 0.014). 
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Principal component analysis 
For variables relevant from a clinical point of view we performed a principal component 
analysis, varimax rotation with Kaiser normalization (KMO measure of sample adequacy 
0.611; Bartlett's test of sphericity: chi square 1010.20; P < 0.001). This analysis was 
performed for the entire sample and, separately, for each gender. Table 8 presents the major 
extracted components (eigenvalue > 1; no restriction on selected number of components). For 
the entire sample, eight components accounted for 67.05% of phenotype variability. By 
gender analysis retrieved only seven components for each gender. 
For the entire sample, the first major component (% variance explained = 14.33%) included 
age- and PSG-related variables: age at diagnosis; diagnostic delay and non-REM sleep stage 1 
(positively); TST and SE (negatively; Table 8). The second component (% variance 
explained = 12.68%) accounted for sleepiness, with ESS score, presence of EDS, and number 
of SOREMPs during MSLT (positively) and mean MSLT (negatively). Components three and 
four (% variance explained = 7.7% and 7.6%, respectively) were represented by sleep 
variables. The frequency of cataplexy was extracted (positively) together with the presence of 
sleepiness, HHs and SP as part of component five (% variance explained = 7.1%). First 
symptom, diagnostic delay and BMI, SOL, and CSF hypocretin-1 levels with stage 1 
(positively) and mean MSLT (negatively) were extracted separately within components 6–8. 
By gender analysis revealed effects that could not be assessed by other analysis. Compared 
with the entire sample, the most important variability in men was due to sleepiness and its 
correlates. In men, diagnostic delay was influenced by the severity of cataplexy and the first 
symptom (if cataplexy was the first symptom, the diagnostic delay was shorter). In women, 
those who had cataplexy as the first symptom had a lower REM-onset latency. 
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Other sleep-related disorders 
Respiratory parameters were not systematically assessed in most sleep laboratories when 
evaluating a patient suspected of NC. In 240 patients detailed breathing parameters were 
available. The mean AHI was 5.1 ± 10.6 per hour, with 26.3% having an AHI ≤ 5 per hour, 
8.7% an AHI between 5 and 15 per hour, and 4.1% an AHI ≥15 per hour. The AHI was higher 
in men than in women (7.63 ± 13.3 versus 3.3 ± 6.7, P = 0.007), and correlated with BMI 
(r = 0.208, P = 0.002). No significant correlation was found with sleepiness (MSLT latency: 
r = 0.012, P = 0.86; ESS: r = 0.36, P = 0.617). Patients with AHI > 30 per hour tended to be 
older than those with AHI <30 per hour (40.5 ± 23 versus 35.3 ± 17.2, P = 0.22), and had 
higher BMI (30.6 ± 5.6 versus 27 ± 5.4, P = 0.043). 
The PLMSI was available in 174 patients only. The mean PLMSI was 1.5 ± 25.8 per hour of 
sleep, with a median at 4.6 per hour; 49.4% had a PLMI > 5 per hour and 30.4% a PLMI > 15 
per hour. 
In a subgroup of 295 patients, the presence of REM sleep behavior disorder (RBD; confirmed 
during diagnostic PSG or clinically suspected) was established in 46% of men and 54% of 
women. No differences between patients with NC with and without RBD were found for sex 
distribution, age at diagnosis, ESS score or mean latency during MSLT. 
Two-hundred and seventy patients were evaluated for other parasomnias than RBD. The most 
frequent parasomnias were: sleep talking (17%); arousal disorders (confusional arousals, 
sleepwalking, sleep terrors, in 8.1%); and bruxism (5.9%). Four patients (1.4%) exhibited 
characteristics of sleep-related eating disorders: one associated with arousal disorders, another 
associated with sleep talking, and two without other associated parasomnias. 
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Genome-wide association 
To verify if any gene variant may be associated with narcolepsy phenotypes, we performed a 
GWAS in 585 patients who had been genotyped as part of a case–control GWAS recently 
published (Hor et al., 2010). Among potential associations, 13 top hits were genotyped in 387 
additional narcolepsy patients for replication. Table 9 shows the associations between the top 
13 hits for the original, the replication and the whole sample metanalysed. None of the 
selected variants reached a genome-wide significance level (P < 5E-08). Nevertheless, a SNP 
(rs2859998) within the UBXN2B, an adaptor protein required for Golgi and endoplasmic 
reticulum biogenesis, was strongly associated (metanalysis P = 1.28E-07) with the age at 
onset of EDS. A similar strong association was also found between rs12425451 near the 
transcription factor TEAD4 and the age at onset of cataplexy (metanalysis P = 1.97E-07). The 
later association was the only significant one in the replication sample (P = 0.048), suggesting 
a potential true signal that needs further replication in other independent samples. 
Discussion 
In this study we were able to analyse phenotypic and genetic data of 1099 sporadic HLA–
DQB1*06:02 positive patients with NC from the retrospective database of the EU-NN 
connecting sleep laboratories from France, the Netherlands, Germany, Spain, Italy, Denmark, 
Switzerland, Poland, Slovakia, Czech Republic, Austria, Finland and UK. This is, to our 
knowledge, the largest published population of well-defined NC. We used this large sample of 
patients to further describe the clinical picture and the PSG characteristics of NC, to review 
the major features of NC, and genetic association with all available phenotypes. Below we 
will discuss the major findings. 
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Diagnostic phenotypes 
Although NC can be clinically diagnosed by the presence of EDS and cataplexy, this is still 
not accurate enough in many cases, in particular in incomplete and atypical forms, or in 
patients with co-morbidities such as sleep apnea. In addition, EDS is common in other sleep 
disorders, and cataplexy, especially incomplete attacks, is not always easy to identify. For 
these reasons several other phenotypic criteria are widely used to support the diagnosis. 
Among these, HLA, hypocretin-1 and MSLT criteria are the most widely accepted ones. In 
our population, all cases had documented cataplexy and were HLA–DQB1*06:02 positive, 
allowing us to evaluate the contribution of other phenotypic variables. Although available in 
only 294 patients (but still the largest sample ever reported), normal hypocretin-1 levels were 
found in only seven patients (2.38%), indicating, as reported by others, that hypocretin 
deficiency is the most reliable and sensitive biological marker for NC, even if not practically 
performed in everyday clinical practice. Among 927 patients with MSLT, 74 (8%) had a 
mean MSLT > 8 min and 79 (8.5%) had <2 SOREMPs, suggesting that MSLT criteria have a 
lower diagnostic value. Using the criteria proposed by Poli et al. (2013) (EDS and 
unambiguous cataplexy and MSLT mean sleep latency ≤8 min or MSLT SOREMPs ≥2), 
96.9% of the patients met the criteria. Nevertheless, among 79 with < 2 SOREMPs, 41 (53%) 
had a SOREMP during the preceding night PSG. Adding the PSG SOREMPs to those with 1 
SOREMP during MSLT brings the percentage of patients with SOREMPs > 2 up to 94.1%, 
suggesting a good diagnostic value that can be routinely used, as recently suggested 
(Andlauer et al., 2012). Interestingly, among seven hypocretin-1 normal patients, MSLT data 
were available in three, and all three had mean MSLT <8 min with more than 2 SOREMPs. 
The same observation was found in two out of the four patients with intermediate hypocretin-
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1 levels. Overall, EDS, cataplexy and DQB1*06:02 best characterize the condition, in the 
absence of hypocretin-1 measure. MSLT data together with PSG SOREMPs remain highly 
valuable, especially if the HLA typing is not available. Also note that in our population mean 
MSLT negatively correlated with the ESS score (r = −0.302, P < 0.001). Accordingly, 
principal component analysis identified ESS, mean MSLT and number of SOREMPs 
contributing to the same factor with strong correlations between them. In other disorders with 
EDS as the leading symptom this correlation cannot be demonstrated (Chervin and Aldrich, 
1999; Shpirer et al., 2006). 
Time between narcolepsy onset and diagnosis 
The delay between the first symptom and diagnosis has been previously reported to range 
from the same year to more than 60 years (Morrish et al., 2004; Parkes et al., 1995), usually 
more than a decade, with a mean delay between 15 and 17 years after the onset of EDS 
(Moldofsky et al., 2000; Morrish et al., 2004). Although it is generally claimed that the 
diagnostic delay has considerably shortened in recent years, in our population the mean 
diagnostic delay is still substantial (14.6 ± 14.3 years). Interestingly, patients with older age at 
onset had longer diagnostic delay, while younger patients (mainly children and adolescents) 
have the shortest diagnostic delay. Also, patients with EDS as the first symptom have longer 
diagnostic delay as compared with those with both EDS and cataplexy or cataplexy as the first 
symptom. Age at symptom onset and age at diagnosis varied amongst countries. Obviously 
several factors might be involved, including but not limited to differences in the recruitment 
population (child versus adult patients) and history of narcolepsy research in each country. 
Another interesting finding is the significant between-country differences in diagnostic delay, 
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with the shortest in France (11.9 ± 13.7 years) and the longest in Spain (21.1 ± 14.7 years). 
Nevertheless, the diagnostic delay also depended on the year of diagnosis, with those 
diagnosed before 1991 having the shortest delay (8.0 ± 4.7 years). This paradoxical finding 
can be explained by a sharp increase in awareness and the number of narcolepsy specialists in 
the 1980s. In summary, the best predictors of a short diagnostic delay are the young age at 
diagnosis, the first symptom including cataplexy, and the higher frequency of cataplexy. 
These observations are in accordance with previous reports indicating that the year of 
symptom onset and whether or not cataplexy is one of the initial symptoms show a significant 
correlation with the diagnosis delay (Morrish et al., 2004). Overall, the onset or worsening of 
cataplexy often prompts patients to look for medical assistance (Rye et al., 1998), the interval 
between symptom onset and diagnosis is greater in patients whose symptom onset was further 
in the past (Dauvilliers et al., 1998), and a reduction in the diagnosis delay is found in patients 
with a more recent date of birth (Furuta et al., 2001). 
Age and gender contributions 
Gender differences in narcolepsy phenotypes are poorly investigated. Here we found a 
significantly longer diagnostic delay in women. Also, the age at onset for EDS was lower in 
women. These differences seem robust as there were no gender differences between countries 
or the time of diagnosis, while the age at onset for cataplexy was highly significantly different 
between countries. Mean sleep latency at MSLT was significantly shorter in women, in 
addition to several PSG and BMI differences. Our findings clearly indicate that narcolepsy 
symptoms are strongly affected by age and especially gender, needing further investigations. 
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Multivariate analysis 
Using the most typical phenotypes in our multivariate analysis, we identified up to eight 
factors explaining their variance in a large NC population. As expected, the most significant 
one included age at diagnosis and diagnostic delay negatively correlated with TST and SE, 
and positively with the amount of stage 1 non-REM sleep. The second most significant 
component includes variables related to EDS, with ESS score and number of SOREMPs 
during MSLT being negatively correlated with mean sleep latency during MSLT. BMI 
segregated positively with stage 1 non-REM sleep and REM latency at night, and negatively 
with diagnostic delay and nocturnal REM sleep. Of interest, the levels of hypocretin-1 
positively correlated with stage 1 non-REM sleep and negatively with mean latency during 
MSLT. Note that none of the night PSG variables was associated with subjective (ESS) or 
objective measures of sleepiness (MSLT), suggesting that EDS in narcolepsy does not result 
from poor quality night sleep, as already proposed (Broughton et al., 1994). Overall, our 
analysis successfully identified groups of correlated symptoms, each explaining between 5.8 
and 14.33% of phenotypic variance (total variance explained by eight factors = 67%). 
Genetics of narcolepsy phenotype 
We performed the first GWAS on narcolepsy clinical and laboratory phenotypes. Although 
many suggestive variants were found, only one, associated with the age at onset of cataplexy, 
showed a nominal significant association in the replication sample. The major explanation for 
this negative result is the complexity of the analysed phenotypes where genetic variants 
explain a small proportion of the phenotypic variance. Also, our original sample (585 
patients) is somehow too small to have enough power to detect a genome-wide significant 
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signal (note also that data for different phenotypes were not available in all 585 patients 
further reducing the statistical power). Nevertheless, the variant rs12425451 associated with 
the age at onset of cataplexy is in the vicinity of the transcription factor TEAD4. TEAD4 is an 
important transcription factor controlling neuronal fate and survival (Cao et al., 2008). This 
interesting finding needs replication. 
Conclusion 
In this large sample of well-defined patients with NC, our findings are compatible with 
previously published studies, extending data collected in smaller case-series. In addition we 
have identified several unexplored relationships between narcolepsy phenotypes. The long 
delay between the onset of symptoms and diagnosis implies that many cases still remain 
undiagnosed, and that major efforts need to be made to spread the knowledge of the disease 
among the population and in particular among physicians. Note that longer diagnostic delay is 
found here associated with higher BMI, suggesting that late diagnosis and/or undiagnosed 
cases are at higher risk for metabolic and cardiovascular diseases. Our findings also 
emphasize a large heterogeneity in the clinical presentation and laboratory variables of the 
disease, and point out the fact that accurate diagnosis needs to take into account the full 
clinical presentation and a critical interpretation of PSG and MSLT results. Although not 
routinely proposed, the measurement of hypocretin-1 concentration in the CSF could be an 
important diagnostic tool in dubious cases. Future studies should also take into account the 
gender as a major contributor. 
Finally, we acknowledge several limitations of our study. Although the diagnosis was made in 
reference sleep laboratories with long-lasting expertise in narcolepsy following virtually 
identical diagnostic criteria, several procedures vary between laboratories, and complete and 
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uniform data could not be obtained from all patients included, introducing some diagnostic 
site effects (a structured prospective database has been launched by the EU-NN in 2010). 
Some of the parameters analysed in the study (e.g. onset of EDS) were based on the reliance 
on subjects of correctly recalling symptoms, or in the analysis of retrospective data obtained 
from medical charts, which may vary according to differences in interpretation or in 
conducting clinical interviews between sites. We did not compare our patients with a 
reference population. Comparisons with subjects recruited from the same populations and 
diagnosed either with other hypersomnias or without any sleep disorder could have allowed 
identification of the most specific (in terms of specificity and sensitivity) narcolepsy 
phenotypes and comparisons of co-morbidities or the search for environmental risks factors 
implicated in the pathophysiology of the disease. 
In conclusion, this study provides a detailed description of the clinical and PSG characteristics 
of a large and homogeneous group of patients with NC. Despite major advances during recent 
years in our understanding of the neurobiological basis of narcolepsy, NC is still an under-
recognized condition. A better knowledge of the nosology of NC may allow earlier diagnosis 
of this life-long disabling condition. 
Acknowledgements 
This work was supported by a grant from the EU-NN and by an unrestricted grant from UCB-
Pharma SA. The French cohort was partly founded by the grant ‘PHRC Narcobank 2007’. 
REFERENCES  
Aldrich, M. S., Chervin, R. D. and Malow, B. A. Value of the multiple sleep latency test (MSLT) 
for the diagnosis of narcolepsy. Sleep, 1997, 20: 620–629. 
American Academy of Sleep Medicine. The International Classiﬁca- tion of Sleep Disorders: 
Diagnostic and Coding Manual, 2nd edn. American Academy of Sleep Medicine, Westcherter, IL, 
2005. 
163 
Andlauer, O., Moore, H., Drake, C. et al. Short REM latency as screening tool for narcolepsy. 
Sleep, 2012, 35: A269. 
Anic-Labat, S., Guilleminault, C., Kraemer, H. C., Meehan, J., Arrigoni, J. and Mignot, E. 
Validation of a cataplexy questionnaire in 983 sleep-disorders patients. Sleep, 1999, 22: 77–87. 
Aran, A., Lin, L., Nevsimalova, S. et al. Elevated anti-streptococcal antibodies in patients with 
recent narcolepsy onset. Sleep, 2009, 32: 979–983. 
Bassetti, C. and Aldrich, M. S. Idiopathic hypersomnia. A series of 42 patients. Brain, 1997, 8: 1423–
1435. 
  Bassetti, C., Gugger, M., Bischof, M. et al. The narcoleptic border- land: a multimodal diagnostic 
approach   including cerebrospinal ﬂuid levels of hypocretin-1 (orexin A). Sleep Med., 2003, 4: 7–
12.  
Baumann, C. R., Scammell, T. E. and Bassetti, C. L. Parkinson’s disease, sleepiness and 
hypocretin/orexin. Brain, 2008, 131: e91. Billiard, M. Diagnosis of narcolepsy and idiopathic 
hypersomnia. An update based on the International Classiﬁcation of Sleep Disorders. 2nd 
edn.Sleep Med. Rev., 2007, 11: 377–388. 
Broughton, R., Dunham, W., Weisskopf, M. and Rivers, M. Night sleep does not predict day sleep 
in narcolepsy. Electroencepha- logr. Clin. Neurophysiol., 1994, 91: 67–70. 
Cao, X., Pfaff, S. L. and Gage, F. H. YAP regulates neural progenitor cell number via the TEA domain 
transcription factor. Genes Dev., 2008, 22: 3320–3334. 
Carskadon, M. A., Dement, W. C., Mitler, M. M., Roth, T., Westbrook, P.R. and Keenan, S. Guidelines 
for the multiple sleep latency test (MSLT): a standard measure of sleepiness. Sleep, 1986, 9: 519– 
524. 
Chervin, R. D. and Aldrich, M. S. The Epworth Sleepiness Scale may not reﬂect objective measures 
of  sleepiness  or sleep apnea. Neurology, 1999, 52: 125–131. 
Chervin, R.D. and Aldrich, M.S. Sleep onset REM periods during multiple sleep latency tests in 
patients evaluated for sleep apnea. Am. J. Respir. Crit. Care Med., 2000, 161: 426–431. 
Cvetkovic-Lopes, V., Bayer, L., Dorsaz, S. et al. Elevated Tribbles homolog 2-speciﬁc antibody 
levels in narcolepsy patients. J. Clin. Invest., 2010, 120: 713–719. 
Dauvilliers, Y., Molinari, N. and Calander, B. Delay of diagnosis of narcolepsy in a European and 
in a North American population. J. Sleep Res., 1998, 7: 56. 
Dauvilliers, Y., Montplaisir, J., Molinari, N. et al. Age at onset of narcolepsy in two large 
populations of patients in France and Quebec. Neurology, 2001, 57: 2029–2033. 
Dauvilliers, Y., Baumann, C. R., Carlander, B. et al. CSF hypocretin- 1 levels in narcolepsy, Kleine-
Levin syndrome, and other hyper- somnias and neurological conditions. J. Neurol. Neurosurg. 
Psy- chiatry, 2003, 74: 1667–1673. 
Dodel, R., Peter, H., Spottke, A. et al. Health-related quality of life in patients with narcolepsy. Sleep 
Med., 2007, 8: 733–741. 
Fronczek, R., Baumann, C. R., Lammers, G. J., Bassetti, C. L. and Overeem, S. Hypocretin/orexin 
disturbances in neurological disor- ders. Sleep Med. Rev., 2009, 13: 9–22. 
Furuta, H., Thorpy, M. J. and Temple, H. M. Comparison in symptoms between aged and younger 
patients with narcolepsy. Psychiatry Clin. Neurosci., 2001, 55: 241–242. 
Hor, H., Kutalik, Z., Dauvilliers, Y. et al. Genome-wide association study identiﬁes new HLA class 
II haplotypes strongly protective against narcolepsy. Nat. Genet., 2010, 42: 786–789. 
Jennum, P., Ibsen, R., Petersen, E. R., Knudsen, S. and Kjellberg, J. Health, social, and economic 
consequences of narcolepsy: a controlled national study evaluating the societal effect on patients 
and their partners. Sleep Med., 2012, 13: 1086–1093. 
164 
Kaplan, K. A. and Harvey, A. G. Hypersomnia across mood disorders: a review and synthesis. 
Sleep Med. Rev., 2009, 13: 275–285. 
Knudsen, S., Jennum, P. J., Alving, J., Sheikh, S. P. and Gammeltoft, S. Validation of the ICSD-2 
criteria for CSF hypocretin-1 measure- ments in the diagnosis of narcolepsy in the Danish 
population. Sleep, 2010, 33: 169–176. 
Kok, S. W., Overeem, S., Visscher, T. L. et al. Hypocretin deﬁciency in narcoleptic humans is 
associated with abdominal obesity. Obes. Res., 2003, 11: 1147–1154. 
Kornum, B. R., Kawashima, M., Faraco, J. et al. Common variants in P2RY11 are associated with 
narcolepsy. Nat. Genet., 2011, 43: 66–71.  
Longstreth, W. T., Jr, Koepsell, T. D., Ton, T. G., Hendrickson, A. F. and van Belle, G. The 
epidemiology of narcolepsy. Sleep, 2007,30: 13–26. 
Mignot, E. Genetic and familial aspects of narcolepsy. Neurology, 1998, 50: S16–S22. 
Mignot, E., Lin, L., Rogers, W. et al. Complex HLA-DR and -DQ interactions confer risk of 
narcolepsy-cataplexy in three ethnic groups. Am. J. Hum. Genet., 2001, 68: 686–699. 
Mignot, E., Lammers, G. J., Ripley, B. et al. The role of cerebrospinal ﬂuid hypocretin measurement 
in the diagnosis of narcolepsy and other hypersomnias. Arch. Neurol., 2002, 59: 1553–1562. 
Mignot, E., Lin, L., Finn, L. et al. Correlates of sleep-onset REM periods during the multiple 
sleep latency test in community adults. Brain, 2006, 129: 1609–1623. 
Moldofsky, H., Broughton, R. J. and Hill, J. D. A randomized trial of the long-term, continued 
efﬁcacy and safety of modaﬁnil in narcolepsy. Sleep Med., 2000, 1: 109–116. 
Morrish, E., King, M. A., Smith, I. E. and Shneerson, J. M. Factors associated with a delay in the 
diagnosis of narcolepsy. Sleep Med., 2004, 5: 37–41. 
Morrison, I., Buskova, J., Nevsimalova, S., Douglas, N. J. and Riha,R. L. Diagnosing narcolepsy 
with cataplexy on history alone: challenging the International Classiﬁcation of Sleep 
Disorders (ICSD-2) criteria. Eur. J. Neurol., 2011, 18: 1017–1020. 
Nishino, S., Ripley, B., Overeem, S., Lammers, G. J. and Mignot, E. Hypocretin (orexin) deﬁciency 
in human narcolepsy. Lancet, 2000, 355: 39–40. 
Ohayon, M. M., Priest, R. G., Caulet, M. and Guilleminault, C. Hypnagogic and hypnopompic 
hallucinations: pathological phe- nomena? Br. J. Psychiatry, 1996, 169: 459–467. 
Ohayon, M.M., Zulley, J., Guilleminault, C. and Smirne, S. Preva- lence and pathologic 
associations of sleep paralysis in the general population. Neurology, 1999, 52: 1194. 
Overeem, S., Dalmau, J., Bataller, L. et al. Hypocretin-1 CSF levels in anti-Ma2 associated 
encephalitis. Neurology, 2004, 62: 138–140. 
 Overeem, S., van Nues, S. J., van der Zande, W. L., Donjacour, C.E., van Mierlo, P. and 
Lammers, G. J. The clinical features of cataplexy: a questionnaire study in narcolepsy patients 
with and without hypocretin-1 deﬁciency. Sleep Med., 2011, 12: 12–18. 
Ozaki, A., Inoue, Y., Nakajima, T. et al. Health-related quality of life among drug-naive patients 
with narcolepsy with cataplexy, narco- lepsy without cataplexy, and idiopathic hypersomnia 
without long sleep time. J. Clin. Sleep Med., 2008, 4: 572–578. 
Parkes, J. D., Clift, S. J., Dahlitz, M. J., Chen, S. Y. and Dunn, G. The narcoleptic syndrome. J. 
Neurol. Neurosurg. Psychiatry, 1995, 59: 221–224. 
Partinen, M. and Hublin, C. Epidemiology of sleep disorders. In:M. Kryger, T. Roth and W. C. 
Dement (Eds) Principles and Practice of Sleep Medicine. Elsevier Saunders, Philadelphia, 2011: 694–
715. Poli, F., Plazzi, G., Di Dalmazi, G. et al. Body mass index-indepen- dent metabolic 
alterations in narcolepsy with cataplexy. Sleep,2009, 32: 1491–1497. 
165 
Poli, F., Overeem, S., Lammers, G. et al. Narcolepsy as an adverse event following immunization: 
case deﬁnition and guidelines for data collection, analysis and presentation. Vaccine, 2013, 31: 
994–1007. 
Ripley, B., Fujiki, N., Okura, M., Mignot, E. and Nishino, S. Hypocretin levels in sporadic and 
familial cases of canine narcolepsy. Neurobiol. Dis., 2001a, 8: 525–534. 
Ripley, B., Overeem, S., Fujiki, N. et al. CSF hypocretin/orexin levels in narcolepsy and other 
neurological conditions. Neurology, 2001b, 57: 2253–2258. 
Rye, D. B., Dihenia, B., Weissman, J. D., Epstein, C. M. and Bliwise, 
D.L. Presentation of narcolepsy after 40. Neurology, 1998, 50: 459–465. 
Sharpless, B. A. and Barber, J. P. Lifetime prevalence rates of sleep paralysis: a systematic review. 
Sleep Med. Rev., 2011, 15: 311– 315. 
Shpirer, I., Miniovitz, A., Klein, C. et al. Excessive daytime sleepiness in patients with Parkinson’s 
disease: a polysomnography study. Mov. Disord, 2006, 21: 1432–1438. 
Singh, M., Drake, C. L. and Roth, T. The prevalence of multiple sleep-onset REM periods in a 
population-based sample. Sleep, 2006, 29: 890–895. 
Sturzenegger, C. and Bassetti, C. L. The clinical spectrum of narcolepsy with cataplexy: a 
reappraisal. J. Sleep Res., 2004, 13: 395–406. 
Vignatelli, L., D’Alessandro, R., Mosconi, P. et al. Health-related quality of life in Italian 
patients with narcolepsy: the SF-36 health survey. Sleep Med., 2004, 5: 467–475. 
Table 1 Demographic characteristics of the sample 
Parameter n (All) Mean ± SD Men Women t/v2 P 
Age at diagnosis (years) 755 36.87 ± 17.13 36.80 ± 17.40 36.91 ± 16.86 NS NS 
Age at EDS onset (years) 990 22.73 ± 11.88 23.74 ± 12.43 21.49 ± 11.84 107 302 0.003* 
Age at cataplexy onset (years) 685 25.80 ± 12.84 26.05 ± 13.25 25.45 ± 12.25 NS 
Diagnostic delay 
First symptom (%) 
738 14.63 ± 14.31 13.82 ± 13.79 15.62 ± 14.94 60 950 
NS 
0.044* 
Cataplexy 47 7.40 8.10 6.50 
Cataplexy and EDS 310 48.80 51.30 45.50 
EDS 278 43.80 40.60 48.00 
BMI 903 27.34 ± 5.59 27.77 ± 4.56 26.80 ± 6.55 82 629 <0.001 
Gender (% men) 590 54.80 
aMann–Whitney U, t-test for ranks; t: t-test; χ2: Fisher's exact test. BMI, body mass index; 
EDS, excessive daytime sleepiness. 
Table 2. Forward stepwise regression for best predictors of diagnostic delay 
Step no. Vars. entered r R2 P
1 Age at diagnosis 0.714 0.509 0.006
2 First symptom 0.732 0.536 <0.001
3 Cataplexy frequency 0.738 0.545 <0.001
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Table 3. Demographic, clinical and PSG characteristics of the patients, according to BMI 
Age at diagnosis (years) 699 30.54 ± 15.12 42.30 ± 17.41 39.57 ± 17.04 35.77 <0.001
Age at EDS onset (years) 878 19.94 ± 10.29 25.38 ± 12.85 23.62 ± 12.10 17.66 <0.001 
Age at cataplexy onset (years) 642 22.78 ± 11.87 29.52 ± 13.76 25.74 ± 12.30 16.924 <0.001 
Diagnostic delay 686 11.02 ± 12.07 16.70 ± 15.40 17.45 ± 15.58 14.547 <0.001 
First symptom (%) 597 
Cataplexy 6.70 8.70 6.50 1.003 0.606
Cataplexy and EDS 47.30 46.30 53.50
EDS 46.00 45.00 40.00
Gender (% men) 41.80 66.70 54.50 3.536 <0.001
HH (% positive) 65.80 62.50 59.00 2.396 0.302
SP (% positive) 54.80 55.30 50.20 1.501 0.472
HH and SP (% positive) 45.70 45.00 41.30 2.519 0.281
EDS, HH and SP (% positive) 44.40 42.00 38.30 3.041 0.219
ESS score 17.16 ± 3.91 17.63 ± 3.83 17.58 ± 3.91 1.209 0.3
EDS (% positive) 95.10 95.60 95.00 0.094 0.954 
Frequency of cataplexy (%)
1 (one or less cataplexy 4.70 8.90 3.70 2.201 0.333
attacks per year)
2 (more than one cataplexy 13.40 11.70 14.30
attacks per year, but less
than one per month)
3 (more than one attack per 18.10 20.60 16.40
month, but less than one
attack per week)
4 (more than one attack per 22.00 17.50 19.00
week, but less than one
per day)
5 (at least one cataplexy 
attack per day)
41.90 41.20 46.60
Sleep latency in PSG 
TST 686 427.22 ± 69.70 407.38 ± 82.69   392 ± 80.59 22.969 <0.001
SE 761 86.51 ± 16.99 82.59 ± 11.90 81.76 ± 12.04 35.857 <0.001 
Stage1 (% of TST) 722 12.16 ± 8.76 15.26 ± 10.65 16.72 ± 10.72 27.248 <0.001 
Stage 2 (% of TST) 721 43.56 ± 11.27 44.26 ± 12.78 42.82 ± 12.56 1.601 0.449 
SWS (% of TST) 753 19.50 ± 9.53 15.97 ± 10.00 17.20 ± 8.53 21.792 <0.001 
REM (% of TST) 733 20.26 ± 7.51 19.41 ± 8.34 17.21 ± 8.53 14.281 0.001 
REM SOL 743 47.03 ± 55.51 59.24 ± 64.23 52.42 ± 65.50 2.316 0.314 
SOL 752 9.97 ± 15.20 10.57 ± 30.82 8.61 ± 13.61 2.906 0.234 
Mean sleep latency at MSLT 816 3.98 ± 3.06 3.78 ± 3.06 3.79 ± 2.70 1.164 0.559 
Number of SOREMP (%)  777 
0–15  4.40  4.40  3.90  0.382 
0.826
20–40 21.10 21.60 18.60
50–75 29.60 32.40 36.10
80–100 44.90 41.80 41.40
Hypocretin (%) 
0–40 pg mL-1 80.20 89.80 90.10 5.186 0.75 
>40 pg mL-1 19.80 10.20 9.90
Parameter                                     n          BMI < 25 kg m-2          BMI 25–29.9 kg m-2          BMI > 30 kg m-2 F/K–W  P 
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 F-value: derived from one-way ANOVA.  BMI, body mass index; EDS, excessive daytime 
sleepiness; ESS, Epworth Sleepiness Scale; HH, hypnagogic or hypnopompic hallucination; K–W, 
Kruskal–Wallis test for not normally distributed variables; MSLT, multiple sleep latency test; PSG, 
polysomnography; REM, rapid eye movement; SE, sleep efficiency; SOL, sleep-onset latency; 
SOREMP, sleep-onset REM period; SP, sleep paralysis; SWS, slow-wave sleep; TST, total sleep time. 
Table 4. Significant differences due to sleepiness (EDS: upper, MSLT: lower table) 
Diagnostic delay     627  7.81 ± 7.04  14.7 ± 14.6 6.488 0.011
SE 691 87.06 ± 11.2 83.47 ± 11.17 5.491 0.019
Mean sleep latency on MSLT 774 5.99 ± 3.94 3.75 ± 2.9 15.307 <0.001 
Number of SOREMP (%) 803 
0–15 84.20 0.10 90.849 <0.001
20–40 10.50 21.50
50–75 NA 34.50
80–100 5.30 43.80
Variable n MSLT <8 MSLT > 8 v
2/t P
Age at EDS onset (years) 870 23.36 ± 12.14 19.8 ± 11.03 6.727 0.009 
Age at cataplexy onset (years) 623 26.33 ± 12.93 21.94 ± 11.55 5.305 0.021 
ESS 774 17.73 ± 3.69 14.95 ± 4.26 30.978 <0.001 
Number of SOREMP (%) 788 
0–15 3.00 9.80 21.293 <0.001
20–40 18.80 40.90
50–75 33.60 22.90
80–100 44.70 26.20
EDS, excessive daytime sleepiness; ESS, Epworth Sleepiness Scale; MSLT, multiple sleep latency 
test; SE, sleep efficiency; SOREMP, sleep-onset rapid eye movement period 
Table 5. Significant differences due to the severity of cataplexy 
Variable/frequency
of cataplexy 1 2 3 4 5 F/K–W P
Diagnostic delay 16.67 ± 14.76 18.30 ± 15.84 15.11 ± 14.29 14.88 ± 14.59 11.91 ± 12.82 4.480 0.001
EDS, HH and SP 17.50 28.70 42.50 40.60 51.40 10.125 <0.001 
(% positive)
F-value: derived from one-way ANOVA. EDS, excessive daytime sleepiness; HH, hypnagogic or 
hypnopompic hallucination; K–W,  Kruskal–Wallis test for not normally distributed variables; SP, 
sleep paralysis. 
Variable                                                      n                      ESS 0–10                   ESS > 10  t  P 
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Table 6. Clinical variables 
Parameter n (all) Mean ± SD Men Women t-test P
HH (% positive) 587 63.10 58.90 68.00 8.030 0.005
SP (% positive) 488 52.60 50.20 55.50 NS
HH and SP (% positive) 402 43.60 40.40 47.60 6.622 0.01
EDS, HH and SP (% positive) 301 41.80 38.90 44.60 NS
ESS score 803 17.45 ± 3.86 17.33 ± 3.91 17.57 ± 3.80 NS
EDS (% positive) 765 95.30 95.40 95.10 4.488 0.034 
Frequency of cataplexy (%)
1 (one or less cataplexy attacks per year) 48 5.80 6.80 4.60 NS
2 (more than one cataplexy attacks per 108 13.00 11.40 15.30
year, but less than one per month)
3 (more than one attacks per month, 154 18.60 18.60 18.50
but less than one attack per week)
4 (more than one attack per week, but 
   less than one per day) 
5 (at least one cataplexy attack per day) 
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347
20.70 
41.90
19.20 
44.10
22.60 
39.00
Table 7. PSG and MSLT variables and hypocretin-1 levels 
Parameter n (all) All mean ± SD Men Women t-test P
TST 751 411.70 ± 80.45 410.33 ± 79.85 414.26 ± 80.38 NS
SE 848 83.80 ± 11.53 82.86 ± 11.20 84.95 ± 11.82 74 791 <0.001* 
Stage 1 (% of TST) 772 14.62 ± 10.36 16.46 ± 10.89 12.96 ± 9.21 55949.9 <0.001* 
Stage 2 (% of TST) 773 43.75 ± 12.3 43.04 ± 12.55 44.74 ± 11.91 66203.5 0.03* 
SWS (% of TST) 808 17.54 ±9.97 16.36 ± 9.88 18.86 ± 9.89 67725.5 <0.001* 
REM (% of TST) 788 19.17± 8.54 19.27 ± 8.16 19.04 ± 8.98 NS 
REM-onset latency 835 54.59 ± 65.30 55.03 ± 67.39 53.92 ± 62.91 NS 
SOL (PSG) 844 10.33 ± 23.80 11.86 ± 28.35 9.30 ± 14.75 NS 
Mean sleep latency (MSLT) 
Number of SOREMP (%)
927 3.92 ± 3.03 4.10 ± 3.23 3.67 ± 2.70 NS 
0–15 34 4.00 3.80 4.30 NS
20–40 169 20.50 22.90 17.70
50–75 265 32.10 27.90 36.80
80–100 358 43.40 45.30 41.30
Hypocretin (%) 
Undetectable (<40 pg mL-1) 254 86.40 55.11 44.89
(>40 pg mL-1) 40 13.60 57.50 42.50
*Mann–Whitney U-test, t-test for ranks. MSLT, multiple sleep latency test; PSG, polysomnography;
REM rapid eye movement; SE, sleep efficiency; SOL, sleep-onset latency; SWS, slow-wave sleep; 
TST, total sleep time. 
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Table 8. Principal component analysis 
BMI, body mass index; EDS, excessive daytime sleepiness; ESS, Epworth Sleepiness Scale; HH, hypnagogic or 
hypnopompic hallucination; MSLT, multiple sleep latency test; REM, rapid eye movement; SE, sleep efficiency; 
SOL, sleep-onset latency; SOREMP, sleep-onset REM period; SP, sleep paralysis; SWS, slow-wave sleep; TST, 
total sleep time. 
Table 9. Genome-wide association analysis of narcolepsy phenotypes 
Phenotype rs# aA aB x1 p1 x2 p2 x_meta p_meta
ESS (n1 = 418, n2 = 252) rs16966122 A G -2.3655 9.11E-07 -0.8656 6.82E-02 -1.601 2.08E-06
Age EDS onset (n1 = 530, 
n2 = 319)
rs2859998 A G -4.6048 2.33E-07 -3.0064 2.20E-01 -4.4145 1.28E-07 
Age EDS onset (n1 = 530, rs6072697 C T 14.8434 4.29E-06 4.4731 2.76E-01 10.8306 1.84E-05
n2 = 319)
Age cataplexy onset (n1 = 
435, n2 = 305)
rs12425451 C T -7.9529 7.30E-07 -4.5204 4.83E-02 -6.7866 1.97E-07
HH (n1 = 458, n2 = 310) rs10160605 A G 0.8865 3.84E-06 0.0294 8.48E-01 0.363 2.43E-03
TST (n1 = 442, n2 = 180) rs304468 C T -28.7108 1.18E-06 9.1773 2.65E-01 15.7748 1.00E-03
TST (n1 = 442, n2 = 180) rs890227 A G 149.2937 4.11E-07 -16.656 3.77E-01 31.3251 4.82E-02 
SE (n1 = 451, n2 = 268) rs1515773 C T -5.6438 3.37E-07 3.083 1.80E-01 -3.9944 6.10E-05
SE (n1 = 451, n2 = 268) rs2426087 A G 11.638 4.30E-07 -1.9517 7.94E-01 10.463 1.98E-06 
SOREMPs (n1 = 490, 
n2 = 298)
rs9397716 C T -11.7672 2.13E-05 0.0022 9.40E-01 0.0009 9.75E-01 
SOREMPs (n1 = 490, 
n2 = 298)
rs9551427 A G -10.883 2.28E-05 0.0345 1.32E-01 0.0336 1.41E-01
BMI (n1 = 463, n2 = 307) rs1882687 A C 2.1251 3.90E-07 -0.3574 4.95E-01 1.1544 4.13E-04
REMS (n1 = 429, n2 = 260) rs17294110 A G 3.0476 8.91E-06 -2.5829 8.55E-02 2.0692 9.07E-04 
  rs#: SNP; aA and aB: minor and major alleles; x1 and x2: effect size for discovery and replication; meta: 
metanalysis; n1 and n2: number of patients in discovery and replication analyses. BMI, body mass index; EDS, 
excessive daytime sleepiness; ESS, Epworth Sleepiness Scale; HH, hypnagogic or hypnopompic hallucination; 
REMS rapid eye movement sleep; SE, sleep efficiency; SOREMP, sleep-onset REM period; TST, total sleep
Rotated component matrix
Component
1 2 3 4 5 6 7 8
BMI 0.312 0.073 0.306 0.039 -0.191 -0.314 -0.210 0.023
Age at diagnostic 0.776 0.109 0.089 0.150 -0.195 0.157 -0.142 -0.074 
Diagnostic delay 0.730 0.112 0.102 0.058 -0.198 0.331 -0.134 -0.199 
Frequency of cataplexy -0.027 -0.039 0.069 -0.053 0.733 -0.158 0.008 0.062 
TST -0.749 0.015 -0.076 0.086 -0.148 0.145 -0.153 -0.022 
SE -0.737 0.011 -0.048 0.012 -0.124 0.183 -0.189 -0.028 
Stage 1 0.442 -0.045 0.460 -0.203 -0.014 -0.174 -0.248 0.429 
Stage 2 -0.178 0.057 0.103 0.869 -0.095 0.124 0.120 -0.226 
SWS -0.279 0.093 -0.056 -0.754 -0.062 0.136 0.137 -0.290 
REM -0.165 0.038 -0.733 -0.178 -0.032 0.040 0.047 -0.028 
SOL 0.089 0.008 0.085 0.007 -0.041 -0.047 0.875 0.094 
REM latency -0.002 0.011 0.731 -0.031 0.051 0.184 0.246 -0.173 
Mean MSLT 0.061 -0.506 -0.031 0.039 0.193 0.120 -0.043 -0.330 
No. SOREMPs -0.027 0.871 0.026 0.007 0.037 0.014 -0.031 0.057 
ESS score 0.098 0.885 -0.049 -0.029 0.049 0.073 -0.054 0.021 
EDS 0.107 0.693 -0.025 0.031 0.245 0.041 0.069 -0.094 
Hypocretin -0.138 0.116 -0.125 0.034 0.090 0.228 0.135 0.738 
EDS + HH + SP 0.002 0.261 -0.024 0.026 0.730 0.150 -0.044 -0.013 
First symptom 0.005 0.038 0.080 0.010 -0.047 0.811 -0.057 0.137 
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Abstract 
Study Objectives: To evaluate the association between objective sleep measures and 
metabolic syndrome (MS), hypertension, diabetes and obesity. 
Design: Cross-sectional study. 
Setting: General population sample. 
Participants: 2162 subjects (51.2% women, mean age 58.4±11.1). 
Interventions: Subjects were evaluated for hypertension, diabetes, overweight/obesity and 
MS, and underwent a full polysomnography (PSG). 
Measurements and Results: PSG measured variables included: Total sleep time (TST), 
percentage and time spent in slow wave sleep (SWS) and in rapid eye movement (REM) 
sleep, sleep efficiency and arousal index (ArI). In univariate analyses, MS was associated 
with decreased TST, SWS, REM sleep, sleep efficiency and increased ArI. After adjustment 
for age, gender, smoking, alcohol, physical activity, drugs that affect sleep and depression, the 
ArI remained significantly higher, but the difference disappeared in subjects without 
significant sleep disordered breathing (SDB). Differences in sleep structure were also found 
according to the presence or absence of hypertension, diabetes and overweight/obesity in 
univariate analysis. However, these differences were attenuated after multivariate adjustment 
and after excluding subjects with significant SDB. 
Conclusions: In this population-based sample we found significant associations between 
sleep structure and MS, hypertension, diabetes and obesity. However, these associations were 
cancelled after multivariate adjustment. We conclude that normal variations in sleep 
contribute little if any to MS and associated disorders. 
Keywords: Polysomnography, metabolic syndrome, hypertension, diabetes, obesity 
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Introduction 
Cardiovascular diseases (CVD) are the main cause of death worldwide, and are expected to 
increase in the forthcoming years1. Lifestyle factors such as tobacco use, high-fat diet and 
physical inactivity strongly increase CV risk factors, but they may not fully account for their 
development2. It is therefore important to identify new underlying determinants of CVD. 
Recent research identified relationships between sleep quantity and CV risk factors. 
Numerous population studies, summarized in recent meta-analyses, suggested that sleep 
duration may be associated with obesity3, hypertension4, type 2 diabetes5, the metabolic 
syndrome (MS)6, cardiovascular outcomes (including coronary heart disease, stroke and total 
CVD)7 and overall mortality8. In particular, for most of these outcomes there seems to be a U-
shaped relationship with sleep duration. 
Some of the above studies evaluating the association between sleep duration and 
cardiovascular and metabolic outcomes yielded conflicting results that can be explained by 
methodological heterogeneity. Caution has been expressed, from different perspectives, about 
the interpretation of these findings in critical reviews9, 10. One important limitation of prior 
epidemiological studies is that the definition of ‘‘short’’ and ‘‘long’’ sleep varies across 
studies. More importantly, almost all previous studies are based on subjective assessments of 
the duration of sleep, generally based on responses to a single question or by questionnaires 
that have not been validated against objective sleep measures. 
Finally, it was suggested that the effect of sleep on CV risk may be mediated by poor sleep 
quality. For example, difficulties in initiating or maintaining sleep were associated with a 
greater risk of type 2 diabetes5. Again, these conclusions are based on subjective assessments 
and do not allow the identification of sleep variables directly linked with CV risk outcomes. 
Laboratory studies in young healthy adults indicated that selective suppression of slow wave 
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sleep (SWS) without any change in total sleep time affects glucose homeostasis, potentially 
increasing the risk of type 2 diabetes11, and can produce a significant reduction in blood 
pressure (BP) dipping12. Even if these findings demonstrate that sleep structure, 
independently of sleep duration, can play a role in metabolic disorders, they have not been 
replicated in large general population studies. 
Thus, the aim of this study was to explore the association between sleep structure, objectively 
measured by polysomnography (PSG) and several CV risk factors, specifically MS, 
hypertension, diabetes and obesity in a large unselected middle-aged general population 
sample. We analyzed these associations in the entire sample and after excluding subjects with 
a significant oxygen desaturation index (ODI>15/h), as intermittent hypoxia related to 
respiratory disturbances (apneas/hypopneas) plays an independent role in the pathophysiology 
of CVD13. 
Methods 
Population sampling 
The HypnoLaus Sleep Cohort study is based on the first follow up of the epidemiologic 
CoLaus/ PsyCoLaus study. Details of the CoLaus/PsyCoLaus study were previously 
described14, 15. Briefly, the CoLaus/Psycholaus study included a random sample of 6733 
subjects (range age: 35-75 years) selected from the residents of Lausanne city (Switzerland) 
between 2003 and 2006. HypnoLaus evaluated the subjective and objective sleep 
characteristics of the study population. During the first follow up of the cohort, five years 
after the initial phase, all subjects who responded underwent a new physical (n=5064) and 
psychiatric (n=4000) examination and were given questionnaires by trained interviewers, 
which included questions on demographic, medical, and treatment history as well as smoking 
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and alcohol consumption. Sleep-related complaints and habits were investigated using the 
Pittsburgh Sleep Quality Index (PSQI)16, the Epworth Sleepiness Scale (ESS)17 and the Berlin 
questionnaire for sleep disordered breathing (SDB)18.
CoLaus/PsyCoLaus and Hypnolaus were approved by the Ethics Committee of the University 
of Lausanne and a written informed consent was obtained from all participants at the baseline 
and the follow-up assessments. 
Polysomnography 
3051 consecutive subjects were invited to undergo a full night in-home PSG recording. No 
selection of the subjects was made based on the questionnaires and the investigators were 
blinded to the questionnaires’ results. During a visit at the Center for Investigation and 
Research in Sleep (Lausanne University Hospital, Switzerland), trained technicians equipped 
the subjects with the PSG recorder (Titanium, Embla® Flaga, Reykjavik, Iceland) between 5 
and 8 PM. All sleep recordings took place in the subjects’ home environment and included a 
total of 18 channels: six electroencephalography, two electrooculography, three surface 
electromyography (one submental, two for right and left anterior tibialis muscles), one for 
electrocardiogram, nasal pressure, thoracic and abdominal belts, body position, oxygen 
saturation and pulse rate. 
All PSG recordings were visually scored by two trained sleep technicians (DA and NT) using 
Somnologica software (Version 5.1.1, by Embla® Flaga, Reykjavik, Iceland) and reviewed by 
a trained sleep physician (JHR). Random quality checks were performed by a second 
physician (RH). Quality control for concordance rate between the two PSG scorers was 
implemented periodically to ensure that both scorers achieved at least a 90% level of 
agreement for sleep stages and respiratory events and an 85% level of agreement for 
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arousals19. Sleep stages, leg movements and arousals were scored according to the 2007 
AASM criteria20. The ODI represents the number ≥3% oxygen saturation drops per hour of 
sleep. Apneas/hypopneas were scored according to the AASM 2013 rules21. The average 
number of apneas/hypopneas per hour of sleep (apnea-hypopnea index [AHI]) was calculated. 
Cardiovascular risk factors 
BP was measured in triplicate on the left arm and values averaged between the last two 
readings. Arterial hypertension was defined as a systolic BP (SBP) ≥140 mmHg and/or a 
diastolic BP (DBP) ≥90 mmHg or current use of antihypertensive medication. A fasting blood 
sample was collected for various analyses (including glucose, total cholesterol, high-density 
lipoprotein (HDL) cholesterol and triglycerides). Diabetes was defined as a fasting blood 
glucose level ≥7 mmol/L (126 mg/dL) or current use of antidiabetic medication. The body-
mass index (BMI) was calculated and subjects were classified as overweight if their BMI was 
between 25 and 30 kg/m2 and obese if BMI ≥30 kg/m2. The MS was defined according to the 
Adult Treatment Panel III report (ATP-III)22 in the presence of 3 of the following 5 factors: 
abdominal obesity (waist circumference >102 cm in men and >88 cm in women), elevated 
triglycerides (≥1.7 mmol/L, >150 mg/dL), reduced HDL cholesterol (<1.03 mmol/L (40 
mg/dL) in men and <1.20 mmol/L (50 mg/dL) in women), elevated BP (≥130/≥85 mmHg) (or 
hypertension), or elevated fasting glucose  (≥ 5.6 mmol/L) (or type 2 diabetes mellitus). 
Other variables 
Smoking habit was self-reported and was dichotomized as current smoker/ex-smoker or 
never-smoker. Alcohol drinking was dichotomized as currently drinking or no alcohol 
consumption. Regular exercise was defined as reports of exercising ≥3 times a week. 
Medication use, recorded at the time of sleep studies, was coded according to the World 
Health Organization ATC classification (http://www.whocc.no/atcddd). Diagnosis of lifetime 
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major depressive disorder was assigned according to DSM-IV criteria with information 
collected using the French translation23 of the semi-structured Diagnostic Interview for 
Genetic Studies (DIGS)24. PSGs were recorded between Mondays and Fridays. As Saturday is 
generally considered to be a day off, the day of week (Friday versus other week days) was 
considered as a covariate. 
Statistical analysis 
All statistical tests were performed using Stata 11 (StataCorp, College Station, TX, USA). For 
descriptive statistics, continuous variables were summarized as mean±standard deviation, 
while categorical variables were summarized as number of subjects and percentages. 
Descriptive statistics were also used for sleep characteristics of the subjects based on presence 
or absence of MS, hypertension, diabetes and obesity. Student’s t-test or one-way analysis of 
variance were used to evaluate univariate differences between PSG variables. These included: 
sleep duration or total sleep time (TST): total minutes of any stage of sleep from sleep onset 
to morning awakening; percentage of slow wave sleep (SWS): percentage of TST spent in 
stage N3/SWS; SWS min: time in minutes spent in stage N3/SWS; rapid eye movement 
(REM) sleep: percentage of TST spent in REM sleep; REM min: time in minutes spent in 
REM sleep; sleep efficiency: ratio between the total sleep time and time spent in bed; arousal 
index (ArI): number of arousals divided by hours of TST. These variables are routinely used 
in clinical practice to describe both sleep continuity and sleep architecture. The PSG variables 
were considered as continuous variables. SWS min and REM min were log transformed 
(natural log) for analysis. Although extremes of sleep duration were previously associated 
with adverse CV risk outcomes, TST was also evaluated as a continuous variable given the 
low prevalence of long sleepers (0.3% slept more than 10 hours) and short sleepers (8% slept 
less than 5 hours) in the Hypnolaus study. However we also compared the short sleepers and 
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long sleepers, stratifying the subjects in 4 groups according to the TST: <6 h, 6-7h, 7-8h, 8+ 
h. These analyses are presented in supplementary tables.
At a second step, two multivariate models were used: the first was adjusted for age, gender 
and day of PSG recording; the second model was adjusted for the same variables plus the 
following additional covariates: smoking, alcohol use, regular exercise, depression and use of 
medications that affect sleep (hypnotics, benzodiazepines, antidepressants, neuroleptics 
and/or antihistamines). BMI was included as a covariate for hypertension and diabetes, but 
not for the MS as BMI is strongly associated with abdominal obesity and overadjustment 
might occur. A multivariate analysis with subjects stratified in groups according to the TST 
(<6 h, 6-7h, 7-8h, 8+ h) was also performed, and results are presented as supplementary data. 
When studying the association between sleep and cardiovascular morbidity and mortality, 
SDB constitutes a key phenotype as it is an independent risk factor for hypertension25 and 
insulin resistance26, and is associated with the MS27. SDB describes a group of disorders 
characterized by abnormalities of respiratory patterns during sleep. These abnormalities cause 
sleep disturbances (secondary to arousals to resume normal ventilation) and/or repetitive 
oxygen desaturations. Intermittent hypoxia in SDB seems to be a critical factor in the 
pathophysiology of cardiovascular and metabolic consequences13. As the purpose of this 
study was to determine if sleep structure is associated with CV risk factors independently of 
the origin of sleep disruption, we analyzed these associations first in the entire group and 
then, after excluding subjects with a substantial (>15/h) ODI. We choose a cut-off value of 
15/h as the The International Classification of Sleep Disorders (ICSD-3) diagnostic criteria 
for sleep apnea are based on this metric (AHI ≥ 15/hour or ≥ 5/hour with symptoms)28. Of 
note, ODI was also examined as a continuous variable, with the results yielding similar con-
clusions. For simplicity, we present only the results using the dichotomous ODI variable. 
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Multiple testing problems are in a wide variety, ranging from testing multiple doses and 
endpoints jointly, composite endpoint, non-inferiority and superiority, etc.29. In this study, we 
chose to adjust for multivariate adjustment within each MS component, thus allowing a better 
control of the type I error rate while not overtly reducing the chances of finding clinically 
important (and statistically significant) associations. We estimated that within each MS 
component approximately 20 associations would be tested, thus leading to an adjusted p-value 
of 0.05/20=0.001 (Bonferroni method). 
Results 
Feasibility and failures 
Of the 3051 contacted subjects, 2168 (71.1%) agreed to have a PSG at home. Subjects who 
agreed to participate were 8.2 years younger and reported less sleepiness than those who 
declined. BMI (+0.4 kg/m2) and PSQI scores (+0.3 pts) were slightly higher in those who 
declined (Cohen’s D test effect size 0.09 for both). The Berlin score was similar in both 
groups. Technical problems resulting in insufficient data for PSG scoring were encountered in 
60 cases (2.8%), 54 PSG were repeated and 6 subjects declined to repeat the study, resulting 
in 2162 participants (51.2% women, mean age 58.4±11.1 years) included in the final analysis 
(figure 1). 
General characteristics 
Table 1 summarizes the findings for the entire population and in subjects with an ODI ≤15/h 
vs. those with an ODI >15/h. Overall a total of 30.5% individuals had MS, 41.5% 
hypertension, 9.9% diabetes, 41.1% were overweight (25≤BMI<30 kg/m2), and 16.5% were 
obese (BMI ≥30 kg/m2). The mean TST was 401.2±72.1 min, the time spent in SWS and 
REM sleep were respectively 19.7±8.4% and 21.8±6.1% of the TST, the sleep efficiency was 
84.6±10.9%, the ArI was 21.3±11/hour of sleep, and the AHI was 15.5±16.3/h. 
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A total of 751 subjects (34.7% of the sample) had a significant ODI (>15/hour of sleep). 
Subjects with ODI >15/h were older, more frequently male, had higher rates of MS, 
hypertension, diabetes and overweight/obesity than subjects with an ODI ≤15/h. Concerning 
PSG characteristics, subjects with ODI >15/h slept less, spent less time in SWS and REM 
sleep, had lower sleep efficiency, and higher ArI. 
Sleep structure and CV risk factors 
Tables 2 to 5 show the sleep characteristics of subjects according to the presence or absence 
of the MS, hypertension, diabetes and overweight/obesity in the overall sample and in 
subjects without clinically significant desaturation (ODI≤15/h) from models adjusted for age, 
gender and day of week of the PSG recording (P1), and smoking, alcohol, physical activity, 
drugs that affect sleep and depression (P2). 
In bivariate analyses subjects with MS had lower TST, spent less time in SWS and in REM 
sleep, had poorer sleep efficiency and higher ArI than those without MS. The differences 
were attenuated after adjusting for age, gender and the day on which the recording was 
performed (Table 2). Finally, only the ArI remained significantly different after additional 
adjustments (adjusted means: 20.3±0.3 vs. 23.3±0.4/h; p<0.001). However the difference lost 
statistical significance in subjects with an ODI≤15/h (p=0.72). 
In the whole group, hypertension was associated with lower TST, decreased SWS and REM 
sleep, lower sleep efficiency, and higher ArI. Sleep efficiency was different in subjects with 
hypertension when compared with those without hypertension after adjusting for age, gender 
and the day of the PSG recording (85.1±0.3 vs. 84.2±0.4%; p<0.05), but no significant 
differences were found between groups concerning sleep structure after adjusting for 
additional covariates (BMI, smoking, alcohol, physical activity, drugs that affect sleep and 
depression) (Table 3). In subjects without clinically significant ODI, hypertension was 
181 
associated with was slightly lower sleep efficiency in the multi-variable adjusted model 
(adjusted means: 86.9±0.3% vs. 85.4±0.5%; p=0.02). 
Unadjusted analyses showed significant differences in sleep structure between subjects with 
diabetes when compared with subjects without: they spent less time in SWS and in REM 
sleep, had lower sleep efficiency and higher ArI. In the multi-variable adjusted model only 
TST and sleep efficiency remained slightly different between groups (Table 4). In subjects 
with an ODI≤15/h, after adjusting for potential confounders, the differences showed a 
marginal trend (p value for TST =0.11; p value for sleep efficiency = 0.07). 
Unadjusted comparisons of sleep structure showed that subjects with a BMI>25 kg/m2 had 
lower TST, spent less time in SWS and in REM sleep, had poorer sleep efficiency and higher 
ArI than those with a normal weight. These differences were attenuated in the multi-variable 
adjusted model, but SWS (20.8±0.3 vs. 19.5±0.3%; p=0.002), time spent in SWS (82±1 vs. 
78±1 min, p<0.05) and the ArI (19.6±0.4 vs. 22±0.3/h; p<0.001) remained different (Table 
5). In subjects with an ODI≤15/h, the percentage and the time spent in REM sleep were 
higher in overweight/obese subjects (adjusted means: 22.4±0.2% vs. 23.4±0.2%, p=0.002; 
91±1 vs 97±1 min, p<0.005), even though these differences were small. 
As previous population studies suggest a U-shaped relationship between subjective sleep 
duration and cardiovascular outcomes, we performed further analysis stratifying the subjects 
in 4 groups according to the TST: <6 h, 6-7h, 7-8h, 8+ h. These data are presented as 
supplementary tables (Supplemental tables 1 and 2). In this analysis the most consistent 
finding was that the prevalence of hypertension showed an inverse association with sleep 
duration for the whole group, and a U-shaped association in subjects without significant ODI 
(Supplemental table 1). However, in the multivariate logistic regression analysis 
(Supplemental table 2) after adjusting for gender, age, smoking, alcohol, physical activity, 
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drugs that affect sleep, BMI and depression, the odds ratio (95% confidence interval) for 
hypertension for subjects sleeping less than 6h was 1.19 (0.87 - 1.62) for the whole 
population and 1.45 (0.97 - 2.16) for those without significant ODI, taking as reference 
subjects with a sleep duration of 7-8 h. Significant differences between groups were found for 
the prevalence of the MS in the whole group, as subjects with a TST <6h had a higher 
prevalence of MS than the other groups (no U-shaped relationship), but this difference was 
not found in subjects without significant ODI (≤15/h). No significant differences between 
groups were found in the multivariate logistic regression analysis. No U-shaped association 
was found between groups concerning the prevalence of diabetes. In the multivariate logistic 
regression analysis, the OR for diabetes was lower in subjects with a TST less than 6h 
compared with the reference group (OR 0.57, CI: 0.35 - 0.93) in the whole group, but not in 
the subjects without significant sleep disordered breathing. Finally, a U-shaped association 
was found for the prevalence of BMI >25 kg/m2 in the whole group, but not when considering 
subjects with ODI ≤15/h. However, in the multivariate logistic regression analysis the OR for 
a BMI >25 kg/m2  was significantly higher in subjects with a TST more than 8h and no 
significant ODI, when compared with the reference group (1.63 (1.09 - 2.43)). Overall, these 
analyses confirm that TST, whether used as a continuous or a categorical variable, does not 
show consistent associations with CV risk factors. 
Discussion 
To the best of our knowledge, this one of the largest population-based study assessing the 
relationship between sleep variables, objectively measured by PSG, and CV risk factors, 
specifically, the MS, hypertension, diabetes and obesity. In our study the MS was more 
prevalent in subjects whose sleep was shorter, lighter (as measured by decreased SWS and 
REM sleep), more fragmented and with lower sleep efficiency. However, these differences 
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were attenuated when adjusting for potential confounding factors and only the ArI remained 
significantly higher in subjects with the MS in the multivariate model. This association 
disappeared in subjects without significant ODI (clinical cutoff of ODI≤15/h), suggesting that 
the increased ArI in subjects with MS in the whole group could be related to the presence of 
respiratory disturbances. Another possibility would be a reduction in statistical power due to 
the decrease in sample size. 
Crude unadjusted analyses also showed significant differences in sleep duration and structure 
between subjects according to the presence or absence of hypertension, diabetes and 
overweight/obesity. But, as for the MS, these differences disappeared in subjects without 
significant ODI after controlling for confounders. In a conservative approach to avoid the 
possibility to find significant differences due to chance we preferred a p-value <0.001 for 
statistical significance. Choosing a less rigorous p-value of <0.05 leads to a statistically 
significant association between hypertension and sleep efficiency, in subjects without 
significant ODI and after adjusting for possible confounding factors, yet, these differences are 
very small (86.9±0.3% vs. 85.4±05%, p=0.02). In the same way, overweight subjects without 
significant ODI spent more time in REM sleep, but again these differences were small 
(22.4±0.2% vs. 23.4±0.2%, p=0.002; 91±1 vs. 97±1, p<0.005). As pointed by others10, such 
small differences in epidemiological studies, even if statistically significant, are of 
questionable clinical value as this association must be the result of sleeping habits for 
longtime, and can be easily modified by other behavioral factors, as short exercise exposures 
or dietary changes. Taken together, these findings suggest that normal variation in sleep 
duration and structure does not seem to be associated with the MS, hypertension, diabetes and 
obesity. 
Indirect evidence suggests that sleep deprivation may trigger biological changes contributing 
to MS. Laboratory studies demonstrated that reduced sleep amount produces short-term 
184 
adverse effects, as changes in circulating levels of leptin and ghrelin, impaired glucose 
tolerance, increased cortisol secretion, altered growth hormone metabolism, and changes in 
BP and sympathetic activity30, 31. Also, changes in sleep structure, in particular suppression of 
SWS, without any change in total sleep time, resulted in decreased insulin sensitivity and 
reduced glucose tolerance11. In the same way, Sayk  et al. showed that selective deprivation of 
SWS for one night by acoustic stimulation in healthy subjects produces a significant reduction 
in BP dipping, but no significant changes in morning BP, urine catecholamine excretion, or 
HR variability12. It should be noted that in laboratory studies, the carefully controlled 
experimental conditions allow changes in sleep patterns (as major shortening of the sleep 
duration that cannot be tolerated beyond a few days or the complete absence of SWS) that are 
not experienced in everyday life in the general population. Additionally, in most of these 
studies subjects are selected on the basis of the absence of sleep disorders and other 
comorbidities that can have a significant impact on the development of CV risk factors. 
Our observations differ from those of previous epidemiological surveys that have identified 
several associations between sleep and adverse CV risk factors. Almost all epidemiologic 
studies examining these associations used subjective sleep assessments, such as self-reported 
sleep duration, which may lead to major methodological issues considering that there is no 
validated evidence for direct relationships between subjective and objective measures of 
sleep. The correlation between self-reported and objectively-measured sleep was shown to be, 
at best, moderate, and biased by systematic over-reporting32.  Comparing self-reports of sleep 
duration vs. those obtained by wrist actigraphy shows that people subjectively overestimated 
their sleep by up to an hour, with R2 values between these two indices being only 0.22. People 
estimating their sleep at 5 h usually only slept about 4 h, and those estimating 7 h only slept 
about 6.6 h32. Self-perceived sleep duration is likely to be influenced by factors such as sleep 
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disorders, sociodemographic profile, social demands, or measures time in bed instead of 
actual sleep duration. 
As pointed out by Kurina et al.,33 in a recent critical review of the studies looking at the 
association between sleep duration and mortality, another major issue is that different 
definitions are used for long and short sleep. Short sleep duration in different studies varied 
from 4 hours or fewer, to fewer than 7 hours per night, and long sleep from more than 8, to 12 
or more hours. The reference “normal” category varied from 7 to 9 hours. From some 
previous studies causal inference is also difficult to draw due to the lack of control for major 
confounders. 
Only a limited number of studies analyzed the relationship between objectively measured 
sleep patterns by PSG and morbidity-mortality. In a prospective study of 184 older adults, 
Dew et al34 showed that short sleepers (<6 h) did not have significantly higher mortality than 
the rest of the sample. However, increased mortality was associated with sleep latency >30 
min, sleep efficiency <80%, and SWS <1%. The percentage of SWS was not associated with 
mortality after controlling for age, gender, and baseline medical burden and the potential role 
of other possible confounders, as the presence of sleep-disordered breathing, were not 
analyzed.  Also in older adults a prospective analysis of 784 subjects participating in the 
Outcomes of Sleep Disorders in Older Men Study revealed that the amount of time spent in 
SWS was inversely related to the development of incident hypertension independently of 
sleep duration and sleep-disordered breathing, and after adjusting for age, race and body mass 
index35. From the same cohort, polysomnographic data from 2745 older men also showed a 
significant inverse association between quartiles of SWS and BMI but the association was 
attenuated in men with a respiratory disturbance index ≥ 15/h36. These studies suggest a 
possible relationship between SWS and hypertension and obesity in selected populations 
(older men), but they cannot be generalized to the whole population. 
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Data from the Penn State cohort showed that insomniacs who slept <6 hours had a 
significantly increased risk of type 2 diabetes37, hypertension38 and mortality39 compared to 
the "normal sleep duration, no insomnia" group, after adjusting for confounders. Insomnia 
with objectively measured short sleep duration but not normal variation in sleep seems to 
constitute a vulnerability sleep-associated phenotype. In a recently published prospective 
study on this cohort, self-reported short sleep duration, but not objective sleep duration, was 
associated with a significant increased risk of incident obesity40. Again, perception of one’s 
sleep, as a surrogate marker of emotional stress and subjective sleep disturbances rather than 
objective sleep duration, seems to be the underlying factor beyond the association. 
Two previous studies specifically analyzed the association between sleep and MS using PSG. 
Nock et al41 analyzed PSG data from 533 adults participating in the Cleveland Family Sleep 
Study. The subjects were selected from families with siblings having extreme high or low 
values for AHI. They found that sleep disturbance was a significant component of MS. They 
defined a sleep disturbance factor that included 4 measures: the AHI, the ArI, the percentage 
of sleep time when oxygen saturation was less than 90%, and the SWS%. Again, disturbances 
in sleep but not normal sleep were identified as the risk factors. More recently, Hall et al42 
analyzed the association between sleep and MS in a group of 368 multi-ethnic middle aged 
(mean age 51 years) women participating in the SWAN Sleep Study. They analyzed various 
sleep parameters derived from PSG including EEG power spectral analysis. In bivariate 
analyses, MS was associated with decreased sleep duration and efficiency and increased 
NREM beta power and AHI. When entered simultaneously in a multi-variable adjusted model 
to evaluate their independent contributions, only sleep efficiency and AHI appeared to be 
independent correlates of MS. Respiratory disturbances seem to be clearly associated with 
MS, as evidenced in our and in previous studies27, 43, but the sleep efficiency is unrelated to 
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MS in our study after adjusting for confounders. Nevertheless, we did find a non statistically 
significant association between hypertension and sleep efficiency, which was lower in 
hypertensive subjects. One main explanation for this discrepancy is that we included men and 
women in our study, while Hall et al.42 only included women. In addition, our subjects were 
older and had a higher AHI. 
Strengths and limitations 
The major strengths of our study is its population-based design, the large sample size, the 
availability of detailed information on a number of potential confounders and the use of PSG 
to obtain objective measures of sleep structure and sleep co-morbidities as SDB. 
Nevertheless, we acknowledge potential limitations. Firstly, our results are based on a single 
PSG, and even if the PSG is considered the gold standard for sleep studies, a single recorded 
night may not fully capture the complexity of a phenomenon like sleep. Night-to-night 
variability in sleep is observed in subjects who undergo PSG related to the so called “first 
night effect”, which can be due to discomfort caused by electrodes, limitation of movements, 
and the unfamiliar environment of the sleep laboratory44. Thus, in order to limit the impact of 
the first night effect, we performed the PSG at home under “habitual” sleeping environment, 
and subjects were instructed to maintain their usual sleeping habits. Further, we repeated the 
PSG in a randomly selected sample of 20 Hypnolaus participants to determine the short-term 
variability of 2 nights of home-PSG. Only the percentage of TST spent in REM sleep was 
marginally different between nights (21.4±6.7 vs. 24±5%, p=0.04, Supplemental Table 3). 
Repeated home-PSG in the Sleep Heart Health Study cohort revealed similar results, with no 
evidence of a major “first-night effect”45. Secondly, the Hypnolaus study is a monocentric 
study allowing uniform collection, processing, and analysis of the data, but it is limited to 
middle aged and elderly Lausanne residents; thus, the results may not be easily extrapolated 
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to other populations. Finally, this is a cross sectional study and future prospective studies are 
needed to build upon the present findings. 
In conclusion, in this population-based study, we found significant associations between sleep 
duration and quality and the MS, hypertension, diabetes and obesity. However, these 
associations are not independent of other known CV risk factors, as age, gender, sedentary 
life style, obesity, the ODI, depression, smoking, alcohol, or use of medications that affect 
sleep. We conclude that normal variations in sleep in adults seem to contribute little if any to 
MS, hypertension, diabetes and obesity. 
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Figure 1: Studied population 
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Table 1. Demographic, clinical and polysomnographic characteristics of the participants 
ALL Subjects with 
ODI ≤15/h 
Subjects with 
ODI>15/h 
P value § 
N 2162 (100%) 1411 (65.3%) 751 (34.7%) 
Age, years 58.4  ±  11.1 56.3 ± 10.6 62.8 ± 10.8 <0.001 
Gender female 1106 (51.2%) 866 (61.4%) 240 (31.9%) <0.001 
Metabolic syndrome 659 (30.5%) 284 (20.1%) 375 (50.0%) <0.001 
Hypertension 897 (41.5%) 462 (32.7%) 435 (58.0%) <0.001 
Diabetes 214 (9.9%) 82 (5.8%) 132 (17.5%) <0.001 
BMI, kg/m2 26.2  ± 4.4 25.0  ± 3.9 28.5  ± 4.4 <0.001 
  <25 909 (42.3%) 764 (54.3%) 145 (19.3%) <0.001 
  25-30 884 (41.1%) 509 (36.2%) 375 (49.9%) <0.001 
  >30 356 (16.5%) 134 (9.5%) 222 (29.5%) <0.001 
Smokers/ex-smokers 1233 (58.2%) 785 (56.7%) 448 (61.2%) < 0.05 
Regular alcool 
consumption 
1686 (78.0%) 1078 (76.4%) 608 (80.9%) < 0.01 
Sedentary 1047 (55.7%) 662 (52.7%) 385 (61.7%) <0.001 
Taking drugs that influence 
sleep* 
400 (18.5%) 250 (17.7%) 150 (20.0%) < 0.01 
Depression (lifetime or 
current) 
284 (14.8%) 184 (14.6%) 100 (15.1%) < 0.05 
TST, min 401.2 ± 72.1 406.5 ± 45.3 391 ± 74.2 <0.001 
SWS % 19.7 ± 8.4 21.0 ± 8.1 17.2 ± 8.4 <0.001 
SWS, min 78.6 ± 34.8 84.6 ± 33.1 67.1 ± 35.1 <0.001 
REM % 21.8 ± 6.1 22.7 ± 5.7 20.2 ± 6.6 <0.001 
REM, min 88.6 ± 31.1 93.2 ± 29.8 80.1 ± 31.6 <0.001 
Sleep efficiency % 84.6 ± 10.9 86.1 ± 9.9 81.7 ± 11.9 <0.001 
Arousal index, n/h 21.3 ± 11.0 17.6 ± 7.9 28.3 ± 12.6 <0.001 
AHI, n/h 15.5 ± 16.3 6.9 ± 14.9 31.8 ± 17.6 <0.001 
ODI n/h 14.7 ± 15.2 6.4 ± 10.6 30.5 ± 16.1 <0.001 
Results are expressed as N (%) or mean ± standard deviation. BMI: body mass index; TST: Total 
sleep time/ Sleep duration; SWS%: Percentage of TST spent in slow wave sleep/ stage N3; SWS min: 
time in minutes spent in stage N3/SWS; REM sleep: percentage of TST spent in REM sleep; REM 
min: time in minutes spent in REM sleep; Sleep efficiency: TST / time spent in bed × 100; ArI: 
arousal index; AHI: apnea/hypopnea index; ODI: oxygen desaturation (>3%) index.* Drugs that 
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influence sleep were considered as “present” if participants were using benzodiazepines or derivates 
(ATC codes: N05BA, N05CD, N03AE), hypnotics (N05CF), antidepressants (N06A), neuroleptics 
(N05A) or antihistaminics (R06A). 
§ Comparing ODI≤15/h vs. ODI>15/h.
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Table 2: Sleep characteristics according to the absence or presence of the metabolic syndrome, a) in 
the whole population, b) in subjects without significant ODI (≤15/h) 
a) 
Absent Present Absent Present 
Group size 1503 
(69.5%) 
659 
(30.5%) 
P1 1503 
(69.5%) 
659 
(30.5%) 
P2 
Total sleep time (min) 401 ± 2 401 ± 3 0.79 400 ± 2 401 ± 3 0.72 
SWS (%) 20.0 ± 0.2 19.3 ± 0.3 0.07 20.3 ± 0.2 19.7 ± 0.4 0.18 
SWS (min) § 80 ± 1 77 ± 1 0.12 81 ± 1 78 ± 1 0.42 
REM (%) 22.2 ± 0.2 21.4 ± 0.2 <0.01 22.2 ± 0.2 21.7 ± 0.3 0.09 
REM (min) § 90 ± 1 87 ± 1 0.04 90 ± 1 88 ± 1 0.32 
Sleep efficiency (%) 84.9 ± 0.3 84.3 ± 0.4 0.19 84.8 ± 0.3 85.1 ± 0.4 0.57 
Arousal index (n/h) § 20.3 ± 0.3 23.3 ± 0.4 <0.001 20.2 ± 0.3 22.9 ± 0.5 <0.001 
b) 
Absent Present Absent Present 
Group size 1127 
(79.9%) 
284 
(20.1%) 
P1 1127 
(79.9%) 
284 
(20.1%) 
P2 
Total sleep time (min) 406 ± 2 409 ± 4 0.49 405 ± 2 409 ± 5 0.39 
SWS (%) 21.1 ± 0.2 21.1 ± 0.5 0.99 21.3 ± 0.3 21.4 ± 0.6 0.89 
SWS (min) § 85 ± 1 85 ± 2 0.99 85 ± 1 86 ± 2 0.78 
REM (%) 22.8 ± 0.2 22.5 ± 0.3 0.45 22.8 ± 0.2 22.9 ± 0.4 0.97 
REM (min) § 93 ± 1 94 ± 2 0.90 93 ± 1 95 ± 2 0.48 
Sleep efficiency (%) 86.2 ± 0.3 86.4 ± 0.6 0.73 86.2 ± 0.3 87.3 ± 0.6 0.12 
Arousal index (n/h) § 17.4 ± 0.2 17.5 ± 0.5 0.97 17.4 ± 0.2 17.1 ± 0.5 0.72 
Results are expressed as multivariable adjusted mean ± standard error. P1 : adjusted for gender, age 
and day of week (Friday) ; P2 : adjusted for gender, age, day of week (Friday), smoking, alcohol, 
physical activity, drugs that affect sleep and depression. § between-group comparisons performed 
using log-transformed data. Statistical analysis by analysis of variance. α level set at P < 0.001. 
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Table 3: Sleep characteristics according to the absence or presence of hypertension, a) in the whole 
population, b) in subjects without significant ODI (≤15/h) 
a) 
Absent Present Absent Present 
Group size 1263 897 P1 1263 897 P2 
Total sleep time (min) 402 ± 2 400 ± 3 0.53 402 ± 2 398 ± 3 0.31 
SWS (%) 19.9 ± 0.2 19.7 ± 0.3 0.57 20.1 ± 0.3 20.1 ± 0.3 0.88 
SWS (min) § 80 ± 1 78 ± 1 0.24 80 ± 1 79 ± 1 0.44 
REM (%) 22.1 ± 0.2 21.8 ± 0.2 0.33 22.1 ± 0.2 21.9 ± 0.2 0.53 
REM (min) § 90 ± 1 88 ± 1 0.19 90 ± 1 88 ± 1 0.23 
Sleep efficiency (%) 85.1 ± 0.3 84.2 ± 0.4 <0.05 85.2 ± 0.3 84.5 ± 0.4 0.16 
Arousal index (n/h) § 20.8 ± 0.3 21.7 ± 0.4 0.24 20.7 ± 0.3 21.2 ± 0.4 0.77 
b) 
Absent Present Absent Present 
Group size 949 462 P1 949 462 P2 
Total sleep time (min) 409 ± 2 401 ± 3 <0.05 408 ± 2 400 ± 4 0.08 
SWS (%) 21.1 ± 0.3 21.3 ± 0.4 0.74 21.2 ± 0.3 21.6 ± 0.4 0.49 
SWS (min) § 86 ± 1 84 ± 2 0.28 86 ± 1 85 ± 2 0.64 
REM (%) 22.8 ± 0.2 22.7 ± 0.3 0.90 22.9 ± 0.2 22.8 ± 0.3 0.79 
REM (min) § 94 ± 1 92 ± 1 0.23 94 ± 1 92 ± 2 0.26 
Sleep efficiency (%) 86.8 ± 0.3 85.1 ± 0.5 <0.005 86.9 ± 0.3 85.4 ± 0.5 0.02 
Arousal index (n/h) § 17.7 ± 0.3 16.9 ± 0.4 0.17 17.7 ± 0.3 16.6 ± 0.4 0.09 
Results are expressed as multivariable adjusted mean ± standard error. P1 : adjusted for gender, age 
and day of week (Friday) ; P2 : adjusted for gender, age, day of week (Friday), smoking, alcohol, 
physical activity, body mass index, drugs that affect sleep and depression. § between-group 
comparisons performed using log-transformed data. Statistical analysis by analysis of variance. α 
level set at P < 0.001. 
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Table 4: Sleep characteristics according to the absence or presence of diabetes, a) in the whole 
population, b) in subjects without significant ODI (≤15/h) 
a) 
Absent Present Absent Present 
Group size 1948 214 P1 1948 214 P2 
Total sleep time (min) 401 ± 2 407 ± 5 0.20 399 ± 2 413 ± 6 0.02 
SWS (%) 19.9 ± 0.2 19.3 ± 0.6 0.32 20.1 ± 0.2 20.2 ± 0.7 0.92 
SWS (min) § 79 ± 1 77 ± 2 0.25 80 ± 1 81 ± 3 0.58 
REM (%) 22.0 ± 0.1 21.2 ± 0.4 0.06 22.1 ± 0.1 21.7 ± 0.5 0.43 
REM (min) § 89 ± 1 87 ± 2 0.86 89 ± 1 90 ± 2 0.25 
Sleep efficiency (%) 84.7 ± 0.2 85.0 ± 0.7 0.65 84.8 ± 0.2 86.5 ± 0.8 0.04 
Arousal index (n/h) § 20.9 ± 0.2 24.0 ± 0.7 <0.005 20.9 ± 0.2 21.8 ± 0.8 0.30 
b) 
Absent Present Absent Present 
Group size 1329 82 P1 1329 82 P2 
Total sleep time (min) 406 ± 2 413 ± 8 0.38 405 ± 2 419 ± 8 0.11 
SWS (%) 21.1 ± 0.2 21.6 ± 0.9 0.64 21.3 ± 0.2 20.9 ± 1.0 0.69 
SWS (min) § 85 ± 1 86 ± 4 0.81 85 ± 1 85 ± 4 0.61 
REM (%) 22.8 ± 0.2 21.7 ± 0.6 0.08 22.9 ± 0.2 21.8 ± 0.7 0.13 
REM (min) § 94 ± 1 92 ± 3 0.95 94 ± 1 93 ± 4 0.70 
Sleep efficiency (%) 86.2 ± 0.3 86.9 ± 1.1 0.58 86.3 ± 0.3 88.4 ± 1.1 0.07 
Arousal index (n/h) § 17.4 ± 0.2 17.5 ± 0.9 0.83 17.3 ± 0.2 17.7 ± 1.0 0.67 
Results are expressed as multivariable adjusted mean ± standard error. P1 : adjusted for gender, age 
and day of week (Friday) ; P2 : adjusted for gender, age, day of week (Friday), smoking, alcohol, 
physical activity, body mass index, drugs that affect sleep and depression. § between-group 
comparisons performed using log-transformed data. Statistical analysis by Student’s t-test or analysis 
of variance. α level set at P < 0.001. 
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Table 5: Sleep characteristics according to the absence or presence of overweight/obesity (body 
mass index ≥ 25 kg/m2), a) in the whole population, b) in subjects without significant ODI (≤15/h) 
a) 
Absent Present Absent Present 
Group size 909 1240 P1 909 1240 P2 
Total sleep time (min) 399 ± 2 402 ± 2 0.27 399 ± 2 401 ± 2 0.46 
SWS (%) 20.7 ± 0.3 19.2 ± 0.2 <0.001 20.8 ± 0.3 19.5 ± 0.3 0.002 
SWS (min) § 82 ± 1 77 ± 1 <0.01 82 ± 1 78 ± 1 <0.05 
REM (%) 21.9 ± 0.2 22.0 ± 0.2 0.62 21.8 ± 0.2 22.3 ± 0.2 0.09 
REM (min) § 88 ± 1 90 ± 1 0.34 88 ± 1 90 ± 1 0.09 
Sleep efficiency (%) 85.0 ± 0.3 84.5 ± 0.3 0.28 85.0 ± 0.4 84.9 ± 0.3 0.80 
Arousal index (n/h) § 19.5 ± 0.3 22.4 ± 0.3 <0.001 19.6 ± 0.4 22.0 ± 0.3 <0.001 
b) 
Absent Present Absent Present 
Group size 764 643 P1 764 643 P2 
Total sleep time (min) 403 ± 2 410 ± 3 0.06 403 ± 3 409 ± 3 0.12 
SWS (%) 21.6 ± 0.3 20.6 ± 0.3 <0.05 21.7 ± 0.3 20.8 ± 0.4 0.06 
SWS (min) § 86 ± 1 84 ± 1 0.23 86 ± 1 84 ± 1 0.37 
REM (%) 22.5 ± 0.2 23.1 ± 0.2 <0.05 22.4 ± 0.2 23.4 ± 0.2 0.002 
REM (min) § 92 ± 1 96 ± 1 <0.01 91 ± 1 97 ± 1 <0.005 
Sleep efficiency (%) 86.3 ± 0.3 86.2 ± 0.4 0.90 86.3 ± 0.4 86.5 ± 0.4 0.63 
Arousal index (n/h) § 17.0 ± 0.3 17.9 ± 0.3 0.09 17.1 ± 0.3 17.6 ± 0.3 0.47 
Results are expressed as multivariable adjusted mean ± standard error. P1 : adjusted for gender, age 
and day of week (Friday) ; P2 : adjusted for gender, age, day of week (Friday), smoking, alcohol, 
physical activity, drugs that affect sleep and depression. § between-group comparisons performed 
using log-transformed data. Statistical analysis by Student’s t-test or analysis of variance. α level set 
at P < 0.001. 
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